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ABSTRACT 
 
The most important prognostic factor in breast cancer is the presence or absence of 
metastases in axillary lymph nodes. Frozen section and touch imprint cytology are 
conventional intra-operative methods used in the detection of metastatic breast 
cancer with varying sensitivities and specificities.  The limitation of these methods led 
to the development of alternative molecular diagnostic tests, such as GeneSearch, a 
commercial real-time quantitative Polymerase Chain Reaction (RT-qPCR) assay that 
allows for an intra-operative diagnosis of metastatic breast cancer. When the 
GeneSearch assay was discontinued, Metasin was developed as an in-house RT-qPCR 
replacement assay. Metasin targets the epithelial cell marker cytokeratin 19 (CK19) 
and the breast marker mammaglobin (MGB) mRNA to confirm the presence or 
absence of metastatic disease, whilst the reference gene porphobilinogen deaminase 
(PBGD) acts as a positive control for the performance of the assay. The optimised assay 
can produce a result within 32 minutes allowing it to be used in the intra-operative 
setting to detect metastatic breast cancer in sentinel lymph nodes.    
 
154 archived lymph node homogenates that were previously analysed by both 
GeneSearch and histology in parallel were used to validate Metasin. Out of 154 cases, 
148 showed concordance with both GeneSearch and Metasin with 111 cases being 
negative and 37 cases being positive. There were six discordant cases, four in which 
only Metasin detected metastases and two in which only GeneSearch picked up 
metastases. Out of the four Metasin-only positive cases, three were found to be 
positive on histology after deeper levels were cut in the slices sent for histological 
assessment. Therefore, one case could not be shown histologically to be positive for 
metastases. There were two cases that were missed by Metasin but picked up by 
GeneSearch. One case was positive on histology and the second case negative for 
histology. The error rate for Metasin was 3.89%. The sensitivity and specificity of the 
Metasin assay were found to be 95% and 98% respectively, and the positive and 
negative predictive values were 90% and 98% respectively. These results are 
comparable to those of GeneSearch.  Metasin had an assay time of less than 45 
minutes and was operated by biomedical scientists.  The results of the validation 
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process were deemed acceptable for the assay to be run live and used in the clinical 
setting.  Metasin continues to provide breast cancer patients at Princess Alexandra 
Hospital with all the advantages that a molecular intra-operative diagnostic service 
provides. 
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PART I. INTRODUCTION 
 
The introduction gives a brief overview of the characteristics, diagnosis and 
management of breast cancer and particularly focuses on detecting lymph node 
metastases and the concept of the sentinel lymph node. It then goes on to describe 
the conventional methods used in intra-operative diagnosis of metastases in sentinel 
lymph nodes. Molecular pathology and its application in medicine and in particular 
breast cancer is briefly introduced with emphasis on real-time quantitative polymerase 
chain reaction (RT-qPCR) and its application in the GeneSearch assay. Finally, an 
analysis of GeneSearch from various studies is discussed and the aims of the 
investigation expanded. 
 
Chapter 1  
 
1.1 Breast cancer 
 
This chapter aims to describe the epidemiological and histopathological characteristics 
of breast cancer, including the main histological subtypes and the criteria required for 
grading and staging the cancer. The diagnosis and management of patients is discussed 
with a more detailed description of the concept of sentinel lymph nodes and the 
current intra-operative diagnostic techniques of frozen section and touch imprint 
cytology to detect metastatic tumour. Molecular pathology is introduced as an 
important emerging tool used in the diagnosis and management of patients with 
breast cancer with emphasis on gene expression profiling and the role of RT-qPCR. A 
brief technical description of how PCR works is also provided. Finally, the concept of 
the GeneSearch assay and a review of its performance is described.  
 
1.1.1 Epidemiology of breast cancer 
 
Breast cancer is the commonest cancer in women in the UK accounting for 31% of all 
new cancer cases in women. The latest figures show that there were 48,788 new cases 
of breast cancer (371, <1% in men) in 2009. The incidence of breast cancer in women is 
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strongly related to age. 81% of cancers were diagnosed in the over 50 age group. 48% 
of breast cancer cases are diagnosed in the 50-69 year old age group where breast 
screening is offered (CRUK, 2012). 
 
Figure 1: Distribution of breast cancer according to age (CRUK, 2012) 
 
1.1.2 Risk factors for breast cancer 
 
Risk factors for breast cancer include the following:  
• Female gender 
• Peak incidence between the ages of 75-80 years 
• Early age of menarche (women who had their menarche younger than 11 have 
a 20% increased risk of breast cancer) 
• Nulliparous women or women over 35 years having a full term pregnancy have 
a higher risk than women less than 20 years having a full term pregnancy. 
Breastfeeding is thought to lower the risk of breast cancer. 
• A family history of first degree relatives with breast cancer 
• Non-hispanic white women have the highest rates of breast cancer. 1 in 15 in 
this group develop invasive cancer within 20 years after age 50 
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• Exposure to oestrogen, such as in women who take hormone replacement 
therapy (HRT), is a risk factor for developing ER-positive breast cancer 
• BRCA1 and BRCA2 are susceptibility genes in which a single mutation can lead 
to breast cancer. These mutations account for 3 – 5% of all breast cancers  
• A higher body mass index in postmenopausal women (Tavassoli and Devilee et 
al, 2003) 
   
1.1.3 Histological subtypes of breast cancer 
 
The World Health Organisation classification of breast tumours lists many different 
types of epithelial tumours, all with their own histopathological appearances and 
prognosis (Tavassoli and Devilee et al, 2003). Typing invasive carcinomas is known to 
have prognostic value and also provides information on the pattern of metastatic 
spread and tumour behaviour (Ellis et al, 2005). The two commonest types of invasive 
breast cancer are infiltrating ductal carcinoma (IDC) and invasive lobular carcinoma 
(ILC) (Tavassoli and Devilee et al, 2003).  
 
Infiltrating Ductal Carcinoma     
 
Infiltrating ductal carcinoma, not otherwise specified (NOS) is the commonest type of 
breast cancer accounting for 41-75% of all mammary invasive carcinomas in seven 
published series (Elston and Ellis, 2000) and is a diagnosis of exclusion. Therefore, it is a 
tumour that cannot be classified as any special type ie Not Otherwise Specified, (NOS). 
The histological appearances vary considerably with tumour architecture ranging from 
solid to glandular, cords and single cells. The neoplastic cells also vary in appearance 
ranging from mildly atypical to highly pleomorphic (Tavassoli and Devilee et al, 2003).  
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Figure 2. Invasive ductal carcinoma in a desmoplastic stroma. Lymphovascular invasion 
is seen on the left. (x20) 
 
Invasive Lobular Carcinoma 
 
This tumour can be difficult to detect, with bland single tumour cells infiltrating the 
breast tissue. Classically the carcinoma cells are lined up in single file pattern. There is 
targetoid growth with a circumferential growth pattern around ducts and lobules. The 
neoplastic cells can be difficult to detect as the nuclei can look mildly atypical with 
slight hyperchromasia. Intracytoplasmic inclusions and signet-ring cells can be seen. 
Immunohistochemistry (IHC) can be done for e-cadherin, a cell adhesion molecule, the 
absence of which would indicate ILC. Metastases to axillary lymph nodes can be very 
difficult to detect due to the non-descript and subtle appearance of the tumour cells 
(Tavassoli and Devilee et al, 2003). 
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Figure 3 Invasive lobular carcinoma showing characteristic features of the malignant 
cells arranged in single file and singly. (x20) 
 
1.1.4 Grading breast cancer 
 
Grading a cancer is the assessment of its degree of differentiation and in some cancers, 
the number of mitoses and architectural features (Kumar et al, 2010). Grading of 
breast cancer is carried out using the Nottingham/Elston and Ellis grading system (Ellis 
et al, 2005). It involves assessing three parameters, each of which has a score of 1 - 3: 
1. Tubule, glandular or acinar formation: the greater the percentage of tubules, 
the lower the score. If more than 75% of the cancer consists of tubules, it 
scores 1, between 10 and 75%, scores 2 and less than 10%, a score of 3. 
2. Nuclear pleomorphism: slightly enlarged, regular nuclei score 1, moderately 
pleomorphic nuclei score 2 and highly pleomorphic nuclei score 3 
3. Mitotic count: the least differentiated area of the tumour is scanned and the 
number of mitoses in 10 high power fields counted. Depending on the field 
26 
 
diameter, a table listing the number of mitotic figures corresponding to a score 
is read. 
The total score of all three parameters is added up and for those scoring 3-5 the 
tumour is a grade 1, a score of 6-7 a grade 2 and a score of 8-9 a grade 3, the worst 
grade. 
There is a highly significant relationship between histological grade and prognosis 
whereby the overall survival and recurrence-free interval are worse in patients with 
grade 3 or poorly differentiated tumour than those with grade 1 or well differentiated 
tumours. This is illustrated in the graph below (Elston and Ellis, 2000). 
 
Figure 4. The graph illustrates the correlation between histological grade and overall 
survival in women with primary operable breast cancer. The overall survival of women 
with grade 1 breast cancer is better than those with grade 2 or grade 3 breast cancer 
(Elston and Ellis, 2000). 
 
1.1.5 Staging breast cancer 
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Staging a cancer is a combined clinical and pathological assessment. It is based on the 
extent of lymph node spread and presence or absence of metastases. The system used 
to stage breast cancer is the TNM system where T is the size of the tumour and the 
extent of spread ie to the skin or chest wall, N is the number of lymph nodes affected 
and M is the presence or absence of distant metastatic spread (Ellis et al, 2005). 
 
1.1.6 Important prognostic information 
 
The important points to document when reporting breast cancers are the ones that 
hold prognostic information. Poor prognostic indicators include certain tumour 
subtypes, large tumour size, high tumour grade, presence of lymphovascular invasion 
and presence of metastatic spread to the lymph nodes (Ellis et al, 2005). This last 
feature is one of the most important prognostic indicators. 
  
1.1.7 Metastases, their mode of spread and Isolated Tumour Cells (ITCs) 
 
Tumour implants at a distant site from the primary tumour are metastases. This 
characteristic defines a tumour as being malignant as benign tumours are not known 
to metastasize. Around 30% of patients newly diagnosed with a malignant tumour 
present with metastases and 10% of breast patients have metastasis at the time of 
presentation (Kumar et al, 2010). The larger, more aggressive, faster growing tumours 
are the most likely to spread, however, there are exceptions to this rule. 
The commonest sites of metastatic spread in breast cancer are the bone, lungs and 
liver (Kumar et al, 2010). 
There are three ways tumours can spread to other organs of the body: 
• Direct seeding of cavities or surfaces: this is when a tumour penetrates into a 
cavity, such as peritoneal, pericardial and pleural cavities. They can then 
spread directly to other organs within the space. 
• Haematogeneous spread: tumour cells can infiltrate veins and less commonly 
arteries. Tumour cells invading into venous blood vessels follow the venous 
flow, resting in the first capillary bed they meet. The liver, which receives 
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portal blood, and the lungs, which receive caval blood, are the two 
commonest sites for metastasis (Kumar et al, 2010). 
• Lymphatic spread: this is the commonest way in which carcinomas, such as 
breast cancer, spreads. The tumour infiltrates the functional lymphatics close 
to the tumour edge and follows the natural route of lymphatic drainage. 
Carcinomas of the breast that arise in the upper outer quadrant normally 
metastasize to the axillary lymph nodes and those located in the inner 
quadrants spread to the nodes along the internal mammary nodes. The 
infraclavicular and supraclavicular lymph nodes are usually the last group to 
be affected and signify the extensive spread of the tumour. The tumour can 
then spread from the nodes through the lymphatics to distant sites in the 
body (Kumar et al, 2010). 
 
 
Figure 5. A lymph node showing metastatic IDC on the left and normal lymphoid tissue 
on the right. (x20) 
 
Breast cancer metastases to the lymph node are classified as either macrometastases, 
micrometastases or isolated tumour cells based on the size of the deposit (Ellis et al, 
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2005). The larger the size of the deposit, the greater the number of metastatic cells 
there are. Macrometastases are considered to be greater than 2mm. Micrometastases 
are one or more deposits of tumour measuring between 0.2mm up to 2mm. Isolated 
tumour cells (ITCs) are defined as single tumour cells or small clusters not larger than 
0.2mm. These are normally detected or confirmed using immunohistochemistry. They 
are not considered to have any clinical significance and are given a pN0 in the TNM 
staging guidelines (Ellis et al, 2005). 
There is still some controversy about the clinical significance of ITCs. The current 
consensus for the majority is for axillary dissection to be performed after the presence 
of micro- or macrometastases is identified (Bishop et al, 2009). However, several 
studies have been carried out investigating the likelihood of positive non-sentinel 
lymph nodes in cases where only ITCs were found in sentinel lymph nodes. The 
sentinel lymph node is the first node to receive lymphatic drainage from the primary 
tumour site (Mansel, 2006). A systematic review by Carolien H. M. Van Deurzen et al 
(2008) was carried out looking at 29 studies with a total number of 836 patients, of 
whom 108 had non sentinel lymph node involvement. The inclusion criteria included 
patients who had a diagnosis of primary invasive breast cancer and a positive sentinel 
lymph node with ITCs measuring less than 0.2mm. Patients who had had neoadjuvant 
chemotherapy were excluded from the study. It found that the pooled overall risk of 
non-sentinel lymph node involvement in patients with ITCs in the sentinel node was 
12.3%, and of those 63.5% were macrometastases. It listed several characteristics for 
strong predictors of non-sentinel lymph node involvement including the size of the 
metastatic tumour in the sentinel node, a large primary tumour size, lymphovascular 
invasion and the presence of more than one positive sentinel lymph node (Degnim et 
al, 2003). In other studies it was found that in patients with sentinel lymph nodes 
containing micrometastases, approximately 20% will have metastases in non-sentinel 
lymph nodes (Cserni G et al, 2004 and Viale G et al, 2005 and Wada N et al, 2008). It 
has also been reported that the risk of false-negative sentinel lymph node results is 
approximately 7-8% (Lyman GH et al, 2005 and Goyal A et al, 2006). Therefore, in 
patients with ITCs in their sentinel lymph nodes, it could be argued that a wait and see 
policy might be acceptable. However, the 12.3% of patients who had negative sentinel 
lymph nodes but positive non-sentinel lymph nodes (63.5% of which were 
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macrometastases) in the study by Carolien H. M. Van Deurzen et al (2008) would have 
been undertreated if they had not had an axillary dissection. The management of ITCs 
still remains a contentious issue, however, for the time being while large-scale studies 
are still ongoing they are widely regarded as clinically insignificant. 
 
1.1.8 Diagnosis and management of a breast cancer patient 
 
A multidisciplinary approach is needed in order to diagnose and manage a patient with 
breast cancer. From the initial steps of diagnosis to surgical excision and follow-up 
care, there are several health-care professionals who are key to delivering a service 
tailored to the individual patient. The management of a breast cancer patient is 
summarised and the main discussion is centred on the concept of the sentinel node 
and the diagnosis of metastatic breast cancer and staging.   
 
Triple assessment 
Patients may present to the surgeon either having been referred from breast screening 
or from the GP for investigation of breast symptoms. Triple assessment is composed of 
three diagnostic modalities. 
1. Imaging – mammography and/or ultrasound 
2. Clinical examination 
3. Histopathological with or without cytological examination 
 
The main indications for patients to be recalled for assessment are those with a 
significant mammographic abnormality, significant breast symptoms or signs, review of 
short term recall or significant Magnetic Resonance Imaging (MRI) abnormality in 
women at high risk (Liston et al, 2010). 
 
The following flow-charts summarise the general management of a patient with a 
breast lesion at each stage. 
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         Screening     Symptomatic 
       (age 47 - 73)  
     Mammography 
 
Normal (>93%)  Abnormal (<7% prevalent, <5% incident) 
 
Routine screening         Recall for assessment 
 
               Assessment (further imaging)  
 
The flow chart illustrates that of the women who undergo mammographic 
examination at breast screening, more than 93% will have normal findings. However, a 
percentage will be found to have an abnormality detected on mammography and will 
therefore require further assessment in the form of further imaging (Liston et al, 
2010). 
 
                                                  Assessment (further imaging) 
 
 
                            Further Mammography                           Ultrasound (US)  
 
Further mammography      
• To confirm the presence, morphology and site of the mass 
Ultrasound (US)  
• To establish the nature of the mass 
 
There are four types of mammographic abnormalities described, namely masses, 
architectural distortion, asymmetric density and microcalcifications. Each of these 
abnormalities follow different management protocols but usually include needle 
sampling. Once further imaging has been carried out, the next step would be either to 
send the patient back to routine screening or to refer for a clinical examination. 
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Patients who are symptomatic automatically require clinical examination (Liston et al, 
2010). 
 
                                                   Assessment (further imaging) 
 
 
                                          Normal                                      Abnormal 
                                                                                                                                   Symptomatic    
 
                                 Routine screening                        Clinical examination 
  
Clinical examination is mandatory for patients with a confirmed mammographic or US 
lesion that requires needle sampling. It is not necessary for those whose further 
imaging is normal (Liston et al, 2010). 
 
                                                                Clinical examination 
 
 
                                               Normal                                    Abnormal 
 
 
                                      Routine screening                   Needle sampling 
 
 
                                                                      Multidisciplinary team meeting (MDT) 
 
 
                                                                 Normal                          Abnormal 
 
 
                                                            Routine screening                Treatment 
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Needle sampling of the lesion can be done either as a core biopsy or as a vacuum 
assisted biopsy (VACB) depending on the type of lesion identified. Core biopsies 
provide information on tumour type, invasive status, grade and receptor status and 
can diagnose benign conditions. VACBs are recommended for lesions with 
microcalcification, after a B3 or B4 result at core biopsy and for diagnostic excision of 
some papillary lesions and radial scar/complex sclerosing lesion diagnosed on core 
biopsy (Liston et al, 2010). 
 
In patients with invasive breast cancer, ultrasound of the axilla should be carried out to 
assess the possibility of metastatic disease. An axillary lymph node that is entirely 
hypoechoeic, has a cortex greater than 2mm, has a focal cortical bulge or a short-long 
axis ratio greater than 0.5 should be considered as potentially abnormal. Core biopsy 
and/or fine needle aspirate cytology (FNAC) should be carried out on the abnormal 
lymph node. A pre-operative diagnosis of metastatic disease in the lymph node will 
render sentinel lymph node biopsy as inappropriate (Liston et al, 2010). 
 
All needle sampling results should be reviewed at the MDT meeting where the 
management of the patient is discussed with all the team members. 
It is widely regarded that holding regular multidisciplinary team meetings is the best 
way to decide and co-ordinate patient management (Keeson, 2012). Each discipline 
involved in patient care should be represented. These can be divided into the 
diagnostic team and the cancer treatment team (Bishop, 2009). 
 
Diagnostic team 
• The breast surgical team including consultant, registrars or trainees 
• Consultant Radiologist 
• Consultant Histopathologist 
 
Cancer treatment team  
• Clinical Oncologist 
• Medical Oncologist 
• Breast cancer care nurse 
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• Research nurse 
• Lymphoedema specialist 
• Palliative care team 
• Members of the diagnostic team 
 
There are three main outcomes of the MDT. The patient could be reassured and 
discharged back to routine screening, referred for open surgical biopsy or referred for 
treatment. Decisions on further management and treatment options are discussed and 
a consensus reached. The patient is then informed of the decision, ideally by a clinician 
and a clinical nurse specialist, and their views discussed (Liston et al, 2010). 
     
1.1.9 Surgical management 
 
Once a diagnosis of breast cancer has been made, a care plan is drawn up and there is 
close communication between surgeon and oncologist. There are three broad 
categories the breast cancer diagnosis can be placed in. 
1. Operable breast cancer 
Surgery is usually the first treatment. Neoadjuvant chemotherapy can be given 
to down-stage a tumour. Neoadjuvant endocrine therapy for Oestrogen 
receptor (ER) positive tumours may also be used to de-bulk the tumour and aid 
in breast-conserving surgery.  
2. Locally advanced primary breast cancer 
In these circumstances, initial treatment with chemotherapy or radiotherapy 
may be appropriate before surgery. 
3. Metastatic breast cancer 
At this stage, the main aim is palliation and to improve quality of life. Life 
expectancy is approximately two years. Oncologists and palliative team 
members are more involved in the management of these patients. (Bishop et 
al, 2009). 
 
The type of surgical procedure depends largely on the size and extent of the tumour. 
Whether breast conservation surgery or mastectomy is chosen depends on the results 
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of clinical examination, US and mammography findings and on patient choice. MRI is 
also used in certain situations where invasive lobular carcinoma is suspected, the 
breast tissue is dense or the clinical and radiological assessment of extent disagree. For 
patients undergoing breast conservation surgery, the margins of excision are very 
important. The surgeon needs reassurance that the tumour has been completely 
removed from the patient and relies on the histopathological examination of the 
margins to confirm this. The breast specimen is orientated to allow the pathologist at 
cut-up to block the correct tissue to assess the margins. There are no nationally 
accepted guidelines on the minimum distance of tumour to the excision margin. There 
should be locally determined acceptable margin widths and each case should be 
discussed in multi-disciplinary meetings to assess the need for further excision to 
obtain clear margins if deemed appropriate (Bishop et al, 2009). 
 
The most powerful prognostic determinant in breast cancer is the presence of axillary 
node metastases (Veronesi, 1997). A pre-operative assessment of the axilla involves 
ultrasound assessment with or without FNAC and a core biopsy to diagnose the 
presence of metastases. A positive result would lead to an axillary clearance. This 
would involve all the lymph nodes taken from the axilla. In over 90% of patients this 
would mean at least 10 nodes (Veronesi, 1997). The majority of axillary staging should 
be done by sentinel node biopsy, however, there may be some situations where 
axillary sampling (at least four nodes) or axillary clearance may be used. The policy in 
place at Princess Alexandra Hospital is for patients to undergo sentinel node biopsy for 
axillary staging. 
 
1.2 Sentinel lymph node 
 
In metastatic disease, the first step in the vast majority of breast cancers is spread to 
the ipsilateral axillary nodes via the lymphatics. In 98% of metastatic cases, the cancer 
is known to spread to the first, then second and then third level (Veronesi, 1987). 
Historically, the surgical management of breast cancer would have involved removal of 
the tumour either by breast-conserving surgery or mastectomy and staging of the 
cancer by removal of the lymph nodes in an axillary clearance. Clearing all or most 
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axillary lymph nodes carries with it a high risk of morbidity and poor quality of life in 8-
15% of patients (Cserni, 2000). There are no therapeutic benefits of axillary lymph 
node dissection in node negative patients. Patients who were found to have screen 
detected breast cancer were generally found to have smaller, less advanced tumours 
and therefore a higher rate of node negative cancers (pN0) (Cserni, 2000). A solution 
was needed to avoid overtreatment of node negative patients.  
 
The concept of the sentinel lymph node biopsy (SLNB) was born out of this need to 
avoid unnecessary overtreatment in node-negative patients who had undergone 
axillary dissection. A sentinel lymph node (SLN) is the first node to receive lymphatic 
drainage from the primary tumour site (Mansel, 2006). It relies on the theory that the 
spread of mammary carcinoma through the lymphatic vessels follows an orderly 
pathway (Cserni, 2002). The sentinel lymph node concept was first investigated in 
penile carcinoma. The investigators used lymphangiograms via the dorsal lymphatics of 
the penis to locate the presence of the sentinel lymph node. In 15 patients found to 
have a positive sentinel lymph node, 12 patients had negative clearances, 
demonstrating that the sentinel node is the first node to receive tumour cells, showing 
that all lymphatic channels draining into the iliac lymph nodes would always first drain 
into a sentinel lymph node. The study concluded that if the sentinel lymph node was 
found to be negative, then a clearance of all the nodes was unnecessary (Cabanas, 
1977). They showed that there is a hierarchical organisation through which lymph 
flows in a systematic order. Therefore, the identification of the first lymph node the 
lymph drains into is the first step. The further management of the patient would 
depend on whether the sentinel lymph node was positive or not. Cutaneous malignant 
melanoma was the first cancer in which SLNB first altered staging and management. 
Breast cancer was the second type.  
 
Over 40,000 new breast cancer cases per annum are diagnosed in the UK of which 25-
30,000 will be suitable for SLNB (CRUK, 2012 and Kumar et al, 2010). The SLN is 
successfully localized in 99% of patients using a combined technique of radioactive 
(TcM99m) labelled nanocolloid and 2mls of diluted Patent V blue dye. (Garcez and 
Harper, 2009). The combined use was shown to be the most accurate in identifying the 
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sentinel node. Thirty-nine peer-reviewed pilot studies were carried out to report the 
validity of the sentinel lymph node with following axillary dissection as confirmation. 
Fifteen studies used radioisotope alone, twenty studies used blue dye alone and 
eleven studies used both. The identification rates were 92%, 81% and 93% respectively 
with false negative rates of 7%, 9% and 5% respectively. The lowest false-negative rate 
of 5% was attributed to the increased likelihood of more than one sentinel node being 
picked up by the combination method (Bonnema, 2002). The NEW START programme 
is a national SLNB training programme for surgeons who will be carrying out the 
procedure (Garcez and Harper, 2009). 
 
Over 40,000 new breast cancer cases per annum are diagnosed in the UK of which 25-
30,000 will be suitable for SLNB (CRUK, 2012 and Kumar et al, 2010). The SLN is 
successfully localized in 99% of patients using a combined technique of radioactive 
(TcM99m) labelled nanocolloid and 2mls of diluted Patent V blue dye. (Garcez and 
Harper, 2009). The combined use was shown to be the most accurate in identifying the 
sentinel node. Thirty-nine peer-reviewed pilot studies were carried out to report the 
validity of the sentinel lymph node with following axillary dissection as confirmation. 
Fifteen studies used radioisotope alone, twenty studies used blue dye alone and 
eleven studies used both. The identification rates were 92%, 81% and 93% respectively 
with false negative rates of 7%, 9% and 5% respectively. The lowest false-negative rate 
of 5% was attributed to the increased likelihood of more than one sentinel node being 
picked up by the combination method (Bonnema, 2002). The NEW START programme 
is a national SLNB training programme for surgeons who will be carrying out the 
procedure (Garcez and Harper, 2009). 
   
1.2.1 Sentinel Lymph Node Biopsy vs Axillary Clearance  
 
There are two important criteria for SLNB to be preferable to axillary clearance (AC). 
The first is the reduced impact SLNB has on patient quality of life. The second is the 
concordance between the two procedures. The SLNB approach would not be adopted 
if the local recurrence of axillary metastases is unacceptably high. There have been 
numerous studies showing the level of concordance is high. Veronesi et al (1997) 
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identified the SLN in 160 out of 163 patients. Out of those 160 patients, 81 had 
positive SLNs and 79 had negative SLNs. Of the SLN positive patients, 32 were found to 
have only the sentinel node positive and 49 had other positive axillary nodes as well as 
the sentinel node. Of the SLN negative patients, 75 had negative axillary lymph nodes 
and 4 had positive axillary lymph nodes. Therefore, 5% of patients with negative SLNs 
were found to have positive axillary lymph nodes, a small proportion of the 160 patient 
population.  
 
Naik et al (2004) found an extremely low rate of axillary recurrence in SLN-negative 
patients of 0.12% (3/2340). The conclusion reached in both studies was that a SLN-
negative result would justify not performing an axillary clearance. A meta-analysis of 
19 studies comparing SLNB with AC in early breast cancer patients from 1996-1999 
was performed by Fraile et al (2000) in which the sensitivity ranged from 83% – 100% 
and the pooled data from the meta-analysis gave a global sensitivity of 91%. They 
concluded that SLNB was a practical alternative to AC.   
 
The ALMANAC trial is a multi-centre randomized trial that compares the quality-of-life 
(QOL) outcomes between patients who underwent SLNB and AC. The trial assessed the 
known side effects of axillary dissection including: 
 
• Lymphoedema: a well known complication seen in 10-20% of patients 
• Arm numbness/sensory deficit 
• Impairment of shoulder movement: most affected is flexion and abduction 
 
It was found that in all three complications, SLNB was associated with less arm and 
shoulder morbidity than AC. Patients who had had SLNB returned to normal domestic 
activity sooner than AC patients. Other benefits of SLNB were the reduction in 
healthcare costs associated with lymphoedema. AC patients undergo wound drainage. 
By having a SLNB the need for wound drainage is eliminated which reduces the 
number of clinic visits and reduces costs. Also, the length of inpatient stay for patients 
who had undergone AC was longer than those with SLNB. The study concluded that 
SLNB is a safe and effective alternative to routine AC for staging breast cancer. SLNB 
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was associated with less arm morbidity and better QOL and also reduced costs to the 
healthcare service (Mansel, 2006). 
 
Patients found to have positive sentinel lymph nodes undergo AC. However, there 
have been few studies assessing the outcome of patients with positive sentinel lymph 
nodes who did not go on to have ACs. The Z0011 trial (Giuliano et al, 2011) is a 
prospective trial that examined the survival of patients with positive SLNs who did not 
have axillary clearances compared to those that did. The primary end point was overall 
survival and the secondary end point disease-free survival. The inclusion criteria 
included women over 18 years of age with clinical T1 or T2, N0, M0 breast cancer. All 
patients had lumpectomies and had their positive SLNs confirmed by either frozen 
section, touch imprint cytology or permanent section. AC was defined as level I and II 
dissection with a minimum 10 lymph nodes. Exclusion criteria included patients with 
three or more positive SLNs, as well as those with gross extranodal disease, positive 
lumpectomy margins and metastases detected by Immunohistochemistry only. Over 
95% of patients received adjuvant systemic therapy (both chemotherapy and 
hormonal therapy) and all had whole breast irradiation. Of the planned 1900 patients 
with final analysis after 500 deaths, only 891 patients were enrolled as the study 
closed early due to a lower than expected mortality rate. 445 patients were 
randomized to have AC and 446 to SLN dissection only. At a median follow up of 6.3 
years, it was found that those in the SLN-only arm did not have a statistically inferior 
overall survival than those in the AC arm. The five-year overall survival rates were 
92.5% (95% CI, 90.0% – 95.1%) and 91.8% (95% CI, 89.1% - 94.5%) in the SLN-only arm 
and AC arm respectively. Disease-free survival also did not differ significantly with a 
five-year disease-free survival rate of 83.9% (95% CI, 80.2% - 87.9%) and 82.2% (95% 
CI, 78.3% - 86.3%) in the SLN-only arm and AC arm respectively. In summary, the trial 
found that women with a positive SLN and clinical T1-T2 tumours that have undergone 
breast conserving surgery with radiation therapy and systemic therapy do not benefit 
from AC in terms of local control, overall survival and disease-free survival. The 
discovery of further positive lymph nodes in an AC does not in the majority of cases 
affect further treatment and as AC is associated with a significant increase in 
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morbidity, the results raise the possibility of eliminating the need for AC in patients 
who match their inclusion criteria.       
    
1.2.2  Histopathological assessment of the sentinel lymph node 
 
Locating the SLN is the crucial first step carried out by surgeons using the combined 
technique described previously (section 1.2). The next crucial step in the evaluation of 
the SLN is the presence or absence of metastasis determined by histopathological 
examination. Since there is usually one or a few nodes submitted for pathological 
examination, it has allowed a more vigorous and concentrated pathological effort on 
staging.  
 
There is no consensus on the histopathological assessment of SLNs nationally and in 
Europe. A European questionnaire-based survey carried out by the European Working 
Group for Breast Screening Pathology (Cserni et al, 2004) found that out of 240 
institutions surveyed, there were 123 different protocols used in the histological 
assessment of the SLN. The methods ranged from using one H&E stained level for each 
block to performing multilevel sectioning for each block to using both multilevel 
sectioning and immunohistochemistry (IHC). The distance between each step also 
varied from 2µm to 250µm. The IHC marker employed was mainly a pan-cytokeratin 
marker, usually AE1/3 or MNF116. However, other markers such as CK7, CK8, ER, PR 
and EMA were also used (Cserni, 2004). Several studies have shown that using a 
combination of multiple level sectioning and IHC would provide the lowest false-
negative rate (Torrenga et al, 2001). Some investigators have shown that by re-
examining axillary lymph node dissection (ALND) specimens by step sectioning, 8-13% 
of previously node-negative patients were found to have positive nodes. Turner et al 
(2001) found that by using a combination of Haematoxylin and Eosin staining (H&E) 
and IHC, 20% of patients previously thought to be node negative were found to be 
node-positive. However, the workload associated with complete serial sectioning 
would be unreasonable, especially in a busy department with limited resources and 
staff. An acceptable and realistic workload which did not jeopardise sensitivity is the 
optimum goal. There have been several studies trying to establish the optimum 
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number of levels and the interval between them (Cserni, 2004, 2002, 1999 and 
Torrenga et al, 2001). All agree that the number of SLNs found positive increased with 
each new level and that the percentage of micrometastases and ITCs increased when 
using IHC.  The NHS breast screening recommendations as stated in the ‘Pathology 
Reporting in Breast Cancer Screening’ report (2005) are that block dissection 
techniques can be an alternative to high numbers of serial sectioning. It recommends 
the following: 
 
• For lymph nodes greater than 5mm: not more than 3mm slices taken 
perpendicular to the long axis 
• For lymph nodes less than 5mm: bisected or alternatively embedded whole 
 
Further assessment techniques carried out include multiple levels and 
immunohistochemistry, however, these are not recommended in routine practice due 
to the significant resources required. The report acknowledges that the universally 
accepted optimum way of examining SLNs is still under discussion and that research is 
ongoing. 
 
An important point to note is that while IHC staining using a pancytokeratin marker has 
been shown to increase sensitivity, the specificity can be variable. Pitfalls associated 
with IHC and in some cases morphology as well include: 
 
• Mistaking rare benign epithelial inclusions for tumour such as benign 
glandular, apocrine or squamous epithelium as illustrated in figure 4. 
However, these are found in less than 1% of SLNs and can usually be 
identified by morphology 
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Figure 6. Epithelial inclusion cysts within a lymph node (x10). The epithelial component 
is positive for pancytokeratin markers. 
 
• Mistaking positive dendritic reticulum cells or macrophages for tumour cells. 
In most cases, cellular morphology can help distinguish these from tumour 
cells. 
• Staining artefacts which can appear dot-like but are not associated with 
morphology 
• Carryover from cutting blades, prior needle biopsy or other surgical 
interventions 
 
It is recommended that IHC positivity should be correlated with morphology (Cserni, 
2006 and Turner et al, 2001).  
 
SLNB has been widely accepted as the preferred choice of axillary staging in patients 
with clinically negative lymph nodes. Those patients who had a negative SLNB were 
spared the complications of an AC and those patients who had a positive SLNB would 
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have a second operation to remove the axillary lymph nodes. This was accepted as 
best practice, however, it soon became clear that an intra-operative diagnosis would 
be more beneficial. It would allow patients with a positive SLN to undergo an axillary 
clearance during the same operation, thus avoiding the prospect of a second 
operation.  
   
1.2.3 Current intra-operative techniques 
  
Two techniques for the intra-operative diagnosis of sentinel lymph nodes are frozen 
section (FS) and touch imprint cytology (TIC). There have been many studies comparing 
the sensitivity and specificity of each technique in assessing sentinel lymph nodes 
(Salem et al, 2002, Chilosi et al, 1994, Liu et al, 2011, Lumachi et al, 2012, Menes et al, 
2003, Mori et al, 2006).  Each test has its own advantages and disadvantages. Attempts 
to increase the accuracy of diagnosis have been tried including combining the two 
methods and using rapid staining for cytokeratins. However, there still remains no 
internationally accepted standard for the intra-operative assessment of sentinel lymph 
nodes.   
 
1.2.3.1  Frozen section (FS) 
 
This method involves freezing the tissue in order to take thin slices to mount on a slide. 
A cryostat is a microtome in a freezer which is capable of slicing tissue 1µm thick. The 
specimen is placed on a metal disc and the tissue frozen to between -20°C to -30°C. A 
gel consisting of polyethylene glycol and polyvinyl alcohol is used to embed the frozen 
tissue. The frozen tissue is then cut with the microtome, mounted on a slide and 
stained with haematoxylin and eosin (H&E) and examined. The whole process takes 
approximately ten minutes. 
 
The advantages of this method includes allowing: 
• A tissue diagnosis and architectural information 
• A distinction between micro- and macrometastases 
 
44 
 
There are common disadvantages to using this method of intra-operative diagnosis 
including: 
 
• Freezing artefacts hindering diagnosis 
• Loss of tissue 
• Being expensive to run 
• Being time-consuming in inexperienced hands 
• Relying on a trained biomedical scientist (BMS) and experienced Consultant 
Histopathologist to be on call 
(Cserni, 2006) 
 
1.2.3.2  Touch Imprint Cytology (TIC) 
 
TIC involves dabbing the slice of tissue onto a glass slide, which is then immersed into a 
90% alcohol solution and stained using the Papanicolaou method. 
 
Advantages of TIC: 
• It is cheap 
• The method is fast and easy to carry out 
 
The disadvantages to this method include: 
• No architectural morphology can be assessed 
• Relying on an experienced consultant histopathologist to be on call 
• Assessing fewer cells than other methods 
• Rarely differentiating between macro- and micrometastases 
• Cells such as histiocytes and follicle centre cells being misinterpreted or 
suspected of being atypical and therefore having a C3/C4 diagnosis, a deferred 
diagnosis (Cserni, 2006). 
 
1.2.3.3 Frozen Section vs Touch Imprint Cytology 
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Comparisons have been made between FS and TIC with different results reported. 
However, the majority of findings suggest that FS has a better sensitivity and a 
marginally better or comparable specificity. A meta-analysis of nine studies comparing 
TIC and FS included a range of cases examined from 20 to 429. The analysis showed 
that TIC sensitivity ranged from 47.1% to 98%, compared with FS which ranged from 
52% to 90.2%. The overall sensitivity was found to be higher with FS. The specificity of 
both FS and TIC were high, averaging 99% to 100% with only one study reporting a 
90.8% specificity with TIC (Mori et al, 2006). 
A study comparing FS, TIC and a combination of both showed that TIC used on its own 
was the least sensitive and that FS was better. However, combining the two 
techniques showed had an even better sensitivity (Lumachi et al, 2012).        
 
A large meta-analysis was carried out to determine the accuracy of FS results. 47 
studies were included with a total of 13,062 patients with 32% having positive sentinel 
lymph nodes. Summary Receiver Operating Characteristic (SROC) curve analysis was 
applied to account for the differences between each study where the threshold for 
defining a positive result may be different. It found that the mean sensitivity for 
detecting metastases using the SROC model was 73% and the mean specificity 100%. 
18 studies compared FS in macro- and micrometastases. It found that the mean 
sensitivity for detecting macrometastases was 94% compared to the sensitivity of 
micrometastases of 40%. It concluded that for macrometastases, it was a valid test 
with a high sensitivity. However, it could not be relied upon to diagnose the majority of 
micrometastases (Liu et al, 2010). 
 
The accuracy of TIC is even more variable than FS. A meta-analysis of 31 studies 
evaluating TIC showed the pooled sensitivity to be 63% and specificity 99%. For 
macrometastases, the pooled sensitivity was 81% but the pooled sensitivity of 
micrometastases was only 22%. It found that although TIC is fast and cost effective 
with a high sensitivity for macrometastasis, it does not have a good sensitivity for 
micrometastases (Tew et al, 2005).   
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IHC staining in an intra-operative setting was dependant on the length of time taken to 
stain the slide. A rapid immunostaining method was developed using the enhanced 
polymer one-step staining system. Primary antibodies and horseradish peroxidise is 
linked to dextran, a chemically inert polymer complex. A few minutes of incubation at 
room temperature was found to be enough to provide sufficient immunostaining (Tew 
et al, 2005 and Bisgaad et al, 1993).   
 
A prospective study comparing TIC, FS and rapid cytokeratin immunostaining (RCI) was 
carried out on 100 patients with 297 sentinel lymph nodes. 20 patients were found to 
have positive sentinel lymph nodes, 12 with macrometastasis and 8 with 
micrometastasis. TIC, FS and RCI were compared singly as well as a combination of TIC 
and FS and a combination of FS and RCI. The H&E section was taken to be the gold 
standard. The results showed that TIC used on its own was the least sensitive with a 
value of 50%. It was found to be particularly bad at detecting micrometastases, 
identifying only 1 case out of 8. However, the specificity was 100%. FS on its own was 
the next least sensitive with 72.2%, detecting all 12 macrometastases but failing to find 
5 micrometastases. RCI had a sensitivity of 77.8% missing 4 micrometastases. This 
sensitivity was the same as combining TIC with FS. The most sensitive combination was 
that of FS and RCI achieving 83.3%. The specificities of the last four tests were found to 
be the same (97.5%). The study concluded that FS and RCI were the most sensitive 
diagnostic tool (Krishnamurthy et al, 2008).  
 
By comparing the different intraoperative tests, it is clear that there is no consensus on 
the best method, with some authors reporting wildly different sensitivities and 
specificities for each test singly and in combination. This discrepancy is related to the 
variations of the studies. These variations include the study design, the number of 
patients included, the type of breast cancer they had and how many of them had 
positive nodes. Other aspects that would have led to variation include the experience 
of the pathologist, the skill of the technicians or BMS staff in preparing the FS and TIC 
slides and the ability of the surgeons in recognising and excising the sentinel lymph 
node (Safai and Razeghi, 2012). 
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An alternative to the current methods of FS and TIC is the use of molecular diagnostic 
technology. There have been rapid advances in molecular pathology related to breast 
cancer providing an alternative to conventional histological and cytological 
assessment.  
 
1.3 Molecular pathology and its application in breast cancer 
 
Molecular pathology uses the techniques of molecular biology to enhance the 
understanding, diagnosis and therapy of disease. It is the testing of nucleic acids within 
a clinical context (Tubbs and Stoler, 2009). Molecular pathology is a rapidly expanding 
field and is fast becoming an everyday tool for diagnostic and prognostic purposes. The 
impact and potential advantages of molecular pathology in breast cancer has been 
growing at an exponential rate (Weigelt et al, 2010). 
The growing number of treatment options including hormonal therapies, combination 
chemotherapy regimens and targeted treatment options such as Herceptin for Her2-
positive patients have highlighted the need for a way to divide patients according to 
the likelihood of disease recurrence after completion of local therapy. Identifying 
patients more likely to develop disease recurrence so that the best treatment can be 
given is an aim that needs to be met. There are morphological indicators of prognostic 
value that the histopathologist can record, as well as the subtype of cancer. However, 
it is known that there is considerable molecular heterogeneity between each type of 
cancer and between each patient. These variations will make an important impact on 
the response to therapy the patient receives. They can be identified by the gene 
expression profile of the tumours, ie which mRNAs are being made and in what 
quantities (Weigelt et al, 2010). 
 
1.4 Gene expression  
 
The control of gene expression is complex, involving diverse and specific processes 
that can either activate or repress expression. The control of expression occurs in the 
transcriptional and post-transcriptional levels, allowing a gene to be either ‘turned on’ 
or ‘turned off’. Transcription factors are proteins that mediate transcription control. 
48 
 
Some factors can increase the rate of transcription by binding to enhancer sequences 
while others can repress transcription by binding to ‘silencer’ sequences in the DNA. 
Post transcriptional control of gene expression affects various processes including 
export of the mRNA from the nucleus to the cytoplasm, mRNA stabilization and mRNA 
degradation. Other types of RNA have emerged as important regulators of reducing 
gene expression. These include micro RNA (miRNA) and short interfering RNA (siRNA). 
They are both between 21 and 26 nucleotides long and function to inactivate specific 
mRNAs in sequence specific manners. They do this by binding to target mRNA 
sequences using a protein complex called the RNA induced silencing complex (RISC). 
When siRNA binds to RISC, the target mRNA is cleaved and degraded. When miRNA 
binds to RISC, it base pairs with the 3’ untranslated region of the mRNA, preventing 
translation. The regulatory pathways that these short RNAs mediate are called RNA 
interference or RNA silencing (Watson et al, 2007). 
  
1.4.1 Gene expression profiling 
 
Molecular gene expression profiling using array technology has expanded knowledge 
of the biological and clinical diversity of breast cancer. Gene expression profiling allows 
for the analysis of the expression of thousands of genes at once, giving a global picture 
of cellular function. All cells contain the same genome, however, not all genes are 
expressed. It is this selectivity in turning genes ‘on’ or ‘off’ that differentiates one cell 
type from another. Gene expression control occurs at the transcriptional and post-
transcriptional level, that is whether to make the mRNA of a certain sequence coding a 
specific protein and how much of it (Watson et al, 2007).  
 
There are several methods of carrying out gene expression profiling, including serial 
analysis of gene expression (SAGE), massively parallel signature sequencing (MPSS), 
oligonucleotide arrays and complementary DNA (cDNA) arrays, the last two being the 
most commonly used (Pollock, 2002). A microarray is a solid surface, either made of 
plastic, glass or silicon, on which is a 2-dimensional array of compartments that are 
accessed by their position in the array. An array is defined as a set of items that are 
randomly accessible by numeric index (Bruns et al, 2007). DNA microarrays rely on the 
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property of mRNA to hybridise with its cDNA. On the solid surface, known DNA 
fragments are denatured and as many as several million are deposited in an orderly 
array on the solid surface by robotic machines. mRNA is extracted from normal tissue 
and tissue containing tumour and reverse transcribed to cDNA. During the process, 
fluorescent nucleotides are added and different ones are used in both tissues, for 
example red dye for the tumour sample and green dye for the normal tissue. The 
labelled cDNAs are then bathed onto the surface and each one hybridises to its known 
complementary DNA fragment. A special scanner is then used to measure the intensity 
of the fluorescence for each labelled cDNA. The amount of fluorescence of each 
particular gene corresponds to the amount of mRNA being produced by the sample, ie 
whether that gene is being expressed and how much. The more active a gene, the 
more intense the fluorescent signal. The masses of data generated is analysed using 
sophisticated biostatistical and bioinformatics methods such as hierarchical cluster 
analysis. This involves ranking the genes according to how similar their gene 
expression levels are. To visualise this information easily, a heat map is generated 
whereby each data point is shown as green or red. If a spot is red, it means the gene is 
overexpressed in the tumour. If it is green, it is underexpressed and if it is yellow is 
equally expressed in both tissues. In this way, the gene expression profile of the 
tumour is known, highlighting genes which are over or under expressed (National 
Human Genome Research Institute, 2011). Three fields of discovery are introduced 
when analysing the information from these gene expression profiles (Weigelt et al, 
2010).  
 
Class discovery studies and Class comparison studies 
Discovery studies are where microarrays are used to identify distinct subgroups in an 
apparent homogenous series of samples. These subgroups are then analysed with 
specific correlations in mind, for example, with disease progression. Class comparison 
studies compare two or more known gene expression profiles to identify the molecular 
differences between the groups.     
Four molecular subtypes have been identified in breast cancer (Perou et al, 2000). 
These are the positive oestrogen receptor (ER) cancers luminal A and luminal B and the 
ER-negative cancers Her-2, basal-like and normal breast-like cancers: 
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• Luminal: This group can be further subdivided into luminal A and luminal B. 
These are ER positive cancers that show similar expression patterns to those of 
normal luminal epithelium cells. Luminal A cancers usually have low histological 
grades, lower proliferation rates and a good prognosis compared with luminal B 
cancers which usually have a higher histological grade, higher proliferation rate 
and a worse prognosis.  
• Normal breast-like cancers: these are still poorly characterised and are shown 
to have gene expressions similar to those expressed by adipose tissue. 
Fibroadenomas and normal breast samples are clustered together in this group. 
• Her-2: These tumours overexpress Her-2 and are associated with high 
histological grade and a poor prognosis. 
• Basal-like: these cancers are shown to express genes normally expressed by 
basal or myoepithelial cells. These tumours are also typically triple-negative i.e. 
negative for ER, progesterone receptor (PR) and Her2, and are characterised by 
high histological grade, have high mitotic indices, central necrosis, pushing 
tumour borders, conspicuous lymphocytic infiltration and have atypical/typical 
medullary and metaplastic-like features. These tumours show a high response 
rate to chemotherapy treatment (Perou et al, 2000). 
 
It is now thought that breast cancer is a heterogenous disease constituting multiple 
diseases affecting the same site. Molecular classification of breast cancer is still in the 
early stages and the subjective nature of how the subtypes were discovered, the 
stability of each subtype and the lack of reproducibility of the subgroups limits 
molecular classification for diagnostic purposes. Until an internationally accepted 
molecular subtype classification is agreed on, the applicability of this methodology to 
patient management remains limited. 
 
Class prediction studies 
Once the transcriptional or molecular differences between two or more groups are 
identified, a ‘gene signature’ can be defined for each group in order to predict the class 
of a new sample. Examples of gene signatures for breast cancer include the 
MammaPrint® 70 gene signature and the Oncotype DX®.  
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MammaPrint® is a 70-gene assay used as a breast cancer multigene classifier (Gokmen-
Polar and Badve, 2012). It has been found to successfully predict disease outcome 
(Dobbe et al, 2008). The patients in the initial analysis comprised 78 patients younger 
than 55 years with breast cancers measuring less than 5cm and with negative lymph 
nodes. By comparing the gene expression profiles of those patients who developed 
metastasis within 5 years (poor prognosis) with those who did not (good prognosis), a 
prognostic signature of 70 genes was identified. Patients who were grouped into the 
good prognosis category could be spared the toxic effects of chemotherapy. The 
signature has since been validated in various retrospective studies and was shown to 
outperform other established systems based on clinical and histological parameters in 
predicting disease outcome (Buyse et al, 2006, Mook et al, 2009, Bueno-de-Mesquita 
et al, 2009). MammaPrint® has received Food and Drug Administration (FDA) approval 
to be offered as a prognostic test for breast cancer patients. The inclusion criteria for 
these patients are those aged less than 61 years, have tumours measuring less than 
5cm, to be node negative and to be stage I/II. The drawbacks with this methodology is 
its limited clinical use in ER-negative breast cancers as only 0-4% of patients with ER-
negative breast cancers are considered to have a good prognosis using MammaPrint®. 
Patients with Her-2 positive breast cancer (5-22%) were shown to have a good 
prognosis 70 gene signature, however, withholding appropriate anti-Her-2 therapy 
would be considered controversial. Finally, none of the validation studies were 
performed using randomized clinical trial populations. Despite these drawbacks, 
proponents of MammaPrint® state that the results could be used as a replacement for 
clinicopathological parameters (Weigelt et al, 2010).     
 
Microarray experiments provide crucial information about tumour biology; however, 
they are too cumbersome to be used in day to day work in the laboratory or clinic and 
unlikely to be used for clinical work. Therefore, identifying a smaller subset of the most 
important, clinically relevant genes and testing for them in a quick and easy assay is 
the most desirable outcome. Real Time-quantitative Polymerase Chain Reaction (RT-
qPCR) is a molecular tool that allows clinicians to do just that. By using formalin-fixed 
paraffin-embedded breast cancer tissue, RT-qPCR can be used to quantify the 
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expression of clinically relevant tumour-related gene transcripts. A more detailed 
description of the PCR methodology is given in section 1.6.  An important example of 
this is the Oncotype DX®, a validated assay that detects 5 reference genes and 16 
tumour-related genes. These were chosen from 250 candidate genes that were 
selected by various methods including literature searches, and cDNA microarray 
analysis. These 16 genes were found to have a consistently strong correlation with the 
likelihood of disease recurrence when tested on 447 breast cancer patients with ER 
positive tumours and negative lymph nodes. By using an algorithm based on the genes’ 
level of expression, a recurrence score (RS) was calculated for each breast sample. 
Three risk groups were identified: low risk (<18), intermediate risk (18-31) and high risk 
(>31). The RS has been shown to be consistently accurate in several studies.  
 
Further studies have shown that the RS is predictive for tamoxifen efficacy and for 
response to chemotherapy. Those patients with a low RS receive the greatest benefit 
from tamoxifen therapy and are unlikely to gain any further benefit from 
chemotherapy. Those patients with a high RS benefit most from chemotherapy. 
Therefore, patients with a low RS can be assigned hormonal therapy only and those 
with a high RS can receive both hormonal and chemotherapy. In this way, Oncotype 
DX® can triage patients based on their molecular expression of these 16 genes into 
treatment groups (Dobbe et al, 2008, Tubbs and Stoler, 2009). Oncotype DX® has also 
been approved for use by NICE as a cost-effective option to guide the treatment 
decision of patients with early breast cancer and with an intermediate risk of distant 
recurrence (NICE, 2013).  
Another RT-qPCR based assay is Theros®. The gene expression profiles of 60 patients 
treated with adjuvant tamoxifen were analysed using microarrays. Three strongly 
predictive genes were identified: homeobox gene HOXB13, interleukin 17B receptor 
(IL17BR) and EST AI240933. The expression ratios between HOXB13 and IL17BR 
strongly correlated with recurrence, outperforming other clinical and pathological 
predictors. After further retrospective validation studies, the HOXB13:IL17BR ratios 
were shown to be a predictor of outcome for ER-positive patients treated with surgery 
alone and with negative lymph nodes. The test defines the risk of recurrence and 
benefit from endocrine therapy (Ma et al, 2004, Weigelt et al, 2010).  
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Lastly, MapQuant Dx® is an 8-gene RT-qPCR assay used to determine the grade of 
breast cancers. Histological grading is subject to varying concordance between 
different pathologists, in the range 50% - 86% (Robbins et al, 1995). It was shown that 
histological grade I tumours had a distinctive gene expression pattern to histological 
grade III breast cancers (Ma et al, 2003). Sotiriou et al, 2006, tried to define the 
molecular basis of histological grading by performing microarray tests on 33 and 31 
histological grade I and grade III ER-positive breast cancers respectively. A 97-gene 
expression grade index (GGI) composed of genes related to cell cycle and proliferation 
was identified. GGI was shown to have a strong association with histological grade 
when applied to a dataset. GGI was also shown to have a stronger association with 
relapse-free survival than histological grade. The assay could also stratify histological 
grade II tumours into GGI low grade and GGI high grade which correspond to grade I 
and grade III cancers respectively. GGI is shown to be an independent prognostic factor 
and a predictor of outcome in tamoxifen-treated patients (Loi et al, 2007).    
 
In summary, the level of understanding of the genetic mutations and pathway changes 
that lead to breast cancer is expanding. New insights into the clinical course of 
different subtypes of tumours and recognising new predictive and prognostic markers 
for response to targeted therapies is a major advantage in the molecular profiling of 
breast cancer. The prognostic and predictive signatures provided by MammaPrint®, 
Oncotype DX®, Theros® and MapQuant® still need to be validated using larger datasets 
in prospective studies before they are accepted into clinical decision-making. However, 
the information provided by microarrays and the prognostic and predictive gene 
signatures produced promise to become invaluable in the trend towards tailoring 
individual therapy by recognising patients with a good prognosis in whom 
chemotherapy and its toxic side effects could be omitted as well as recognising 
predictive therapeutic markers that could identify patients who would benefit from 
chemotherapy (Weigelt et al, 2010).    
 
1.4.2 Nucleic acid extraction, purification, isolation and quantification 
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All molecular pathology tests rely on nucleic acid extraction, purification and isolation. 
Some also require quantification of the nucleic acid (Tubbs and Stoler, 2009).       
 
Nucleic acid extraction 
Cell lysis starts the process of nucleic acid extraction. The kind of extraction depends 
on several factors, including the type of tissue, desired purity of the nucleic acid and 
the downstream application. Detergents or enzymatic digestion can be used to cause 
chemical disruption of the cells. Mechanical disruption can involve sonication or 
homogenization. Fresh solid tissue should be homogenized in an appropriate buffer 
first before sonicating.  
 
Purification and isolation of nucleic acids 
There are several different ways of purifying and isolating nucleic acids. These include 
silica binding, anion-exchange chromatography and magnetic bead binding. Silica 
binding is based on the known affinity nucleic acids have to bind to silica in a high salt 
concentration. By applying binding and wash buffers, nucleic acids can be separated 
from their cellular components. This is the method of isolation used in many 
commercially available products, including the RNeasy silica membranes in the spin 
columns from Qiagens RNeasy kit. Anion-exchange chromatography uses columns that 
are made of an anion-exchange resin that binds the nucleic acids by attracting the 
negatively-charged phosphate backbone of the nucleic acid to the positively charged 
residues in the resin. The magnetic bead binding technique binds magnetic particles to 
nucleic acids which are then pulled to the side of a tube by magnetic currents while the 
cellular components and debris are washed away. 
 
Nucleic acid quantification 
Nucleic acid quantification can be measured using a spectrophotometer. The device 
measures the absorbance of the nucleic acid solution at several wavelengths of 
ultraviolet light. Nucleotides have a maximum absorbance of 260nm (A260) and 
proteins of 280nm (A280). The ratio of A260:A280 gives an estimate of the purity of 
the sample. Pure RNA has a ratio of 2.0. Protein contamination would lead to a lower 
ratio.  
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Electrophoresis is a method used to identify DNA based on their molecular weight. The 
DNA is loaded onto a liquid or gel with an electric field. Agarose gel is commonly used 
and the concentration depends on the number of base pairs the DNA targets have. 1% 
concentration agarose gels are used to separate DNA composed of 1-20kbp and the 
higher concentration gels are used to separate smaller fragments of DNA. As DNA is 
negatively charged, it migrates towards the positively charged end of the field, the 
anode. The mobility of the DNA molecule is inversely proportional to the log of its size. 
Therefore, smaller molecules travel through the gel quicker. Other factors influencing 
mobility include the net charge of the molecule, temperature and pore size of the 
matrix. By adding ethidium bromide, the DNA can be visualised when illuminated by 
ultraviolet light. Ethidium bromide molecules are planar and can intercalate between 
the bases of double stranded DNA (dsDNA). By exposing the gel to UV light, the 
ethidium bromide-stained DNA fragments fluoresce. By comparing the location of the 
DNA to DNA with known molecular weights in a nearby lane of the gel, the molecular 
weight can be determined. The quality of the DNA is confirmed by a sharp band that 
implies high-quality, intact DNA. Smeared DNA with a thicker band extending down the 
well implies DNA degradation has taken place (Tubbs and Stoler, 2009).       
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Figure 7. The figure shows a gel with marker weights on either side with bands 
corresponding to known masses (base pairs) and three end products of a PCR reaction. 
The three bands are compared to the marker weight ‘ladder’ and the mass confirms 
the presence of the desired PCR product (Alaska BioPREP, 2011). 
 
It is important to note the difference in stability between RNA and DNA when 
extracting either one. DNA is highly robust due to the instability of DNase enzymes and 
is far less reactive than RNA due to the absence of the –OH group in deoxyribose. In 
contrast, RNA is easily degraded by RNase enzymes present in the cell. RNases are 
stable and can regain function after denaturation. Therefore, during the process of 
RNA extraction, cellular RNases should be inhibited and degraded as soon as possible 
with the addition of either guanidine isothyocyanate (GITC) or beta-mercaptoethanol. 
GITC is also used in spin columns that use silica based membranes to promote 
solubility of non-polar proteins in water, promoting adsorption of nucleic acids to the 
spin column (Tubbs and Stoler, 2009).       
 
1.4.3 The use of PCR in clinical practice  
 
The polymerase chain reaction (PCR) is a molecular tool used to amplify targets of 
DNA. This is done by designing primers – short DNA sequences – that bind at the 
beginning and end of the desired DNA target. The DNA is added to a mixture 
containing primers, free nucleotides and DNA polymerase, an enzyme involved in DNA 
synthesis. A thermocycler is used to heat and cool the mixture at temperatures that 
allow PCR to take place. Details of how PCR works is given in section 1.6.2.  
  
There are many applications of PCR in a variety of areas including detecting known 
specific genetic variants in pathological conditions and detecting the presence of new 
targets for therapy such as chromosomal rearrangements or micro-organisms.  A 
tumour’s genetic mutation or chromosomal abnormality can be detected by PCR and 
used as a disease-specific marker. That information can be used to direct cancer 
treatment by appropriate selection of chemotherapy, aid in assessing disease 
remission, monitor the patient during therapy and provide prognostic information. 
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Several important examples of applications of PCR in the clinical setting are briefly 
described (Tubbs and Stoler, 2009).       
 
Detecting known genetic mutations 
PCR is very effective in detecting known genetic mutations such as substitutions, 
deletions and insertions. These processes are found in many oncologic diseases and 
identifying these alterations allows the diagnostician to confirm the diagnosis, identify 
carriers of the genetic mutation, provide prognostic information, monitor for disease 
recurrence and help in selecting appropriate treatment regimes.  This last example can 
be illustrated by the advances in treating patients with lung cancer who carry specific 
epidermal growth factor receptor (EGFR) mutations (Tubbs and Stoler, 2009).       
 
Detecting chromosomal rearrangements 
Rearrangements include translocations, deletions, inversions and insertions. If the 
breakpoints between the two genes are known, primers can be used that span across 
the breakpoint, amplifying it. Follicular cell lymphomas are an example of a disease 
characterised by a translocation, the commonest translocation in lymphoid 
malignancies. Bcl2 is an anti-apoptosis protein which allows germinal centre B cells to 
survive. Normal germinal centres in lymphoid follicles have some B cells undergoing 
apoptosis. In follicular lymphoma, apoptosis is halted due to the overproduction of 
bcl2. This overproduction is secondary to a translocation between chromosome 14 and 
chromosome 18 that places the bcl2 gene next to the immunoglobulin heavy chain 
locus gene enhancer resulting in unopposed bcl2 production. (Kumar et al, 2010) 
 
Microsatellite amplification 
Hereditary nonpolyposis colon cancer (HNPCC) is an autosomal dominant condition 
caused by inactivation of mismatch repair genes. Microsatellites are 1-9 base pair 
sequences that are repeated several times. These are prone to errors during 
replication and in such cases, corrected by the DNA mismatch repair system. Defects in 
these genes lead to microsatellite instability which can lead to adenocarcinoma of the 
colon (Kumar et al, 2010). There are at least five mismatch repair genes but the two 
most commonly implicated are MutS homologue 2 (MSH2) and MutL homologue 1 
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(MLH1). Germline mutations in these two genes resulting in loss of expression 
accounts for 80-90% of HNPCC cases. Epigenetic silencing, involving methylation of the 
MLH1 promoter is responsible for sporadic cases. PCR can be used to screen 
individuals with these genetic defects, aiding in the management of these patients. 
(Tubbs and Stoler, 2009). 
  
1.5 RT-qPCR as an alternative to FS and TIC 
 
An alternative to frozen section and touch imprint cytology is the application of 
quantitative real- time reverse transcriptase polymerase chain reaction (RT-qPCR) in an 
intra-operative assay to detect the presence of markers of metastatic spread in the 
lymph node. It fulfils the requirements needed for a fast, specific, sensitive and cheap 
assay.  
 
1.6 DNA replication and PCR  
 
PCR is a tool that has revolutionised molecular pathology. It can be thought of as a 
DNA photocopier, mimicking DNA replication in the nucleus of the cell, allowing 
exponential amplification of a specific target sequence of DNA, leading to a plentiful 
supply which can be easily detected. 
 
1.6.1 DNA replication in the cell 
 
DNA replication is a complex process but ultimately relies on the separation of the 
double-stranded DNA (dsDNA) by the enzyme DNA helicase into two strands, with 
each strand acting as a template for the formation of a new strand. 
Deoxyribonucleotide triphosphates are coupled onto the growing strand of 
complementary DNA by the DNA polymerases. This is achieved by adding a phosphate 
group onto the 3’-OH group, thus synthesising new DNA molecules in the 5’-3’ 
direction. The leading strand of DNA is synthesised in the 5’-3’ direction using a single 
RNA primer, however, the lagging strand is synthesised in pieces (called Okazaki 
fragments) as DNA polymerase can only add to the 3’ end. RNA primers allow the DNA 
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polymerase to initiate extension. Primers consist of short (10-20) nucleotides and are 
synthesised by RNA polymerase. They are later replaced by DNA (Manson et al, 2002).     
 
 
 
 
Figure 8. The figure illustrates the process of DNA replication whereby the dsDNA is 
separated and two complementary strands are produced to form two new dsDNA 
molecules (About.com, 2011). 
 
1.6.2 PCR steps 
 
PCR aims to replicate the cellular process of DNA replication and therefore requires a 
DNA template, DNA polymerase and the four deoxyribonucleotide triphosphates 
(dNTPs) and a forward and reverse primer to target the sequence to be copied. The 
essential element for successful PCR is thermal cycling. The amplification process is 
based on repeated cycles of three steps with differing temperatures. 
 
Step 1: Denaturation 
Usually held at 95°C, this brief step of up to 30 seconds (s) breaks the hydrogen 
bonds between the dsDNA, resulting in two single strands of DNA.  
Step 2: Annealing 
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Temperatures range between 45-60°C and this step allows hybridization or 
annealing of the forward and reverse primers to their complementary strands.  
Step 3: Extension 
What follows is the DNA polymerase recognizing and binding to the primers 
and begins the process of replication by adding complementary dNTPs to the 
3’ end of the primer strand. The optimal temperature depends on the DNA 
polymerase used, usually at 72°C. The time taken for this step depends on the 
length of the target to be amplified (Tubbs and Stoler, 2009).       
 
At the end of the first cycle, two strands are produced, one from each original 
template strand. These serve as templates for the next cycle and so on, thereby 
resulting in an exponential amplification of the target. In the early stages of the 
reaction, the number of amplicons doubles with each cycle and the efficiency of the 
PCR is 1.0. However, there comes a time when the efficiency plateaus and no more 
amplicon product is made. This is the result of either a limiting factor in the reaction of 
one of the reagents or of the instability of the DNA polymerase due to the high 
number of cycles. Other causes include end product inhibition, competition by 
nonspecific products, incomplete denaturation of the dsDNA strands at higher levels of 
product or incomplete reannealing with higher concentration of product (Tubbs and 
Stoler, 2009).       
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Figure 9. The figure illustrates the three steps in PCR and the exponential amplification 
of product (Tubbs and Stoler, 2009). 
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Each component involved in the PCR is discussed. 
 
DNA polymerase 
Heat stability is an essential requirement for a DNA polymerase. It was discovered that 
the DNA polymerase from the bacterium thermos aquaticus, which lives in water with 
a temperature of 75°C, has an optimum temperature of 72°C and is stable up to 94°C. 
Taq polymerase is one of the most commonly used polymerases (Tubbs and Stoler, 
2009).  
 
The primers 
The specificity of the target sequence is guaranteed by primers, short oligonucleotides 
that contain sequences complimentary to the opposite ends of the target template.  
A primer can be defined as an oligonucleotide that initiates polymerase-catalyzed 
additions of dNTPs by annealing to a template strand (Bruns et al, 2007). There are two 
primers needed for PCR. The forward primer is complementary to the reverse 
template strand at the beginning of the target sequence and the reverse primer is 
complementary to the forward strand at the end of the target sequence. A large 
number of primers are added to the reaction mix as with each cycle they are 
incorporated into the new strands, reducing their concentration. Primers are essential 
in amplifying the correct sequence and they dictate the quality and specificity of the 
amplification reaction. There are software tools that can select the best primers to use 
for a specific target. Several properties of a good primer include: 
 
• Primers that are specific to the amplicon. Amplicons are PCR products and are 
replicated target molecules whose ends are defined by the primers. Primers 
that even partially match other sequences of the DNA can lead to non-specific 
PCR product. When designing primers, common repeated sequences should be 
avoided. Other targets to avoid are pseudogenes. These are genes that, due to 
accumulated mutations, do not result in a functional gene product. Sequence 
variations in these pseudogenes are rarely clinically significant.  
• Avoiding primers that anneal to themselves or to other primers in a multiplex 
reaction. This is especially important at the 3’ end. Primer dimers can occur 
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before PCR begins, when at lower temperatures a primer may anneal to 
another and Taq polymerase may extend it. If it is in turn extended, then 
double stranded products are formed creating primer-dimers. These can 
decrease the efficiency of the PCR reaction and reduce the sensitivity of the 
reaction. Hot start PCR uses an antibody to bind and inactivate the polymerase 
at room temperature, reducing the chances of primer-dimer formation.  
• Avoiding primers with sequences that can be complementary to internal 
sequences of the amplicon 
• Primers with 18-25 bases have a greater chance of being unique in the genome 
than those with fewer bases. 
• Primers that match each other in melting temperature (Tm) so that both 
anneal at the same temperature. The Tm of the primers is defined as the 
temperature in which 50% of the oligonucleotide primers are bound to their 
complementary sequence and 50% separated into single-stranded molecules. 
The Tm depends on the primers’ length ie the number of nucleotides, and their 
sequence composition ie the number of guanines to cytosines and adenines to 
thymidines. The Tm can serve as a guide to the optimum annealing 
temperature, however, in practice this is usually by trial and error.  
• In order to minimise amplification of genomic DNA which can lead to false-
positive results, the primers can be designed to be exon-spanning (Tubbs and 
Stoler, 2009). 
 
The template 
RNA that is extracted from the tissue sample must be reverse transcribed into cDNA in 
order to serve as a template in PCR because Taq polymerase cannot transcribe RNA. 
The enzymes used are from retroviruses that integrate their RNA genomes into host 
genomic DNA. The reverse transcription (RT) step that precedes the main PCR reaction 
involves oligonucleotides that anneal to the template and can occur during a single 
temperature. When RT is combined with PCR it is called a one step RT-PCR reaction. 
This is where all the reagents needed for both RT and PCR are added to the same 
reaction mix. Two different enzymes ie DNA polymerase and reverse transcriptase use 
a DNA polymerase with reverse transcriptase activity eg rTth from the organism 
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Thermus Thermophilus. When manganese ions are present, reverse transcriptase 
occurs. The advantage of one-step RT-PCR over two-step PCR, where the reverse 
transcription is done in a separate reaction tube, is that the risk of contamination is 
reduced as the tube does not need to be disturbed.  
 
Another component of the PCR mixture is magnesium chloride required for activity by 
the DNA polymerase. It is bound by the polymerase and affects the Tm of the 
template, primers and PCR product. Buffer solution is also part of the reaction mixture, 
keeping the pH of the solution constant for the optimum function of the polymerase 
(Tubbs and Stoler, 2009). 
 
Once the desired amplicon has been amplified, there needs to be a way to detect the 
presence and amount of amplicon.  
 
1.7 Real-Time quantitative RT-PCR (RT-qPCR) 
 
Real-time quantitative RT-PCR combines PCR amplification with the detection of the 
amplicon. It is a tool that allows detection and measurement of products generated 
during each cycle. The amount of the amplicon produced is directly proportional to the 
amount of the template. Detection and monitoring of the amplicon can be done by 
using fluorescently-labelled oligonucleotide probes during amplification of the product 
ie in real-time. After each PCR cycle, the fluorescence can be measured either during 
annealing or at the end of the cycle depending on the chemistry used (Arya et al, 
2005). 
 
1.7.1 Hydrolysis probes 
 
Hydrolysis probes, also called Taqman probes, are dual-labelled oligonucleotides. They 
carry a reporter fluorophore at the 5’ end and a quencher molecule at the 3’ end. The 
quencher dye absorbs the light energy that is emitted from the reporter dye. When 
the probe binds to the target sequence during the annealing and extension steps, the 
DNA polymerase cleaves the 5’ end of the probe, releasing the reporter fluorophore. 
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This results in the emission of light from the reporter dye which is detected by the real-
time instrument. The amount of fluorescence is directly proportional to the amount of 
amplicon produced and the more target there is, the earlier the detection of the 
fluorescence occurs (Tubbs and Stoler, 2009). 
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Figure 10. The figures illustrates the sequence of events when the Taqman probe’s 
reporter dye is cleaved, resulting in the emission of fluorescence light which is 
detected by the instrument (DNA Vision, 2011). 
 
Multiplexing is when more than one marker is used in a single RT-PCR reaction. This is 
made possible by using different probe sets. However, the more markers that are 
detected, the more fluorochromes there are in the reaction mixture which might have 
a detrimental effect on the efficiency of the PCR. It has been recommended not to use 
more than four markers in a single reaction, otherwise the efficiency would be affected 
(Tubbs and Stoler, 2009). 
 
1.8 Amplification  
 
The intensity of the fluorescence from a PCR reaction can be plotted against the 
number of cycles to provide an amplification curve. There are certain properties of the 
amplification plot including the threshold, baseline, fluorescence emission and cycle 
threshold (Ct) or quantification cycle (Cq).  
 
The threshold level is in the early stage of the exponential growth phase and is 
arbitrarily chosen by the computer, being instrument and operator specific. It is 
calculated as ten times the standard deviation of the average signal of the baseline 
fluorescent signal between cycles 3 to 15. This threshold can be changed manually in 
experiments so that it is in the area of exponential amplification.  
 
The baseline is also arbitrarily set by the computer software to be between cycles 3 to 
15 and is defined as the cycles where the reporter fluorescent is below the detection 
level of the instrument during its initial accumulation (Arya et al, 2005).   
 
The Cq value is the number of cycles it takes for a set fluorescence intensity threshold 
to be reached. It is the cycle number at which the reporter fluorescence is greater than 
the threshold level which is the minimum detection level. The lower the Cq value, the 
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higher the amount of initial target and the higher the Cq, the lower the amount of 
target. 
 
The fluorescence emission is calculated by the computer software by subtracting the 
fluorescence emission of the baseline by the fluorescence emission of the product at 
each time point. These values are plotted against the cycle number. During the early 
stages of the amplification, the values do not exceed the baseline and then suddenly 
exponentially rises, crossing the threshold level ie the Cq point (Arya et al, 2005).   
 
 
 
Figure 11. The graph gives an example of a RT-PCR amplification curve from the 
LightCycler 2 instrument. It plots the fluorescence emission vs the number of cycles.  
 
1.9 Absolute and relative quantification and reference genes 
 
RT-qPCR can be used to quantify the amount of target produced, either by relative 
quantification or absolute quantification.  
 
Absolute quantification determines the amount of a target (expressed as a copy 
number or concentration) relative to a standard curve. The standard curve is the plot 
Cq 
value 
Amplification 
Plateau 
Baseline 
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of the log of initial target copy number for a set of known standards versus Cq. The 
standard curve is plotted as a straight line and can be calculated by computer software 
on RT-PCR instruments. The known target can be either a plasmid of the gene of 
interest, a single-stranded oligonucleotide for the entire amplicon or a cell line with a 
known copy number or expression level of the gene (Arya et al, 2005). 
 
Relative quantification determines the ratio between the amount of a target and the 
amount of a reference nucleic acid, usually a suitable reference gene (Arya et al, 2005). 
Mathematical equations are used to calculate the expression levels of the target gene 
relative to the reference control. The reference control could be RNA from normal 
tissue. The amount of gene target in the sample can be calculated by subtracting the 
Cq value of the reference gene from the Cq value of the target gene. In order for this 
method to be valid, the amplification efficiencies of both reference and target genes 
should be approximately equal. This can be determined if the Cq values of both genes 
vary with template dilution (Arya et al, 2005). 
 
Housekeeping genes, or reference genes, are genes that are involved in the basic 
functions needed for the cell to survive and are usually always expressed ie always 
turned on (Tubbs and Stoler, 2009). They lend themselves to act as internal controls in 
PCR reactions. Their expression should be constant across all tissues, in all stages of 
development and in different experiments. In PCR reactions, it can be used to 
normalize the reaction. In order to correct sample-to-sample variation caused by RNA 
volume differences, variable RNA quality or differences in efficiency of cDNA synthesis, 
the reference gene can be amplified along with the target gene. It serves as an internal 
reference whereby the RNA values can be normalised against. Examples of reference 
genes include glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β actin. The 
reference gene used as an internal control in the Metasin diagnostic assay is 
porphobilinogen deaminase (PBGD) as it is known to be present in every cell type.   It is 
thought that not one unequivocal reference gene has been found and that therefore, 
using several genes and their mean expression is best practice (Arya et al, 2005). 
 
1.10 Speed is an important factor of intra-operative real time RT-qPCR  
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RT-qPCR lends itself well to functioning as an intra-operative test. As well as accuracy 
of diagnosis and cost of the assay, speed is important. Surgeons will want an answer as 
soon as possible and anaesthetists will not want to delay the operation longer than 
necessary. As time is taken in transporting the material to be tested, every aspect of 
the test should be scrutinised to see if it could be speeded up. There are several ways 
in which to speed up a PCR reaction including using silicon columns and vacuum 
pressure for nucleic acid purification, changing the denaturation and extension times 
and reducing the ramp time by lowering the temperature used in the denaturation 
step for amplicons less than 100 base pairs (McPherson and Moller, 2006). 
 
The fastest method of purifying the nucleic acids after extraction is through applying a 
vacuum pressure and running the homogenate containing the nucleic acids through a 
column containing either silica, cellulose or other material. With a high salt binding 
buffer, the nucleic acids stick to the column and can be washed with a high salt buffer 
to remove any lysis buffer. It can then be eluted using a low salt solution or water.  
 
DNA polymerase enzymes and reverse transcriptases can add 20 to 100 bases per 
second, allowing the target RNA to be copied into cDNA in seconds. The PCR product 
can be replicated with short extension times. To speed up the PCR reaction, the time 
taken for extension can be reduced, especially for amplicons less than 120 base pairs, 
as well as the time taken for reverse transcription. Caution should be used not to 
jeopardise the sensitivity of the assay (McPherson and Moller, 2006). 
 
By using a PCR machine that can heat and cool the PCR mix quickly, ramping times 
between temperatures can be reduced. One of the fastest PCR instruments is the 
SmartCycler. Ramping times can also be reduced by lowering the temperature changes 
needed during cycling. Depending on the number of base pairs the amplicon has, the 
temperature can be lowered. However, during the first few cycles, the PCR target is 
cDNA which denatures at a high temperature, usually around 95°C. Therefore, the 
denaturation temperature can be dropped after the initial cycles (McPherson and 
Moller, 2006). 
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Other ways of reducing the time taken to run an intra-operative assay is to allow for 
analysis of the result during real-time so that once a result becomes obviously positive 
or negative, the user does not have to wait till the last cycle to communicate the result 
to waiting surgeons. By training laboratory staff to carry out the procedure, the assay 
can be run faster (McPherson and Moller, 2006). 
 
Ways of optimising PCR 
A reaction buffer containing potassium chloride and magnesium chloride is usually 
supplied by the manufacturer and the concentration of magnesium ions can be 
changed to optimise the reaction. The efficiency of the primers is important and their 
concentration can also be changed, as well as the concentration of the probes. The 
volume of template can be increased or decreased to try and improve the results 
(McPherson and Moller, 2006). 
 
1.11 Advantages of an intra-operative RT-PCR assay 
 
There are clinical situations in which an intra-operative diagnosis is required. As 
discussed earlier, morphological techniques such as frozen section and touch imprint 
cytology are used in such situations. However, these methods have variable sensitivity 
and specificity. An advantage of PCR assays is the high level of sensitivity, where 
theoretically only a few cells with the target RNA need to be present for the PCR assay 
to detect them. The morphology based tests can only allow representative 
examination of 2 dimensional structures of the tissue whereas PCR allows the whole 
tissue to be examined, reducing the chances of a tumour being missed. The results 
obtained from PCR assays are usually more objective, ie the target is either present or 
not, whereas histopathological assessment in difficult cases can be subjective. This 
may be even more marked in departments where there are inexperienced 
histopathologists reviewing the slides. The PCR assay also reduces the need for a 
Consultant Histopathologist to be on-call when the tissue comes in as the assay can be 
carried out by the biomedical scientist. 
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1.12 Disadvantages of an intra-operative RT-qPCR assay  
 
The specificity of the PCR assay depends on the choice of the target amplicon. Ideally, 
the amplicon needs to be specific for the particular tumour being tested for. 
Unfortunately, for most tumours there is not yet a universally accepted marker. The 
PCR assay may be too sensitive at times, picking up background expression of the 
marker being targeted that may have no clinical significance, for example detecting 
cytokeratin-19 (CK19) in lymph nodes with isolated tumour cells which have no clinical 
significance. A quantitative assay would help to measure the level of expression and 
distinguish it from the background expression. Another potential problem with PCR for 
some Histopathologists is the absence of a morphological picture to accompany the 
PCR diagnosis. With no histology to validate the assay test, the PCR test would have to 
be trusted. Ways of getting around this is to take part of the tissue for 
histopathological assessment and the other part for the assay. However, this could 
lead to sampling errors if the desired target is in only one part of the tissue. 
Contamination is also a problematic issue if it is introduced into the reaction. The 
source of the contamination could be due to neighbouring tissue being introduced to 
the tissue being tested, using the same cutting instrument between different tissues 
and not swapping gloves between handling different tissues and preparing the PCR 
mixture, as well as other ways of contamination. The assay would not be able to 
differentiate between contamination and a true result. Other issues such as cost may 
be a factor in some situations, especially if the assay only supplements and does not 
replace other intra-operative diagnostic tests (Tubbs and Stoler, 2009).     
 
1.13 Markers for detecting metastatic breast cancer in lymph nodes  
 
One of the most important aspects of a PCR assay is the choice of marker and the 
design of the primers.  A suitable marker for metastatic breast cancer should not be 
present in normal lymphoid tissue and should also be present in breast cancer that has 
metastasised. As RT-qPCR is becoming widely accepted as an intra-operative diagnostic 
tool, there have been numerous studies that have searched for and tested suitable 
markers. 
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1.13.1 Technical approaches to identifying overexpression of genes  
 
There are several tools used in identifying genes that are overexpressed in certain 
tumours. If a gene was found to be expressed in a tumour or normal tissue of interest, 
then it could potentially become a marker for the tumour or normal tissue in a RT-
qPCR assay. One of these tools, the microarray, was described in section 1.4.1. 
However, there are certain drawbacks to this method of identifying candidate genes. It 
relies on hybridization of the sample mRNA to oligonucleotides or DNA fragments. 
These must be in greater excess than the mRNA of the sample. The more genes the 
microarray has, the more difficult it is for all the mRNA to hybridize, leading to a false 
impression of its quantity. Cross-hybridization is also a problem if two mRNAs contain 
similar sequences and they bind to the same probe. Another method of identifying 
genes of interest and that avoids the problem of microarrays is DNA sequencing 
(Watson, 2007). Sequencing is any method that determines the order of bases in a 
DNA fragment (Bruns et al, 2007). The Sanger method is the commonest method of 
DNA sequencing. It involves a PCR reaction to produce complimentary strands (cDNA) 
of the target area using primers. Four PCR reaction mixes are prepared, each 
containing regular dNTPs and one of four dideoxynucleoside triphosphate (ddNTP), a 
chain terminating nucleotide. The ddNTPs lack a 3’OH group needed to form a 
phosphodiester bond between two nucleotides, thereby terminating the DNA 
extension. Extension starts at the same location but finishes at different locations. A 
low concentration of ddNTP results in fragments of DNA up to 1000 base pairs whereas 
reaction mixes with a higher concentration of ddNTP would result in shorter DNA 
fragments. At the end of the PCR reaction, different length strands of DNA are present, 
all terminating in the ddNTP that was present in the reaction mix. Determining the 
sequence of a large segment of DNA involves generating many short sequence reads 
from overlapping sections of DNA. A gel is then used with each of the four reactions 
run in one lane where the DNA fragments are separated by size. The DNA sequence 
can then be directly read off the gel or analysed by a computer. By sequencing part of 
the genome of a breast cancer tumour cell, new genes can be identified which could 
possibly be candidates as molecular markers. cDNA libraries are freely available to any 
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researcher wishing to use the genetic sequence of a target of interest. Expressed 
sequence tags (ESTs) are small (200-500bp) sequences of DNA generated by either one 
or both ends of an expressed gene. mRNA is reverse transcribed into cDNA. As the 
mRNA contains only the exons of genes that are being expressed by the cell, it is the 
cDNA that is sequenced. The result are ‘tags’ of DNA sequences that are expressed by 
the target which can be stored in publically accessible databases. Researchers can use 
the frequency of ESTs for each gene as an estimate of the expression level of that 
gene. The limitation with using EST databases is that the researcher is limited to the 
tissues and cells that were analysed previously in EST projects. Despite this, ESTs have 
been invaluable in helping to map the human genome and identifying new gene 
targets in hereditary diseases (National Centre for Biotechnology Information, 2010). 
Finally, another sequence-based technique, serial analysis of gene expression (SAGE) 
allows the study of gene expression in a variety of cells. Like microarray analysis, SAGE 
is a method of quantitatively measuring the expression levels of all transcripts 
expressed by a cell. In tumour cells, this would highlight all the genes expressed by 
them. Where SAGE differs from microarrays, is that there is no hybridization involved 
and therefore no risk of cross-hybridization. It also allows new genes to be discovered 
(National Centre for Biotechnology Information, 2010). There are several main steps. 
First, the mRNA of the cell of interest are bound to beads containing oligo(dT) and 
reverse transcribed into cDNA. Then the cDNA is cleaved by a restriction enzyme, 
leaving the 3’ end attached to the bead. Another restriction enzyme is applied which 
recognises a particular site and cleaves a few bases from it. This releases the tags from 
the sequence which can then be concatenated ie cloned into a vector plasmid, and 
finally sequenced. The abundance of each tag is quantitated allowing the mRNA 
abundance to be known. The genomes of normal and cancerous cells can be compared 
(Watson et al, 2007). In one instance where SAGE has been used in breast cancer, four 
different tumour progression stages were studied (Porter et al, 2001) where it was 
found that the most consistent and dramatic changes in gene expression was the point 
where normal mammary epithelium changes to ductal carcinoma-in-situ (DCIS). The 
genes identified in this transition may become markers for targeted therapy.  
 
1.13.2 Markers identified for breast cancer 
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Various studies have been carried out to try and identify optimum markers for 
detecting breast cancer in a tissue using PCR (Min et al, 1998 and Bostick et al, 1998). 
One such study was carried out by Backus et al (2005) in conjunction with Veridex, the 
makers of the GeneSearch breast lymph node assay. In this study, the investigators 
used microarray analysis, EST libraries and primary literature searches to identify 
candidate markers for diagnosing the presence of metastatic breast cancer cells in 
lymph nodes. EST libraries for normal breast tissue, breast tumour and peripheral 
blood were searched providing several hundred thousand genes. These were whittled 
down by ruling out breast genes that were also found in peripheral blood and those 
that had a low expression in breast tissue or breast tumour. The breast ESTs were then 
compared to ESTs found in colon, lung and ovarian libraries and if any matched, they 
were eliminated.  A literature search was then conducted to see if any of the markers 
were known or thought to be breast tissue or breast tumour specific and given a 
higher priority. Microarray analysis was then employed and the expression levels of 
the probe sets were measured in the RNA samples of various tissues including breast, 
colon, lung, ovary, prostate and blood. The best candidates with the highest 
expression in breast tissue were selected for further testing using RT-PCR on various 
tissues. Those that passed this initial PCR test were then validated using sentinel lymph 
node tissue. Seven markers in all were identified out of the initial several hundred 
thousand candidate markers. They included Mammaglobin (MGB), CK19, PDEF, PIP, 
B305D, GABA and B726. The investigators wanted to identify two or more genes that 
were the most sensitive and specific for metastatic breast cancer. After further testing 
using RT-qPCR, it was found that the optimum markers were a combination of CK19 
and MGB when compared to histology, initially with 90% sensitivity and 94% 
specificity. It had a positive predictive value (PPV) of 85% and a negative predictive 
value (NPV) of 96%. At least three genes were found to be significantly expressed in 6% 
(11 out of 183) of pathology-negative patients and a specificity of 94% was chosen for 
assessing the sensitivity of individual and combination markers.  
 
Out of 254 sentinel lymph nodes tested, 64 were found to be positive for both CK19 
and MGB and histopathological assessment. 172 were found to be negative by both. 
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Regarding the discordant samples, 11 were negative for histology and positive for 
CK19/MGB and 7 were positive on histology and negative for CK19/MGB. The 
investigators describe 5 of the 7 ‘false-negative’ samples as having micrometastases on 
histology, attributing sampling error for the discordance. They also believed the 11 
‘false-positives’ were metastases missed on histology. They arrived at this conclusion 
by comparing the expression of CK19/MGB of these samples to known positive nodes 
and found the level of expression was comparable. They were also positive for the 
other markers being tested. Further histopathological examination of one of these 
samples found the node did contain metastases. On further testing of these discordant 
samples, it was found that the sensitivity of CK19/MGB was 91%, the specificity 97%, 
PPV 93% and NPV 96%. Using statistical analysis, the cut-offs were determined for 
MGB at Cq 31.7 and CK19 at 30.9. In summary, the study identified the markers CK19 
and MGB (90% sensitivity and 94% specificity) as the optimum combination to detect 
metastatic breast cancer from several hundred thousand potential markers by 
employing a genome-wide search using several filters. Previous studies have also 
found these markers to be potential candidates for diagnosing metastatic breast 
cancer (Gillanders et al, 2004, Mitas et al, 2001, Manzotti et al, 2001 and Brown et al, 
2006).   
 
Based on the findings of the study by Backus et al (2005), CK19 and MGB were chosen 
to be the markers for the Veridex GeneSearch assay, with PBGD chosen as the 
reference gene. 
 
1.13.3 Cytokeratin 19 (CK19) 
 
Cytokeratins are intermediate filament proteins which are components of the 
cytoskeleton of all epithelial and some non-epithelial cells, providing mechanical 
support. There are two types of cytokeratins, basic type 2 (cytokeratins 1-8) and acidic 
type 1 (cytokeratins 9-23). Each type 1 pairs with a type 2 cytokeratin so that all 
epithelial cells have two different types of cytokeratin, except CK-19 which does not 
pair with another cytokeratin. They can also be classified according to their size as high 
or low molecular weight cytokeratins. CK-19 is the lowest molecular weight 
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cytokeratin. There are twenty different types of cytokeratin and they are used in the 
diagnostic work-up of tumours, aiding in identifying carcinomas. CK-19 is found in a 
variety of tissues including glandular-type epithelium, such as breast and colon. They 
are useful in confirming whether a metastatic tumour is of epithelial origin (LaCroix, 
2006). In lobular carcinoma, some histopathologists use a pancytokeratin marker to 
identify metastatic tumour cells which can be difficult to pick up from the background 
lymphoid cells. 
 
False-positivity has been known to be a problem when using CK19 in RT-PCR. Four 
sources of potential false positivity are: 
 
Illegitimate transcription  
Small amounts of mRNA may be expressed by genes that have no physiological role in 
the cell or tissue. It is thought that every promoter can be activated by ubiquitous 
transcription factors with an estimate of one tumour marker expressed in 500-1000 
non-tumour cells (Zieglschmid et al, 2005). PCR is very sensitive, theoretically being 
able to amplify one transcript in a single cell and so it would be beneficial to have a Cq 
cut off to help decide whether a tissue is positive or negative for ck19. A breast-specific 
marker, such as Mammaglobin (MGB), with CK19 in an RT-PCR assay can help in 
providing more specificity. 
 
Haematological disorders  
When using CK19 in testing peripheral blood for disseminated tumour cells, its 
expression can be induced by cytokines and growth factors. These are found to 
circulate at higher levels in inflammatory conditions leading to a higher risk of false-
positive results (Ring et al, 2004). 
 
Pseudogenes 
These are defined as a gene that does not result in a functional gene product, usually 
as a result of accumulated sequence changes (Bruns et al, 2007). Two pseudogenes for 
CK19, CK19a and CK19b, have been described as having significant sequence homology 
to CK19 mRNA. Therefore, it is important to design the primers well in order to avoid 
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amplifying pseudogenes leading to a false-positive result (Savtchenko et al, 1988 and 
Ruud et al, 1999). 
 
Contamination  
This is more likely to occur when testing peripheral blood and occurs when epithelial 
cells, for example from skin, could be introduced when taking the sample. This error 
could be minimised by discarding the first sample and testing the second sample of 
blood (Lacroix, 2006). 
 
CK19 has been shown to be more sensitive in detecting metastases in lymph nodes 
than routine histopathological assessment (Noguchi, 1996). There have been many 
studies that use CK19 in a multigene panel and most have shown that CK19 should be 
included in any assay used to detect breast cancer metastases in lymph nodes (Lacroix, 
2006). 
 
1.13.4 Mammaglobin (MGB) (Secretoglobin family 2A, member 1, SCGB2A2) 
 
MGB is a member of the secretoglobin superfamily which also includes uteroglobin 
(Clara cell protein), lymphoglobin and the lipophilins A, B (BU101) and C (lacryglobin, 
mammaglobin B). In breast tissue, MGB is secreted as a glycosylated peptide which is 
covalently associated with lipophilin B. Its function in normal breast tissue is unknown, 
as is its aetiology in breast cancer (Sjodin, 2003). 
 
This marker was discovered by Watson and Fleming and was claimed to be breast 
tissue specific, confined only to the mammary glands. Its expression was also found to 
be independent of tumour stage, grade or histology (Watson and Fleming, 1996, 
1999). However, MGB has since been found to be expressed in other tissues including 
sweat glands in skin, normal uterus, salivary glands, kidney, testis, cervix and rarely in 
other tissues such as thyroid and ovarian tissue (Lehrer et al, 1998, Carter et al, 2002, 
O’Brien et al, 2002 and Zehentner et al, 2002). One study found MGB to be present in 
gynaecological tissues including cervix, uterus and ovary (Zafrakas et al, 2006). MGB 
was also found to be present in only 23% of 35 breast tumour samples (Watson and 
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Fleming, 1996). This could be explained by the finding by O’Brien et al (2005) that 
tumours with a high grade (grade 3) lacked MGB expression. Despite this, MGB has 
been reported to be the most accurate, breast-specific marker by several studies 
(Lacroix, 2006). Gillanders et al (2004) tested MGB, MUC1, CEA, PSE, CK19 and PIP for 
possible candidates in an RT-PCR assay for detecting breast cancer and found MGB to 
be the most informative marker from the panel. It was the most sensitive marker, 
expressed in 114 out of 126 (90.5%) patients found positive by histopathological 
assessment and molecular analysis. They also concluded that the best panel of markers 
would include MGB, CEA, PIP and CK19. However, multiplexing four markers would be 
difficult to achieve without adversely affecting the PCR efficiency (Gillanders et al, 
2004). Another smaller study found MGB expression to be positive in all 13 histology-
positive lymph nodes and negative in 7 histology-negative nodes (Leygue, 1999).  
 
1.14 GeneSearch assay by Veridex  
 
For the intra-operative diagnosis of metastatic breast cancer in sentinel lymph nodes, 
the GeneSearch assay by Veridex was developed, trialled in several pilot sites and 
implemented until 2009 when it was withdrawn due to financial reasons. It was a 
highly successful assay, with high sensitivity and specificity (Blumencraz et al, 2007, 
Mansel, 2008 and Martin Martinez, 2008).      
 
The GeneSearch assay by Veridex is a RT-qPCR intra-operative molecular diagnostic 
tool used to confirm the presence or absence of metastatic breast cancer in sentinel 
lymph nodes. It does this by detecting the expression of the two aberrant genes, 
cytokeratin-19 (CK19) and mammaglobin (MGB), in the sentinel lymph node tissue. 
Normally, these two genes should not be expressed in lymph node tissue and their 
detection confirms the presence of metastatic breast cancer. PBGD is used as the 
reference gene. A result is expected in less than 45 minutes. The cut off values for 
whether a tissue sample is valid ie detects PBGD, and whether it is positive for either 
or both CK19 and MGB is defined by the assay as:   
 
MGB positive for a Cq value less than or equal to 31 
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CK19 positive for a Cq value less than or equal to 30 
PBGD positive for a Cq value less than 36 
 
There have been several studies comparing the accuracy of the GeneSearch assay with 
histopathological assessment. The findings of each study, including the overall 
sensitivity and specificity of the assay, is summarised in the table below.  
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Study group Number 
of nodes 
(patients) 
Positive 
nodes*(% 
of total) 
Negative 
nodes * (% 
of total) 
Number of 
discordants 
(% of total) 
Sensitivity 
% (patient 
basis) 
Specificity 
% (patient 
basis) 
Viale et al, 
2008 
293 (293) 56 (19.1) 210 (71.7) 27 (9.2) 77.8 95 
Mansel et al, 
2008 
124 (82) 8 (6.5) 110 (88.7) 6 (4.8) 88.9 94.6
Martinez et 
al, 2008 
123 (78) 12** 
(15.4) 
63**(80.8) 3** (3.9) 92 97
Tafe et al, 
2009 
72 (59) 13 (18) 54 (75) 5 (6.9) 88.9 93.5 
Funasako et 
al, 2010 
196 (117) 26 (13.3) 157 (80.1) 13 (6.6) 85.1 Not given 
Yan-Hui Liu 
et al, 2010 
158 (97) 26** 
(26.9) 
63**(65) 8** (8.2) 83.9 95.5 
Somasundar
am et al, 
2011 
266 (166) 47 (17.6) 205 (77.1) 14 (5.3) 100 87.1
Cutress et al, 
2010 
467 (256) 69** 
(26.9) 
175** 
(68.3) 
12** (4.7) 96 95 
Veys et al, 
2009 
(250)** 37** 
(14.8) 
195**(78) 18** (7.2) 94 93
Table 1. A summary of each study including their sensitivity and specificity. 
*Both histological assessment and molecular assessment were in concordance 
Detection of ITC in either assay is considered to be negative as it has no clinical significance 
** These are the number of patients in the study as the node number was not given 
 
Some studies have given their results either by counting the nodes or the patients. In 
those studies where the number of nodes were given, the overall sensitivity and 
specificity of the GeneSearch assay is 87.8% and 92% respectively (total number of 
nodes = 951). For those studies that have given the number of patients only, the 
overall sensitivity and specificity of the assay is 93.1% and 94.3% respectively (total 
number of patients = 681). 
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The reason for a higher sensitivity and specificity of the assay when on a patient basis 
is that some patients may have two nodes of which both are positive for metastasis on 
histology. However, the assay may have only picked up one node. Therefore, on a 
patient count, the result is positive, however, one node was missed leading to a lower 
sensitivity on a node basis. 
The results, when compared to the overall sensitivities and specificities to 
conventional intra-operative methods, show a higher sensitivity and a slightly lower 
specificity.  
 
The table below shows a more detailed analysis of the discordants found in the 
studies.   
 
Study group Histology 
positive 
(macro)/GS 
negative 
Histology 
positive 
(micro)/GS 
negative 
Histology 
negative/GS 
positive 
Total number of 
discordant 
nodes (% of 
total nodes) 
Viale et al, 2008 1 15 11 27 (9.2) 
Mansel et al, 
2008 
0 1 5 6 (4.8) 
Martinez et al, 
2008 
0 1** 2** 3** (2.4) 
Tafe et al, 2009 1 0 4 5 (6.9)
Funasako et al, 
2010 
1 2 10 13 (6.6) 
Yan-Hui Liu et al, 
2010 
0 5 3 8** (5.1)
Somasundaram 
et al, 2011 
1 2 11 14 (5.3)
Cutress et al, 
2010 
0 2 10 12** (2.7)
Veys et al, 2009 1 4 13 18** (7.1) 
Table 2. A summary of the discordants of each study. 
GS = GeneSearch assay 
82 
 
** These are the number of patients in the study as the node number was not given 
 
The table shows that macrometastases are rarely missed, with four studies out of nine 
showing no discordance and five having either one case or one node with 
macrometastasis missed. Micrometastases were more commonly missed and all the 
studies attribute the most likely cause as sampling error where the metastasis was 
only in the slices given to histology. Micrometastases are by definition between 0.2mm 
and 2mm and as the node is sliced into 2mm slices, it is reasonable to assume that a 
whole focus could be in only one slice which could be given to histology. In practice, it 
is difficult to accurately slice a fresh lymph node into 2mm and consequently larger 
slices may be cut.  
 
For those cases or nodes which were found positive with GeneSearch and negative on 
histology, there is no way of confirming it histologically, however, the most likely 
conclusion to reach is again of sampling error, especially if the Cq value of the 
discordant node is high, indicating a micrometastasis. One hundred percent 
concordance is not possible due to the nature of sampling the tissue between the two 
tests. A certain discordance rate is inevitable. To investigate further GeneSearch assay-
positive and histology-negative nodes, serial sectioning and IHC can be performed to 
determine whether there are any metastases, vindicating the GeneSearch assay result. 
Several investigators did this and found between 1-3 lymph nodes that were previously 
negative on histology to be converted to node positive. In cases where a 
macrometastasis is found on histology and is negative on the with the GeneSearch 
assay, the investigator should be prompted to repeat the assay to rule out any human 
error. It is less likely that a sampling error could occur unless the deposit is just larger 
than 2mm eg 2.1mm, or the slices were cut particularly thick at cut-up. Overall, the 
conclusion of each of these studies was that the GeneSearch assay was a suitable tool 
for the intra-operative detection of metastatic breast cancer, with the sensitivity 
better than conventional intra-operative techniques. 
 
1.15 Conclusion 
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In summary, molecular pathology is the future of medicine, allowing patient-centred, 
targeted therapy, accurate diagnostic tools, tumour subtyping and prognostic 
information to be possible and improved on. By understanding the biology of the 
tumour and its associated genetic alterations and mutations, dozens of advances can 
be made in diagnosing, treating and monitoring cancer patients. Breast cancer is no 
exception, with advances in tumour subtyping, prognostic information and diagnosis of 
tumour spread to lymph nodes bringing in molecular pathology at a practical level.  
 
Accurate intra-operative assessment of sentinel lymph nodes was regarded as a 
valuable advancement in patient care, avoiding second operations for patients found 
to have a positive node. Thus, the withdrawal of GeneSearch left a gap in the service.  
 
1.16 Aim of the project 
 
The aim of this project was to develop and validate an alternative method for sentinel 
lymph node analysis. This assay has been named Metasin.  
 
The specific objectives are:  
1. Extracting RNA from homogenates 
2. Setting up a PCR reaction mixture with suitable primers and probes 
3. Optimising the RT-qPCR reaction 
4. Validating the assay and comparing the results to the GeneSearch assay 
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PART II. MATERIALS AND METHOD 
 
Chapter 2   
 
Unless otherwise stated, all practical work was largely carried out by myself with 
guidance and support from Dr Sai-Giridhar and Mrs Mascall. 
 
This chapter describes the methods employed in setting up the Metasin assay. A 
detailed inventory of the materials is provided in the appendix pg 189. The first step in 
setting up the assay was the acquisition of suitable primers and probes for the three 
markers CK19, MGB and PBGD. The first thermocycler instrument used was the 
LightCycler 480 (LC480) (Roche). The machine is capable of testing up to 100 samples 
and was chosen to optimise and validate the assay initially. The appropriate 
recommended Roche RT-PCR kit was used and the initial optimising runs were carried 
out. This involved changing the primer and probe concentrations and the template 
volume. Once the Cq values of the samples run on the LC480 matched closely those of 
the GeneSearch assay, validation began. The most important characteristic of an intra-
operative assay is the speed of the assay. Despite attempts to try and speed up the 
time taken to reach results, the run time could not be reduced to an acceptable time 
of less than 26 minutes for one node. The faster SmartCycler (Cepheid) thermocycler 
was chosen to replace the LC480. The assay was then optimised again on the different 
platform and a faster run time achieved. Once comparable Cq values were obtained, 
the homogenates of all nodes were run and the results statistically analysed and 
compared to the GeneSearch results. Cut-off values for negative and positive nodes for 
all markers were established and the in-house assay, Metasin, was run alongside 
GeneSearch, eventually replacing GeneSearch and providing a diagnostic service.  
 
2.1 Ethical approval and Patient selection 
 
All patients undergoing sentinel lymph node biopsy for breast cancer during the period 
2009 to mid 2010 at Princess Alexandra Hospital were approached to consent to be 
part of this study. The inclusion criteria were patients undergoing a surgical excision of 
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a primary operable breast cancer and sentinel lymph node sampling. No exclusion 
criteria were named.  
The study was carried out after approval by Essex 2 Research Ethics Committee (Ethics 
Approval Reference: 07/H0302/129). 
  
2.2 Primer and Probe design 
 
The National Centre for Biotechnology Information (NCBI) GenBank sequence database 
(National Centre for Biotechnology Information, 2009) was interrogated to obtain 
accession numbers for the markers. PBGD accession number NM_000190, CK19 
NM_002276 and MGB NM_002411.  
 
To generate suitable primers for our markers CK19, PBGD and MGB the Roche 
Universal Probe Library (UPL) website was used (Roche, 2009). The suggested 
program-designed primer sequences are shown in table 3.  
 
Marker Probe Forward primer Reverse primer
PBGD probe # 26  tgtggtgggaaccagctc tgttgaggtttccccgaat
CK19 probe # 71 gccactactacacgaccatcc caaacttggttcggaagtcat
MGB probe # 71 ctcccagcactgctacgc tgtggattgattgtcttggaaa
Table 3. Shows the forward and reverse primer sequences for the markers from UPL 
 
The program-designed UPL primers and FAM-labelled probes were used in the initial 
optimisation process of the Metasin assay on the LC480 platform. During the 
optimisation process, it was decided that the primers should be multiplexed in order to 
improve the efficiency of the assay. To multiplex the primers, each one should be 
labelled with a different fluorochrome. Since we did not have access to the Roche 
probe sequences, it was decided to design our own probe sets. The UPL primer 
sequences, along with their marker accession numbers, were sent to TIB MOLBIOL, a 
company expert in designing and manufacturing quality oligonucleotides. The probes 
were made based on the amplicons generated by the primers. The sequences of the 
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probes and primers designed by TIB MOLBIOL and used in the Metasin assay on the 
LC480 are shown in table 4.  
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Table 4. Tib MolBiol-manufactured forward and reverse primer combination sequences, probe sequences, dye label and amplicon 
              length. 
Marker Probe  Probe label Forward primer 5’ to 3’ Reverse primer 5’ to 3’ 
 
Amplicon length 
PBGD ctcctgaactccagatgcggga cyan 500 tgtggtgggaaccagctc tgttgaggtttccccgaat 92 
CK19 cagccagacgggcattgtcg LC610 gccactactacacgaccatc caaacttggttcggaagtcat 128 
MGB ctctggctgccccttattggag LC670 ctcccagcactgctacgc ggattgattgtcttggaaa 69 
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The primer sequences given by the UPL website and the primer sequences developed 
by Tib MolBiol differ by a few bases. The primer annealing temperatures ranged from 
56.2°C to 57.9°C. The primers were designed to be intron-spanning to avoid amplifying 
and detecting contaminating genomic DNA. 
The full list of the DNA sequence for each gene and the location of the primers is 
available in the appendix (pg 193).  
 
While optimising the assay on the LC480, the length of time for the RT-PCR was found 
to be approximately 45 minutes. Despite attempts to try and reduce the run time, the 
time taken for a result was far too long to be acceptable for the clinicians and 
surgeons. Therefore, it was decided to switch the assay to the SmartCycler platform in 
order to improve the speed of the assay. The same primers and probes used on the 
LC480 were also used for the Metasin assay on the SmartCycler.     
 
2.3 Processing tissue for histology 
 
During the intra-operative setting, the sentinel lymph node or nodes arrive in the lab 
where they are booked in and given a lab number allowing the sample to be identified.  
The Consultant Pathologist clears any excess fatty tissue and slices the node into 2mm 
slices. Alternate slices are then given to the Metasin assay and to histology. 
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Figure 12. Slicing and allocation of the sentinel node with alternate slices given to 
histological assessment and the Metasin assay 
 
The slices for histology are placed singly in cassettes and processed per normal 
procedure. After the tissue is fixed in formalin, it is placed in a tissue processor and 
washed first in 70% alcohol and then 100% alcohol for five cycles. It is then washed 
with xylene three times and impregnated with wax. The tissue is then taken to the 
embedding stage where it is orientated and embedded in wax moulds ready for cutting 
into thin slices to place on a slide. 
 
Each block is cut to have three levels. The first level is the first full-face of the slice. 
Then four serials are cut which are kept as spares in case of further work being needed 
such as Immunohistochemistry or levels. Two more levels are cut and after each level 
four serials are cut. 150 microns are cut to get the second and third levels and 2 
microns for each serial.  
HISTOLOGY 
METASIN PCR ASSAY 
2 3 4 5 6 71 
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Trim to reach full-face 
First full-face = Level 1 
2um = serial 1 
2um = serial 2 
2um = serial 3 
2um = serial 4 
150um = Level 2 
2um = serial 1 
2um = serial 2 
2um = serial 3 
2um = serial 4 
150um = Level 3 
2um = serial 1 
2um = serial 2 
2um = serial 3 
2um = serial 4 
 
The slides are then heated in an oven, stained with H&E and a coverslip placed.  
 
2.4 The RNA extraction, PCR preparation and optimisation process on the LC480 
 
This section describes the steps taken to extract RNA for use in the assay on the LC480. 
Steps in preparing the PCR mix for use with cDNA in two-step PCR and RNA in one-step 
PCR are given as well as the steps taken to prepare the primers and probes for 
monoplex and multiplex runs. The optimisation process is detailed, including changes 
in primer, probe and template concentrations and running a dilution series. Finally, 
attempts to reduce the time of the run protocol are described.     
 
2.4.1 RNA extraction using GeneSearch materials 
 
The RNA used for the assay on the LC480 platform was the same RNA previously 
extracted from sentinel lymph nodes to be run on the GeneSearch assay. Therefore, 
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the method of RNA extraction described in this section is the same protocol as that of 
the GeneSearch Breast Lymph Node (BLN) test kit (Veridex, LLC, Warren, NJ).   
 
On receipt of a new kit, certain preparation of the working reagents are carried out. To 
prepare working homogenization buffer (contains ≥ 25% guanidine thiocyanate), 
1.0mL of β-mercaptoethanol, 14.3M (Calbiochem) is added to one bottle of 100mL 
homogenization buffer. Working wash buffer 2 is prepared by adding 8mL of absolute 
200-proof ethanol (Sigma-Aldrich) to the bottle and mixing well.    
 
The lymph node is sliced into 2mm slices with alternating slices going to the assay for 
the LC480 and to conventional histology. The lymph node tissue slices allocated to the 
assay is weighed. The tissue is next diced into small pieces and then added to 
homogenization buffer.  The volume of homogenization buffer to add is dependent on 
the weight of the tissue. The full table showing the volume of homogenization buffer 
to be added according to tissue weight is available in the appendix (pg195). 400µl of 
70% ethanol (Sigma Aldrich) is added to 400µl of the homogenate and mixed 
thoroughly by vortexing.  A certain volume of the homogenate-ethanol mixture is then 
transferred to a RNA spin column (GeneSearch) attached to a vacvalve onto a vacuum 
manifold. The volume of homogenate-ethanol mixture to be transferred to the RNA 
spin column is dependent on the weight of the tissue. The full table is available in the 
appendix (pg 196). The vacuum is maintained between 800-1000 mbars until the 
sample is filtered and the vacuum is turned off. 700µl of wash buffer 1 is added to the 
column and the vacuum turned on again until the buffer is filtered. 700µl of wash 
buffer 2 is next added to the spin column and the vacuum turned on again until the 
mixture is filtered. The columns are then removed and centrifuged for 30 seconds at 
greater than 10,000RPM in a microcentrifuge. The old centrifuge tube is discarded and 
the spin column placed in a new collection tube. 50µl of RNase-free water 
(GeneSearch) is added directly onto the filter membrane of the column. The column is 
then centrifuged for 30 seconds at greater than 10,000 RPM. The column is discarded 
and the collection tube contains 50µl of eluted RNA.  
 
2.4.2 RNA to cDNA conversion (2 step RT-PCR) 
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The steps taken to convert RNA to cDNA are followed in the QuantiTect Reverse 
Transcription Handbook (Qiagen). 
 
Two mixtures are made for the conversion. The first mixture is involved in eliminating 
genomic DNA and contains gDNA wipeout buffer. The second mixture performs the 
reverse transcription step and contains Quantiscript reverse transcriptase (contains 
RNase inhibitor), Quantiscript RT buffer (contains Magnesium and dNTPs) and RT 
primer mix.  
 
The vials containing the gDNA wipeout buffer, Quantiscript Reverse Transcriptase, 
Quantiscript RT Buffer, RT Primer Mix and RNase-free water are thawed, mixed by 
flicking and spinning and stored on an ice block.  
 
Table 5 shows the volume of each reagent for one reaction 
 
Reagent Volume/reaction (µl)
gDNA wipeout buffer, x7 2 
Template RNA 5 
RNase-free water 7 
Total reaction volume 14 
Table 5: Genomic DNA elimination reaction components for one reaction 
 
The reagents are added to a labelled microfuge tube (Aldrich) and incubated at 42°C 
using a waterbath for 2 minutes and then put on ice. 
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The volume of each reagent for the reverse-transcription mastermix is shown in table 
6. 
 
Reagent Volume/Reaction (µl)
Quantiscript reverse transcriptase 1
Quantiscript RT buffer, 5x 4 
RT primer mix 1
Template RNA (see table x) 14 
Total reaction volume 20
Table 6: Reverse-transcription reaction components for one reaction 
 
The microfuge tube containing the reverse-transcription reaction components is 
incubated at 42°C for 15 mins and at 95°C for 3 mins to inactivate Quantiscript reverse 
transcriptase.  
The microfuge tube now contains cDNA which can be used on the LC480 or stored in 
the -20 °C freezer. 
 
2.4.3 Creating the PCR mix for the LC480 platform using cDNA template in 
            two-step RT-PCR 
 
The PCR mix was prepared by following the steps in the LightCycler 480 Probes Master 
kit insert (Roche). The probes two times master mix vial contains FastStart Taq DNA 
Polymerase, reaction buffer and dNTP mix (with dUTP) and 6.4 mM MgCl2 (Roche). 
 
Table 7 shows the volume of each reagent for one reaction 
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Reagent Volume/Reaction (µl)
LightCycler 480 Probes Master, 2x conc 10
Primer-Probe mix, 10x conc 2 
RNase-free water 3 
Total volume 15
Table 7: The volume of each reagent for one reaction using cDNA template on the 
LC480 
 
The primer-probe mix is prepared by diluting the stock of 100µM of primers and the 
stock of 10µM of probes with RNase-free water to 10µM and 1µM respectively. 10µl of 
each primer and probe is added to a single microfuge tube and 10µl of RNase-free 
water added to bring the total volume to 100µl. The final concentration of each primer 
is 1.0µM and of each probe is 0.1µM. 
  
The PCR mix is mixed by pipetting up and down and 15µl added to each well of the 
LightCycler 480 multiwell plate. 5µl of cDNA template is added to each well. The 
multiwell plate is sealed with LightCycler 480 sealing foil and loaded into the LC480. 
 
The run protocol used on the LC480 when using cDNA is shown in table 8. 
 
Program Temperature (°C) Hold (seconds) Number of cycles 
Pre-incubation 95 300 1
Amplification 95 10 45
 60 30
 72 1
Cooling 40 10 1
Table 8: The run protocol on the LC480 in two-step RT-PCR 
   
2.4.4 Creating the PCR mix for the LC480 platform using RNA template in 
one-step RT-PCR 
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When using RNA on the LightCycler 480, the LightCycler 480 RNA Master Hydrolysis 
Probes kit (Roche) was used. The LightCycler 480 RNA Master Hydolysis Probes reagent 
and the Activator reagent are aliquoted into smaller volumes in separate microfuge 
tubes in order to avoid repeated freezing and thawing. The LightCycler 480 RNA 
Master Hydrolysis Probes reagent, 2.7 x concentration, contains Tth DNA polymerase, 
reaction buffer, MgCl₂ and dNTP mix with dUTP. The Activator, 50mM, contains 
Mn(OAC)₂.  
 
Table 9 shows the volume of each reagent for one reaction 
 
Reagent Volume/Reaction (µl)
LightCycler 480 RNA Master Hydrolysis Probes, 2.7x conc 7.4
Primer-Probe mix, 10x conc 2
Activator 1.3
RNase-free water 7.3
Total volume 18 
Table 9: The volume of each reagent for one reaction using RNA template on the LC480 
 
The primer-probe mix used in the pilot runs was prepared by diluting the stock of 
100µM of primers and the stock of 10µM of probes with RNase-free water to 10µM 
and 1µM respectively. When performing monoplex runs, 10µl of the forward and 
reverse FAM-labelled primers and 10µl of the probe of the marker is added to 70µl of 
RNase-free water to make 100µl containing 1µM of primer and 0.1µM of probe. When 
multiplexing the three sets of primers and probes designed by TIB MOLBIOL, 10µl of 
each primer and probe and 10µl of RNase-free water is added to a single microfuge 
tube to bring the total volume to 100µl. The final concentration of each primer is 
1.0µM and for each probe is 0.1µM. 
 
The PCR mix is mixed by pipetting up and down and 18µl added to each well of the 
LightCycler 480 multiwell plate. 2µl of RNA template is added to each well. The 
multiwell plate is sealed with LightCycler 480 sealing foil and loaded into the LC480. 
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The run protocol used on the LC480 when using RNA is shown in table 10. 
 
Program Temperature (°C) Hold (seconds) Number of cycles 
Reverse Transcription 63 180 1
Denaturation 95 30 1
Amplification 95 10 45
 60 30
 72 1
Cooling 40 10 1
Table 10: The run protocol on the LC480 in two-step RT-PCR 
 
2.4.5 Optimising the assay on the LightCycler 480  
 
The following sections describe the methods used in order to optimise the assay on 
the LC480, including optimising the primer, probe and template concentrations. Initial 
pilot runs were performed using monoplexed FAM-labelled primers and later 
multiplexed primers labelled with different fluorochromes. A dilution series was then 
run and the standard curve and efficiency calculated by the LC480 software. Finally, an 
attempt at reducing the run time is described.  
 
2.4.5.1 Changing primer and probe concentrations 
 
RNase-free water is added to the primers and probes to make up stock concentrations 
of 100µM and 10µM respectively and the vials spun. In order to change the 
concentrations, the desired volume of the stock is diluted with RNAse-free water. The 
final PCR mix has a 10X concentration of primers and probes. Primer concentrations of 
0.5µM, 0.8µM and 1.0µM and probe concentrations of 0.05µM, 0.08µM, 0.1µM and 
0.2µM were tested.  
 
2.4.5.2 Changing template concentration 
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Neat RNA was diluted ten fold, 100 fold, 1000 fold and 10,000 fold using RNase-free 
water and the concentrations tested in a single run. 
 
2.4.5.3 Dilution series and standard curve on the LC480  
 
A 10-fold dilution series of neat, 10 fold, 100 fold, 1000 fold and 10,000 fold cDNA 
from known positive samples was run. The primer and probe concentrations used 
were 1.0µM and 0.1µM respectively. The LightCycler software calculated the standard 
curve and the efficiency. 
 
2.4.5.4 Changes to the run protocol 
 
The original run protocol used for optimising the assay is as follows: 
 
 Temperature (°C) Number of Cycles Hold (seconds)
Reverse Transcription 63 1 180
Denaturation 95 1 30 
Amplification 95 45 10  
 60  30  
 72  1 
Cooling 40 1 10  
Table 11. The original run protocol on the LC480 
 
To try and reduce the run time of 52 minutes for 45 cycles, the annealing time of 30s is 
reduced to 20s and then 10s.  
Turbo PCR is then carried out with an annealing time of 30s for 10 cycles, 20s for 10 
cycles and 10s for 15 cycles.  
A known positive sample is used in these runs. 
 
Despite attempts to reduce the run time on the LC480, the approximate time of 45 
minutes was too long for the purposes of providing an intra-operative diagnosis. 
Therefore, it was decided to switch the assay to the SmartCycler platform as this 
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promised a faster RT-PCR time. The SmartCycler is also used in the commercial assay 
GeneSearch BLNA and therefore a quicker run time was already known to be possible. 
 
2.5 The RNA extraction, PCR preparation and optimisation process on the 
SmartCycler 
 
This section describes the preparation of the PCR mix and the primer-probe mix that 
was carried out at the time of optimisation and validation. A more streamlined 
standard operating protocol of the Metasin assay using the SmartCycler is available on 
page 244. 
 
This section starts by introducing the process of RNA extraction using Qiagen 
materials, followed by the steps taken for preparing the PCR mix and the primer-probe 
mix. Finally the optimisation process is described.     
 
2.5.1 RNA extraction using Qiagen materials 
 
The materials used to extract RNA from the sentinel lymph node were taken from the 
RNeasy Mini kit (Qiagen). The steps taken to extract the RNA were followed using the 
GeneSearch Breast Lymph Node (BLN) test kit. The method has been described in 
section 2.4.1 (pg 90). The homogenization buffer is labelled as Buffer RLT in the RNeasy 
Mini kit. Wash buffer 1 is labelled as Buffer RW1 and Wash buffer 2 is labelled as 
Buffer RPE in the RNeasy Mini kit. 
 
2.5.2 Creating the PCR mix for the SmartCycler platform 
  
The PCR mix is prepared by following the guidelines in the LightCycler 480 RNA Master 
Hydrolysis Probes kit insert (Roche).  
 
Table 12 shows the volume of each reagent for one reaction. 
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Reagent Volume/Reaction (µl)
LightCycler 480 RNA Master Hydrolysis Probes, 2.7x conc 9.25
Primer-Probe mix, 10x conc 2.5
Activator 1.625 
RNase-free water 7.625
Total volume 21 
Table 12. Table showing the reagent volumes/reaction 
 
The final volume is 25µl/reaction with 4µl of RNA.  
 
The minimum number of reactions needed for a run is at least 4. These include: 
1. Positive control = 1 reaction 
2. Negative control = 1 reaction 
3. Patient node = 1 reaction 
4. *Spare = 1 reaction  
*An extra volume of reaction mixture is made to compensate for any pipetting errors. 
   
Before the arrival of the node, a 2.0µl microfuge tube is labelled ‘PCR mix’ and the vials 
and primer/probe mix microfuge tubes are thawed on the bench. Depending on the 
number of nodes expected, the correct amounts of the constituents are added to the 
microfuge tube. The mixture is mixed well by shaking and the PCR mix microfuge tube 
is placed in a tray ready to be aliquoted in the reaction tube. The correct number of 
labelled reaction tubes is placed in a cool box and 21µl of PCR mix aliquoted into each 
tube. 
 
Next, the positive and negative controls are thawed. The positive control is a known 
RNA sample that is positive for both CK19 and MGB. The negative control is a known 
negative RNA sample. 4µl of each control RNA are added to the appropriately labelled 
reaction tube containing the PCR mix. Once the patient RNA has been eluted, 4µl is 
added to the appropriately labelled reaction tube containing PCR mix. The reaction 
tubes are spun for 10 seconds and placed in the SmartCycler machine and the program 
started.  
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The results are telephoned through to the surgical team who will either perform an 
axillary clearance if the sentinel lymph node is positive or take the patient to recovery 
if the sentinel lymph node is negative.  
 
2.5.3 Creating the primer/probe mix for the SmartCycler platform 
 
Before the RNA is extracted during testing of a sample, the primer and probe mix 
would have already been prepared, in most cases on the morning of the operation or 
the day before. The following are the steps taken to prepare the mix. 
 
• A working stock of 100µM of each primer and 10µM of each probe is mixed 
well by pippetting and placed in a cool box 
• A 2ml microfuge tube is labelled with the name ‘PBGD/CK19/MGB 
primer/probe mix’ and the date 
• For each primer, a 1.5ml microfuge tube is labelled with the primer name and 
the concentration 2.5µM (the optimum concentration found during the 
optimisation process). The concentration of 2.5µM is the final concentration in 
the assay 
• The primer-labelled microfuge tubes and the ‘PBGD/CK19/MGB primer/probe 
mix’ labelled microfuge tubes are placed in a rack on an icebox 
• 15µl of RNAse-free water is added to each primer-labelled microfuge tube 
• 5µl of each primer is aliquoted into its respective microfuge tube and mixed 
well by pipetting making a solution of 25µM of each primer 
• Into the microfuge tube labelled ‘PBGD/CK19/MGB primer/probe mix’ is added:  
o 37µl of RNase-free water 
o 1µl of each probe (3µl in total) 
o 10µl of each primer (3 sets of primers, 60µl in total) 
In total 100µl of primer/probe mix will be made in each microfuge tube with 
final primer concentrations of 2.5µM and final probe concentrations of 0.1µM 
• The aliquot is mixed well by shaking 
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• The ‘PBGD/CK19/MGB primer/probe’ microfuge tube is placed in the 4 °C fridge 
if it is to be used on the same day. If being stored for longer than one day, 25µl 
of the mixture is added into labelled microfuge tubes and stored in the - 20 °C 
freezer 
• The probe and primer stock are replaced in the - 20 °C freezer 
• Details of the fresh batch is documented including the date it was made  
 
2.5.4 Optimising the assay on the SmartCycler 
 
Pilot runs were initially carried out on the SmartCycler using the same optimised 
variables previously validated on the LC480. The preliminary results were shown to be 
concordant with GeneSearch with similar Cq values for each marker. The assay run 
time was reduced by increasing the time of the RT step and by reducing the annealing 
and denaturing times. The primer concentration and RNA volumes were adjusted to 
provide optimum Cq values after changing the run protocol. The PCR products were 
then run on a gel to confirm the identity of the products. The RNA concentrations of a 
representative group of positive samples were measured on a nanodrop. Monoplexed 
and multiplexed markers were tested on the same positive samples and their results 
compared to identify any changes between their Cq values. Finally, a dilution series 
was run and the efficiency calculated.   
 
2.5.4.1 Reducing the run time on the SmartCycler 
 
The pilot runs were done with the following run parameters 
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 Temperature (°C) Hold (seconds) Number of 
Cycles 
Reverse Transcription 63 180 1
Denaturation 95 30 1
Amplification 95 10 35
 60 30
 72 1
Cooling 40 10 1
Table 13. The run protocol used during the optimisation process on the SmartCycler 
 
The threshold for fluorescence for each marker was set to allow for minimum 
background interference: 
  
PBGD 10.0 
CK19 7.0 
MGB 4.5 
 
The initial run time was 40 minutes and 12 seconds, which was too long if the assay 
was to be used as an intra-operative diagnostic assay. 
The time had to be shortened without compromising the Cq values. The following 
changes were done to try and improve run time: 
 
The time taken for the reverse transcription, denaturing and annealing steps were 
reduced. Turbo PCR was also carried out. The samples used were known positive 
nodes. The Cq values were then compared to the GeneSearch results of the same 
samples.  
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 Temperature (°C) Hold (seconds) Number of cycles
Reverse Transcription 63 180 1
Denaturation 95 30 1
Amplification 1 95 1 5
 60 30
 72 1
Amplification 2 95 1 5
 60 20
 72 1  
Amplification 3 95 1 25 
 60 10
 72 1  
Cooling 40 10 1
Table 13.1. The run protocol for turbo 1  
 
 Temperature (°C) Hold (seconds) Number of cycles 
Reverse Transcription 63 180 1
Denaturation 95 30 1
Amplification 1 95 1 10
 60 30
 72 1
Amplification 2 95 1 25
 60 10
 72 1
Cooling 40 10 1
Table 13.2: The run protocol for turbo 2 
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 Temperature (°C) Hold (seconds) Number of cycles
Reverse Transcription 63 180 1
Denaturation 95 30 1
Amplification 1 95 1 10
 60 30
 72 1
Amplification 2 95 1 25
 60 6
 72 1  
Cooling 40 10 1 
Table 13.3: The run protocol for turbo  
 
Finally, the RT step was changed to 180s, 240s and 300s using the original run protocol. 
 
2.5.4.2 Changing the template volume 
 
RNA volumes of 1-5µl were tested in order to improve the Cq values.   
 
2.5.4.3 Changing the primer concentrations 
 
Primer concentrations of 1.5µM, 2.0µM and 2.5µM were tested in order to optimize 
the assay even further. Two known positive samples were used. The run protocol 
recommended by the LightCycler 480 RNA hydrolysis probes kit (Roche) described in 
section 2.5.4.1 was used. The RNA volume used was 2.5µl.  
 
2.5.4.4 Monoplexed vs multiplexed primers and probes 
 
Six positive nodes were used and on the same run, monoplexes and triplexes were run. 
The final PCR mixes were run on an agarose gel to ensure the correct products were 
being detected.  
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2.5.4.5 Agarose gel electrophoresis of products from the SmartCycler 
 
The loading mixture is prepared by adding 4µl of distilled water, 1µl of 6X blue loading 
dye (Biolabs) and 1µl of DNA ladder and mixed gently. The mix is loaded onto 1.5% 
agarose gel (Fluka Analytical). A 1.5% gel was chosen because the higher the 
percentage of agarose gel, the higher the degree of separation of the lower molecular 
weight DNA.  The gel is prepared using 4.5g of agarose added to 300mls of TRIS borate 
which has a 10x concentration (30 mls TBA buffer and 300mls water). A hotplate stirrer 
is used to aid dissolving. 15µl of 0.5ug/µl ethidium bromide is added to the mixture 
and poured into the tray. ΦX174 HaeIII Digest (Biolabs) yields 11 fragments suitable for 
use as molecular weight standards.  
 
2.5.4.6 Measuring RNA concentration of GeneSearch and Qiagen 
extracted RNA 
 
A nanodrop microvolume spectrophotometer (Thermo Scientific) was used to quantify 
both GeneSearch and Metasin extracted RNA. The purity was assessed using 260/280 
ratios. 
 
2.6 Creating the PCR mix for GeneSearch 
 
The GeneSearch BLNA assay is the commercial assay used as the gold standard when 
comparing the Cq values obtained on the LC480 and SmartCycler platforms. 
 
The GeneSearch RNA Sample Preparation kit (Veridex) provides tubes labelled positive 
and negative control RNA, a tube labelled ‘Mastermix’ and a tube labelled ‘Enzyme 
mix’. 10µl from both the Mastemix and Enzyme mix tubes are added to each of the 
PCR reaction tubes (Cepheid). 5ul of the negative and positive control supplied in the 
kit is added into the tubes designated as the negative and positive controls and 5µl of 
the sample to be tested is added in the last reaction tube. The run program on the 
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SmartCycler is then started. The run protocol used in the commercial GeneSearch 
BLNA assay is unavailable. 
 
2.7 Statistical analysis 
 
The main objectives to be determined statistically were: 
1. Cut-off Cq values for CK19 and MGB for positive and negative nodes 
2. Cut-off Cq values for CK19 and MGB for macrometastases and micrometastases 
3. The sensitivity and specificity of the assay for the chosen cut-off Cq values 
4. The positive and negative predictive value of the assay for the chosen cut-off 
Cq values 
5. The correlation between the two assays using Spearman’s rank correlation 
coefficient 
 
GeneSearch Cq values were taken as the gold standard, and therefore true, for 
comparing Metasin Cq values of CK19 and MGB.  The analysis was done for each node 
to allow for more data to be evaluated. One of the most important factors was to 
choose a cut-off that had the least number of false positives and which did not 
compromise the sensitivity or specificity of the marker.  
 
2.7.1 Determining the cut-off Cq values for positive and negative nodes 
 
When determining the cut-off Cq values for both CK19 and MGB in Metasin, the gold 
standard was taken to be GeneSearch BLNA assay results. Two different methods were 
used to arrive at the cut-offs. The first method involved choosing a range of proposed 
cut-off values for both markers. For each proposed cut-off, the sensitivity and 
specificity was calculated. This was done for all nodes and also for all cases. The cut-
offs chosen were the ones where the results of the maximum number of nodes and 
cases matched those of GeneSearch. Once the best cut-offs were chosen, their 
sensitivities, specificities, positive and negative predictive values were calculated and 
the results were tabulated and compared. The second method involved preparing a 
scatter plot plotting Metasin Cq values for CK19 vs MGB of all nodes. Each point on the 
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scatter plot was also correlated with histology. Vertical and horizontal lines were 
drawn selecting the best Cq value for both markers which incorporated all the true 
positive nodes without creating any false-positive node results. Once these cut-offs 
were established, their sensitivities and specificities were calculated as well as their 
negative and positive predictive values. 
 
2.7.2 Determining the Cut-off values for macrometastases and 
micrometastases 
 
All nodes were analysed. Nodes containing isolated tumour cells (ITCs) were 
considered to be negative. The histology data for each node was used as the gold 
standard. Using the same scatter plot when choosing positive and negative cut-off 
values, lines were drawn whereby the best Cq cut-off values were chosen which 
separated the most macrometastases from micrometastases. The graph is present in 
section 6.2 (pg 149). The sensitivity, specificity and positive and negative predictive 
values for the proposed best Cq cut-off values were calculated.  
 
2.7.3 Calculating sensitivity, specificity, negative and positive predictive 
value 
 
The following were the calculations used to determine the sensitivity, specificity, 
positive and negative predictive values: 
 
Sensitivity:   True Positive / (True Positive + False Negative) 
Specificity:   True Negative / (True Negative + False Positive) 
Positive Predictive Value: True Positive / (True Positive + False Positive) 
Negative Predictive Value: True Negative / (True Negative + False Negative) 
 
2.7.4 The line of agreement  
 
The line of agreement demonstrates the level of agreement between two variables. 
GeneSearch CK19 and MGB Cq values for all positive nodes were plotted against 
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Metasin CK19 and MGB Cq values respectively and a 45° line drawn. The line of 
agreement is where all the points would lie if the two assays were in agreement. The 
graph provides a gauge of how close the data between the two assays agree.  The 
results are included in section 6.4 (pg 155). 
 
2.7.5 Cohen’s kappa 
 
The statistical method of calculating Cohen’s kappa using the statistical software SPSS 
was used in order to show agreement between the Metasin and GeneSearch datasets. 
The assessment was taken on a patient basis and therefore had a sample size of 154 as 
the clinical decision is taken on a patient basis rather than on an individual node basis. 
Cohen’s kappa was chosen because it was thought that as there were cases with more 
than one node, the node results for a patient may not be totally independent of each 
other as a patient with a macrometastasis could be thought to be more likely to have 
metastasis in her other nodes compared to those with a negative lymph node. 
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PART III. RESULTS 
 
Chapter 3  
 
This chapter aims to present the clinical information of the participants and to show 
the results of the optimising steps on the LightCycler 480 and the validation results. 
Firstly, the best primer combinations were determined using known positive samples. 
To optimise the assay on the LC480, the primer and probe concentrations were 
changed to determine the optimum concentrations. The volume of RNA was also 
changed to see if it would improve Cq values. Once the Cq values were comparable to 
those of GeneSearch, all the samples were run to validate the assay. No discordants 
were recorded. Attempts were then made to reduce the run time. However, it became 
clear that the best time obtained on the LC480 was not suitable for an intra-operative 
assay. 
 
3.1 Participant demographics, clinical and pathological information 
 
Various clinical and pathological features of the participants were collected and 
tabulated.  
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    All Patients    
Patients Enrolled age, years   156 Total  
    
mean age at diagnosis positive SN 60.2 62.2  
  negative SN 63.2  
  discordant SN 60.2  
median age at diagnosis positive SN 59 63  
  negative SN 63    
  discordant SN 62    
age range  positive SN 39-92 34-92  
  negative SN 34-87  
  discordant SN 43-68  
Surgery Performed    
Mastectomy positive SN 18 42 (27%)  
  negative SN 18    
  discordant SN 6    
Wide local excision positive SN 18 
100 
(64%)  
  negative SN 82  
  discordant SN 6    
SN/axillary clearance only positive SN 1 7 (4%)  
  negative SN 6  
  discordant SN 0  
Tumour Stage        
pT1 positive SN 18 79 (51%)  
  negative SN 61  
  discordant SN 0  
pT2 positive SN 15 46 (29%)  
  negative SN 28    
  discordant SN 3  
pT3 positive SN 2 4 (2%)  
  negative SN 2    
  discordant SN 0    
Tumour Grade    
Grade 1 positive SN 5 20 (13%)  
  negative SN 15    
  discordant SN 0  
Grade 2 positive SN 20 78 (50%)  
  negative SN 55    
  discordant SN 3    
Grade 3 positive SN 12 29 (19%)  
  negative SN 16  
  discordant SN 1  
Ungradeable positive SN 0 10 (6%)  
  negative SN 9  
  discordant SN 1  
Table 14.1 Patient demographics and clinical and pathological information 
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Type of tumour    All Patients  Total 
IDC positive SN 26 103 (66%)
  negative SN 74
  discordant SN 3
ILC positive SN 6 16 (10%)
  negative SN 9
  discordant SN 1   
Others positive SN 6 32 (20%) 
  negative SN 24   
  discordant SN 2
DCIS positive SN 0 11 (7%)
  negative SN 10
  discordant SN 1
LCIS positive SN 0 1 (0.6%)
  negative SN 1   
  discordant SN 0   
Hormone receptor status       
ER positive  positive SN 36 130 (83%)
  negative SN 88
  discordant SN 6
ER negative positive SN 1 18 (11%)
  negative SN 17
  discordant SN 0   
PR positive positive SN 27 103 (66%) 
  negative SN 71   
  discordant SN 5
PR negative positive SN 10 45 (29%)
  negative SN 34
  discordant SN 1
Her2 positive positive SN 4 13 (8%)
  negative SN 8   
  discordant SN 1   
Her2 negative positive SN 33 127 (81%)
  negative SN 90
  discordant SN 4
Triple negative positive SN 1 14 (9%) 
  negative SN 13
  discordant SN 0
Table 14.2 Patient demographics and clinical and pathological information 
*Her2 scoring: immunohistochemistry 3+ score or ISH amplified 
*ER and PR scoring: Allred score (positive 3+ or more) 
  
The majority of positive patients included in the practical work have IDC 
(27cases/37cases) followed by ILC (5/37), with other less common tumours including 
micropapillary (3/37), tubular (1/37) and mixed IDC and ILC (1/37). 
Commented [SP1]: You have not defined cut-off for negative vs 
positive, as requested previously. 
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3.2 Results of the optimisation process on the LightCycler 480 
 
Results of the optimisation process including the outcome of primer and probe 
concentration changes and changes in RNA volume are given.  
 
3.2.1 Template dilution series, standard curve and efficiency on the LC480 
 
A template dilution series of a positive sample was carried out in order to produce a 
standard curve. The efficiency calculated by the LC480 software was 97-98%. 
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Figure 13. The figure shows the dilution series on the LC480 and the standard curve with an efficiency of 97-98%.
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The following tables show the Cq values for the dilutions carried out for each marker. 
The GeneSearch Cq value is also provided to compare the Cq values. 
 
Marker RNA dilution  Cq value GeneSearch Cq value 
PBGD 1 25.76 32.8 
  0.1 29.76   
  0.01 32.95   
  0.001 35.91   
  0.0001 ND   
Table 15.1   
    
Marker RNA dilution Cq value GeneSearch Cq value
CK19 1 20.43 19.8
  0.1 23.65   
  0.01 27.12   
  0.001 30.93   
  0.0001 35.12   
Table15.2 
    
Marker RNA dilution Cq value GeneSearch Cq value
MGB 1 21.22 17.1
  0.1 25.96   
  0.01 29.79   
  0.001 33.98   
  0.0001 37.89   
Table 15.3  
Tables 15.1 – 15.3 RNA dilution Cq values for each marker compared with GeneSearch  
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3.2.2 Changing primer concentration 
 
When changing the primer concentrations, the probe concentration was constant at 
0.1µM. Table 16.1 shows the different concentrations and their corresponding Cq 
value for each marker. 
 
Marker Primer concentration (µM) Cq value GeneSearch Cq value
PBGD 0.5 39.13 27.3
 0.8 31.81
 0.8 31.95
 1 31.11
 1 31.24
CK19 0.5 46.91 18.9 
 0.8 18.9
 0.8 19.09  
 1 18.42  
 1 18.24  
MGB 0.5 24.56 18.3 
 0.8 18.25
 0.8 18.57
 1 16.79
 1 17.07
Table 16.1. Comparing primer concentrations of 0.5 µM, 0.8µM and 1.0µM. 
 
At a concentration of 0.5µM, the PBGD is very high and would have been considered 
invalid by the GeneSearch assay. There was no significant difference between 0.8µM 
and 1.0µM. Both concentrations gave Cq values which were found to be comparable to 
the GeneSearch assay Cq value for the same sample. Therefore, a 1.0µM primer 
concentration in the assay was used as the calculations would be easier and there was 
no significant difference between 0.8µM and 1.0µM. 
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3.2.3 Changing probe concentration 
 
Probe concentrations of 0.05µM, 0.08µM, 0.1µM and 0.2µM were tested to find the 
optimum concentration. A constant primer concentration of 0.8µM was used. The 
table shows the Cq values for each marker for a known positive specimen.  
 
Marker Probe concentration (µM) Cq value GeneSearch Cq value
PBGD 0.05 31.70 27.3
 0.08 31.85
 0.1 31.11
 0.1 31.24
 0.2 31.34
 0.2 31.58  
CK19 0.05 40.52 18.9
 0.08 40.98  
 0.1 18.42  
 0.1 18.24  
 0.2 18.51  
 0.2 19.12
MGB 0.05 22.27 18.3
 0.08 22.05
 0.1 16.79
 0.1 17.07
 0.2 16.84
 0.2 17.21
Table 16.2 Comparing probe concentrations of 0.1 and 0.2µM 
 
When comparing probe concentrations 0.05µM with 0.08µM, there is very little 
difference between them. There was no significant difference in using 0.1µM or 0.2µM 
of probe. 
The optimum and most economical probe concentration was found to 0.1µM. 
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3.2.4 Changing RNA volume  
 
The optimum primer and probe concentrations were used when comparing the 
different RNA volumes. When running three positive samples, it was found that 
volumes of 1ul, 2µl and 5µl did not significantly change the Cq value. Therefore, a 
volume of 2µl was used as recommended by the LC480 PCR kit insert. The results can 
be found in the appendix (pg197). 
 
3.2.5 Results of multiplexing 
 
When the optimum probe and primer concentrations had been found (0.1µM Probe 
concentration and 1.0µM Primer concentration respectively) they were multiplexed, 
firstly in pairs and then triplexed. Colour compensation was applied to the runs.  
The table shows the Cq Values of the monoplexed and multiplexed markers. 
 
Markers  Cq value
PBGD PBGD 29.84
MGB MGB 22.62
CK19 CK19 24.18
PBGD & CK19 PBGD 31.80
 CK19 40.70
PBGD & MGB PBGD 30.51
 MGB 23.65
CK19 & MGB CK19 25.59 
 MGB 22.83
PBGD&CK19&MGB PBGD 30.27 
 MGB 23.44 
 CK19 25.87 
Table 17. The table shows the Cq values of monoplexed, duplexed and triplexed 
markers 
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When comparing the Cq values of the monoplexed and triplexed markers, the average 
difference in Cq value is 0.98 suggesting little interference between the nine 
primer/probe combinations. 
 
The pilot run was encouraging and therefore a batch of known positive nodes were 
run. Once their Cq values were comparable to GeneSearch, the rest of the positive and 
negative samples were run to validate the assay. 
 
3.3 The validation results on the LC480    
 
In total, 73 patients with 136 lymph nodes were run on the LC480 assay. The following 
sections describe the results of the LC480 by comparing the Cq values to those of the 
GeneSearch assay.  
 
3.3.1 The positive nodes 
 
Thirty-six lymph nodes from twenty patients were found to be positive by both assays. 
There were no discordant results between GeneSearch and the LC480 assay. The same 
cut-offs of the markers PBGD, CK19 and MGB that were used in GeneSearch were also 
applied to the LC480 assay. The table of all samples with their Cq values can be found 
in the appendix (pg 200). 
 
The following three scatter graphs illustrate the difference in Cq values for all three 
markers for each positive node. 
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Graph 1.1 Comparing GeneSearch PBGD Cq value with LC480 PBGD Cq value for positive nodes (V = GeneSearch, 480 = LC480) 
 
In order for the results of a node to be valid, PBGD, the reference gene, should have a Cq value of less than or equal to 36 according 
to the GeneSearch. All the nodes tested by the LC480 achieved PBGD Cq values of less than or equal to 36. 
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Graph 1.2 Comparing GeneSearch CK19 Cq value with LC480 CK19 Cq value for positive nodes (V = GeneSearch, 480 = LC480 
 
The majority of nodes run on the LC480 had Cq values for CK19 similar to those of the GeneSearch. However, three lymph nodes that 
were positive for CK19 using GeneSearch BLN assay were negative on the LC480. No nodes were found to be positive on the LC480 but 
negative by GeneSearch 
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Graph 1.3. Comparing GeneSearch MGB Cq value with LC480 MGB Cq value for positive nodes (V = GeneSearch, 480 = LC480) 
 
All nodes were found to have the same results for MGB. Several nodes were found to have Cq values of 0 with GeneSearch but 
registered a Cq value, albeit higher than the cut-off of 31, with the LC480. 
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In summary, there were no discrepancies in the results of the positive nodes overall, 
however, three nodes found to be positive for CK19 on GeneSearch were negative on 
the LC480. Ck19 detection on the LC480 is less sensitive than on the GeneSearch assay.  
 
3.3.2 The negative nodes 
 
Ninety-nine negative nodes from fifty-two patients were tested and no discordant 
results between GeneSearch and the LC480 were found. For the table showing the Cq 
values of all the negative cases please see the appendix (pg 202). 
 
3.3.3 Discordant case 
 
There were no discordant cases between GeneSearch and the LC480. However, there 
was one discordant case (12395B) when comparing histology with both assays. A 3mm 
macrometastasis was found in one of two slices taken for histology. The GeneSearch 
and LC480 Cq values for CK-19 and MGB were 0 for both. A full explanation is available 
in the discussion chapter.    
 
3.4 Reducing the run time 
 
The original run time using the recommended run protocol was found to be 52 
minutes. This was far too long for an intra-operative assay and so attempts to reduce 
the run time were done.  
 
The table below shows the original run parameters on the LC480 
 
 
 
 
 
 
 
123 
 
 Temperature (°C) Hold (seconds) Number of Cycles
Reverse Transcription 63 180 1
Denaturation 95 30 1
Amplification 95 10  45 
 60 30 
 72 1   
Cooling 40 10  1 
Table 18. The original run parameters on the LC480 
 
The sample used was previously found to be positive on the LC480 for MGB, with a Cq 
value of 29, and negative for CK19, with a Cq value of 0. The Cq value of PBGD was 25. 
The Cq values of the experimental runs are shown along with the time taken for the 
run.    
 
First run 
Amplification 60 °C for 30 s for 35 cycles. Run time: 52 minutes  
 
PBGD CK19 MGB
26.62 ND 30.03
Table 19.1. The Cq values of each marker (60°C for 30s), ND = not detected   
 
Second run 
Amplification 60 °C for 20 s for 35 cycles. Run time: 48 minutes 28 seconds 
 
PBGD CK19 MGB
26.86 ND 32.68
26.75 ND 33.20
Table 19.2. The Cq values of each marker (60°C for 20s), ND = not detected   
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Third run 
Amplification 60 °C for 10 s for 35 cycles. Run time: 43 minutes 28 seconds 
 
PBGD CK19 MGB
ND ND ND 
ND ND ND 
 ND = not detected 
Table 19.3. The Cq values of each marker (60°C for 10s)   
 
In the third run, no markers were detected. The fastest possible time was still too long 
at 48 minutes and 28 seconds. 
 
Fourth run: Turbo PCR 
1. Amplification 60 °C for 30 s: 10 cycles (1 cycle takes 1:38) 
2. Amplification 60 °C for 20 s: 10 cycles (1 cycle takes 1:12) 
3. Amplification 60 °C for 10 s: 15 cycles (1 cycle takes 1:03) 
 
PBGD CK19 MGB 
ND ND ND 
ND ND ND 
ND ND ND 
ND = not detected 
Table 19.4. The Cq values of each marker (Turbo PCR)   
 
No Cq values were obtained.  
 
Despite attempts at reducing the run time, the assay still took far too long and failed to 
detect the markers. The decision was then made to change the platform from the 
LC480 and instead use the SmartCycler machine. GeneSearch also uses this platform 
and so an assay time comparable to GeneSearch was already known to be achievable.  
125 
 
 
Chapter 4 Results on the SmartCycler platform - Optimisation 
 
The Metasin assay was optimised on the SmartCycler platform and the run time 
reduced to a time comparable to that of GeneSearch by reducing the denaturing time 
and running turbo PCR. The assay was optimised by changing the primer concentration 
from 1.5µM to 2.5µM, increasing the RNA volume from 1µl to 5µl and increasing the 
RT step from 120s to 300s. Once the assay was optimised, all the samples had their 
RNA extracted using the RNeasy Mini kit (Qiagen) and the RNA run using the new 
protocol.  
 
4.1 Results of the pilot runs  
 
The first pilot run used multiplexed markers using known positive samples. The Cq 
values are shown in the following tables and compared to the Cq values of GeneSearch 
for the same samples.  
 
Sample Marker Metasin Cq value GeneSearch Cq value
745 PBGD 25.2 26.4
  CK19 17.9 19.2
  MGB 23.8 23.9
13447 PBGD 24.8 32.6
  CK19 17.8 19.5
  MGB 17.6 18.3
Table 20.1 Cq values of two known positive samples compared with GeneSearch from 
the first pilot run. 
 
The results show that the samples had similar Cq values. Further nodes, including 
negative nodes, were tested in a second run and the Cq values compared. 
 
The table below compares the Cq values of Metasin (M) and GeneSearch (G) of both 
positive and negative samples. 
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PBGD 
M 
PBGD 
G 
CK19 
M 
CK19 
G 
MGB 
M 
MGB 
G 
8759F 23.4 26.6 20.1 20.2 34.3 0
8759F 23.5 26.6 19.9 20.2 33.8 0
10762E 25.7 33.9 18.1 18.4 16.1 16.1
10762E 25.6 33.9 18.7 18.4 16.8 16.1
18472C 26.1 27.8 0 0 0 0
18472C 26.5 27.8 0 0 0 0
1978B 27.7 28 0 0 0 0
1978C 26.2 26.6 0 0 0 0
1978D 25.9 26.5 0 0 0 0
Table 20.2. Cq values of known positive and negative samples compared with 
GeneSearch from the second pilot run (M = Metasin, G = GeneSearch). 
 
The second run showed the Metasin results to be more sensitive than the GeneSearch 
results. No discordant results between the assays were recorded.  
 
4.2 Results of optimising the Metasin assay and reducing the run time 
 
The run time was reduced by changing the denaturing and annealing time as well as 
the RT step from 300s to 120s. The time was reduced to a time comparable to that of 
GeneSearch ie approximately 25 minutes for one node. The assay was also optimised 
again by changing the primer concentration from 1.5 to 2 to 2.5µM and RNA volume 
from 1µl to 2.5, 3, 4 and 5µl. It was found that the optimum primer concentration and 
RNA volume was 2.5µM and 4µl respectively.   
  
4.2.1 Reducing the run time 
 
The GeneSearch result of the positive node 16039C is given so as to compare the Cq 
values with those from the runs when changing the run protocol. 
Commented [SP2]: You have nott amended as requested to 
include details  of changes; ie range of concetrations and RNA vol 
tried. 
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16039C     
PBGD CK19 MGB
25.7 20.2 18.6 
Table 21. The Cq values of each marker for the positive sample 16039C with 
Genesearch 
 
2.5µl of RNA were used in these runs. The previously optimised primer and probe 
concentrations of 1.0µM and 0.1µM were used. 
 
Changing the denaturation time 
The denaturation temperature is set at 95°C. The time taken for the denaturation step 
of the PCR reaction was changed ranging from 1s to 10s and the Cq values compared 
to those of GeneSearch. 
 
Temperature (°C) Seconds Temperature (°C) Seconds PBGD CK19 MGB
60 30 95 1 26.5 19.8 23.4
60 30 95 2 26.5 21.7 22.2
60 30 95 4 26.7 21.8 22.3
60 30 95 6 26.6 21.7 22.2
60 30 95 8 26.1 21.8 22.3
60 30 95 10 26.3 21.9 22.3
Table 22.1 The Cq values of sample 16039C when changing the denaturing time 
 
No significant change in Cq values was observed when changing the time of 
denaturation. Therefore, the 95°C step was reduced to 1s. 
 
Changing the annealing time  
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The annealing temperature is set at 60°C. The time taken for the annealing step of the 
PCR reaction was changed ranging from 6s to 30s and the Cq values compared to those 
of GeneSearch. 
 
Temperature (°C) Seconds Temperature (°C) Seconds PBGD CK19 MGB
60 6 95 10 0 34.5 0
60 10 95 10 31.2 28.6 29.5 
60 15 95 10 28.5 25.4 25.8
60 20 95 10 27.4 23.4 24.4 
60 25 95 10 26.8 22.4 22.6
60 30 95 10 26.2 21.7 22.4
Table 22.2 The Cq values of sample 16039C when changing the annealing time 
 
Reducing the 60°C step drastically changed the Cq values. It was decided to try and 
optimise the assay further in order to reduce the annealing time.  
 
4.2.2 Changing the RNA volume 
 
The RNA volume of the sample 16039C was changed using 1µl, 2.5µl, 3µl, 4µl and 5µl 
volumes. The optimised run parameter of 1s at 95°C and the original run time of 30s at 
60°C for 35 cycles were used to try and determine the optimum RNA volume.  
 
The results of the Cq values for each marker are given. 
 
RNA volume (µl) PBGD CK19 MGB 
1 27.6 22.2 21.8 
2.5 28.3 22.5 22.5 
3 27.7 22.4 21.5 
4 27.5 21.7 20.3 
5 28.9 23.4 22 
Table 23 Changing the RNA volume 
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The run shows that by increasing the RNA volume to 4µl, the Cq values are closest to 
those of GeneSearch for those run parameters. However, the assay took 28 minutes 
which is still longer than the GeneSearch time of 25 minutes. 
 
4.2.3 Turbo PCR results 
 
In an attempt to reduce the run time from 28 minutes, the annealing time was reduced 
in a step-wise fashion. 
 
The following two positive samples were used in these runs. 
 
GeneSearch results of the samples to compare with those of the experimental runs 
 
Sample PBGD CK19 MGB 
17502B 25.9 19.2 22.1 
18243B 27.6 22.5 18.1 
Table 24 The GeneSearch Cq values of two positive samples 
 
The results of the three turbo runs, along with their run times, are given in the 
following tables.  
 
Turbo run 1 
Sample PBGD CK19 MGB 
17502B 28.2 21.3 28.4 
18243B 29.3 26.4 22.1 
Table 25.1 Cq values of turbo run 1 
Run time of 17:10:01 – 17:35:14 (25 mins 13s) 
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Turbo run 2 
Sample PBGD CK19 MGB 
17502B 26.8 19.7 24.4 
18243B 28.4 24.8 19.1 
Table 25.2 Cq values of turbo run 2 
Run time of 17:13:24 – 17:38:52 (25 mins 28s) 
 
Turbo run 3 
Sample PBGD CK19 MGB 
17502B 31.5 22.9 30.7 
18243B 32.8 30.1 24.5 
Table 25.3 Cq values of turbo run 3 
Run time of 17:15:05 – 17:38:55 (23 mins 50s) 
 
The run protocol of turbo 2 was the fastest and did not compromise the Cq values.  
 
4.2.4 Changing the RT step 
 
The RT step was increased in order to improve the Cq values. Two known positive 
samples were used.  
 
The table shows the Cq values of the samples used when changing the RT step 
 
Sample PBGD CK19 MGB 
16039C 25.7 20.2 18.6 
13447E 33.3 19.3 18.2 
Table 26 The Cq values of the two positive samples from GeneSearch 
 
The following table shows the Cq values for each marker for the samples and their 
associated RT time. 
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RT time (s) Sample PBGD CK19 MGB
120 16039C 25.4 20 18.5
120 13447E 26.2 19.7 17.6
240 16039C 24.6 17.1 17.2 
240 13447E 25.5 16.1 17
300 16039C 24.3 15.7 17.6 
300 13447E 24.7 15.7 17.2 
Table 27 Increasing the RT step 
The results show no significant difference in the Cq values and so a time of 240s was 
chosen. 
 
4.2.5 Changing primer concentration  
 
The primer concentration was changed in order to improve the Cq values of the 
samples, making them comparable to those obtained by GeneSearch. 
 
Sample = 16039C     
Primer concentration (µM) PBGD CK19 MGB
1.5 24.7 17.2 18.1
2 22.2 17.5 17.7
2.5 23.7 17.1 17.5
Table 28.1 Comparing the Cq values for primer concentrations 1.5, 2 and 2.5µM for 
sample 16039C 
 
Sample = 17502B     
Primer concentration (µM) PBGD CK19 MGB
1.5 25.3 16.7 21.9
2 25.1 16.6 21.6
2.5 25.3 16 21.2
Table 28.2 Comparing the Cq values for primer concentrations 1.5, 2 and 2.5µM for 
sample 17502B 
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2.5µM was chosen as the optimum primer concentration. 
 
4.2.6  Qiagen extracted RNA vs GeneSearch extracted RNA  
 
Up to this point, the RNA used in the optimisation runs had been extracted using 
GeneSearch materials. Once the assay optimisation and run time had been reduced, 
the extraction of RNA was carried out using the RNEasy Mini kit (Qiagen) and the 
results compared. 
 
The table compares the Cq value of each marker with RNA extracted using GeneSearch 
and Qiagen extraction kits. Two negative samples and two positive samples were 
compared. 
 
Sample PBGD Q PBGD G CK19 Q CK19 G MGB Q MGB G
2618A 29.6 29.4 0 0 0 0
2618B 30 30.4 0 0 0 0
3256E 25.1 26.5 28.9 26.8 31.2 30.5 
3258A2 24 24.8 18.9 20.4 31.1 30.3 
Table 29 Comparing the Cq values of RNA extracted using either GeneSearch or Qiagen 
extraction kits, Q = Qiagen, G = GeneSearch. 
 
The Cq values are very similar indicating there is no significant difference between 
Qiagen extracted RNA and GeneSearch extracted RNA. 
 
In concluding this chapter, the optimum primer concentration and RNA volume is 
2.5µM and 4µl respectively. The selection of certain concentrations and volumes was 
influenced mainly by the ease at which calculations could be made and the volumes 
could be pipette as well as by financial constraints of trying to limit the amount of 
reagents used.     
The optimum run protocol of the Metasin assay, with an average run time of 25 
minutes, is shown in the following table. 
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 Temperature (°C) Seconds Number of Cycles
Reverse Transcription 63 240 1
Denaturation 95 30 1
Amplification 1 95 1  
 60 30
 72 1 10 
Amplification 2 95 1  
 60 10
 72 1 25 
Cooling 40 10 1
Table 30 The optimum run protocol of Metasin 
 
Chapter 5 The Metasin validation results 
 
Once the optimisation of the assay and the run time were improved, all the samples 
had their RNA extracted using Qiagen’s RNeasy Mini kit RNA extraction kit and run on 
the Metasin in-house assay. This chapter sets out the results obtained from the 
Metasin assay by first analysing the positive results, then the negative results and 
finally the earlier results from the LC480 were also compared to those of Metasin.  
 
5.1 Positive patients and nodes 
 
Out of 154 cases (352 nodes) there were 37 positive cases (64 positive concordant 
nodes) for both GeneSearch and Metasin, 24% of the total number of cases and 18% of 
the total number of nodes. A full list of the Cq values of these nodes are available in 
the appendix (pg 208).   
The following three scatter graphs compare the Cq values of the positive nodes of 
GeneSearch and Metasin. The Cq values of both assays were plotted against the node 
identification number on the same vertical line.  
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Graph 2.1 Comparing GeneSearch and Metasin Cq values of PBGD of the positive nodes (Veridex = GeneSearch)   
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Graph 2.2 Comparing GeneSearch and Metasin Cq values of CK19 of the positive nodes (Veridex = GeneSearch)     
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Graph 2.3 Comparing GeneSearch and Metasin Cq values of MGB of the positive node (Veridex = GeneSearch)  
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5.2 Negative patients and nodes 
 
For the table showing the Cq values of the negative cases please see the appendix (pg 
210). 
In total, 111 patients with 280 nodes were found to be negative for metastatic breast 
cancer by both Metasin and GeneSearch.  
 
The following scattergraph plots the GeneSearch results against the Metasin results of 
the negative cases for PBGD. 
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Graph 3 Comparing GeneSearch and Metasin Cq values of PBGD of the negative nodes (Veridex = GeneSearch)  
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The PBGD graph shows a concentrated small area showing that the Cq values of the 
reference gene for both assays are similar.  
 
5.3 Comparing the Metasin and LC480 results 
 
The Metasin Cq values of all three markers in 18 positive cases with 32 nodes were 
compared to those of the LC480.  
There were five nodes where CK19 disagrees, 3 nodes where the CK19 with the LC480 
is positive and 2 nodes where Metasin is positive. 
There were 3 nodes where MGB disagreed. All three were positive for Metasin, 
however, they were picked up at a slightly higher CT value with LC480. 
The full table showing the Cq values is available in the appendix (pg 224). 
 
The following scatter graphs compare the Cq values of the three markers. 
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Graph 4.1 Comparing the Cq values of positive nodes of the LC480 and Metasin assay for PBGD 
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Graph 4.2 Comparing the Cq values of positive nodes of the LC480 and Metasin assay for CK19 
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Graph 4.3 Comparing the Cq values of positive nodes of the LC480 and Metasin assay for MGB 
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The scattergraphs show the majority of nodes have similar Cq values. 
 
Chapter 6 Statistical analysis results 
 
Statistical tests were employed to determine the cut-offs for positive and negative 
nodes as well as to distinguish macrometastases from micrometastases. 
 
The main objectives to be determined statistically were: 
1. Cut-off Cq values for CK19 and MGB for positive and negative nodes 
2. Cut-off Cq values for CK19 and MGB for macrometastases and micrometastases 
3. The sensitivity and specificity of the assay 
4. The positive and negative predictive value of the assay 
 
6.1 Proposed Cut-off values for positive and negative nodes: comparing sensitivities 
and specificities  
 
The results of the proposed cut-off values, along with the sensitivities and specificities 
for both CK19 and MGB, are tabulated.  
The following six tables show the results of the number of nodes with the proposed Cq 
cut-off value for CK19. 
 
 Metasin  
GeneSearch Positive Negative 
Positive 53 9
Negative 1 289 
Table 31.1: nodes results for a CK19 cut-off value of 28 
 
 Metasin  
GeneSearch Positive Negative 
Positive 55 7 
Negative 1 289 
Table 31.2: nodes results for a CK19 cut-off value of 29 
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 Metasin  
GeneSearch Positive Negative 
Positive 55 7
Negative 3 287 
Table 31.3: nodes results for a CK19 cut-off value of 30 
 
 Metasin  
GeneSearch Positive Negative 
Positive 55 7
Negative 3 287 
Table 31.4: nodes results for a CK19 cut-off value of 31 
 
 Metasin  
GeneSearch Positive Negative 
Positive 56 6
Negative 4 286 
Table 31.5: nodes results for a CK19 cut-off value of 32 
 
 Metasin  
GeneSearch Positive Negative 
Positive 56 6
Negative 4 286 
Table 31.6: nodes results for a CK19 cut-off value of 33 
 
Proposed CK19 cut off value Sensitivity (95% CI) Specificity 
28 85% (76%-94%) 103%
29 89% (81%-97%) 102%
30 89% (81%-97%) 101%
31 89% (81%-97%) 101% 
32 90% (82%-97%) 100%
33 90% (82%-97%) 100%
Table 32: the sensitivities and specificities for each proposed Cq cut-off value for CK19 
nodes 
 
By adopting a cut-off of 28 for CK19, there would be too many false negatives and the 
sensitivity is the lowest at 85%. At a cut-off of 30 or 31, two cases become Metasin 
positive but GeneSearch negative. When assessing the histology results for these two 
cases, they are found to be positive and therefore represent true positives which were 
missed by GeneSearch. For cut offs 32 and 33, an extra case is added to the Metasin 
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positive and GeneSearch negative box which to make a total of 4 nodes. The fourth 
node was also shown to be positive on histology. The sensitivity of 90% is highest for 
cut-offs 32 and 33. For these cut-offs, there are also less false negatives. The cut offs of 
32 and 33 have the best sensitivities and specificities.   
 
The following six tables show the results of the cases with the proposed Cq cut-off 
value for CK19. 
 
 Metasin  
GeneSearch Positive Negative 
Positive 30 5
Negative 0 119 
Table 33.1: cases results for a CK19 cut-off value of 28 
 
 Metasin  
GeneSearch Positive Negative 
Positive 31 4
Negative 0 119 
Table 33.2: cases results for a CK19 cut-off value of 29 
 
 Metasin  
GeneSearch Positive Negative 
Positive 31 4
Negative 2 117 
Table 33.3: cases results for a CK19 cut-off value of 30 
 
 Metasin  
GeneSearch Positive Negative 
Positive 31 4
Negative 2 117 
Table 33.4: cases results for a CK19 cut-off value of 31 
 
 Metasin  
GeneSearch Positive Negative 
Positive 32 3
Negative 3 116 
Table 33.5: cases results for a CK19 cut-off value of 32 
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 Metasin  
GeneSearch Positive Negative 
Positive 32 3
Negative 3 116 
Table 33.6: cases results for a CK19 cut-off value of 33 
 
Proposed cut off Sensitivity (95% CI) Specificity
28 86% (74%-97%) 104%
29 88% (77%-99%) 103%
30 88% (77%-99%) 101%
31 88% (77%-99%) 101%
32 91% (82%-100%) 100%
33 91% (82%-100%) 100% 
Table 34: the sensitivities and specificities for each proposed Cq cut-off value for CK19 
cases 
 
By looking at the cases with cut-offs of 32 and 33, these had the best sensitivity of 91% 
and specificitiy of 100%. Therefore, the best cut-off for CK19 can be chosen as either 
32 or 33. 
 
The same analysis was done for MGB. 
 
The following six tables show the results of the nodes with the proposed Cq cut-off 
value for MGB. 
  
 Metasin  
GeneSearch Positive Negative 
Positive 42 11
Negative 1 298 
Table 35.1: nodes results for a MGB cut-off value of 29 
 
 Metasin  
GeneSearch Positive Negative 
Positive 46 7
Negative 2 297 
Table 35.2: nodes results for a MGB cut-off value of 30 
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 Metasin  
GeneSearch Positive Negative 
Positive 50 3
Negative 4 295 
Table 35.3: nodes results for a MGB cut-off value of 31 
 
 Metasin  
GeneSearch Positive Negative 
Positive 51 2
Negative 6 293 
Table 35.4: nodes results for a MGB cut-off value of 32 
 
 Metasin  
GeneSearch Positive Negative 
Positive 52 1
Negative 10 289 
Table 35.5: nodes results for a MGB cut-off value of 33 
 
 Metasin  
GeneSearch Positive Negative 
Positive 52 1
Negative 11 288 
Table 35.6: nodes results for a MGB cut-off value of 34 
 
Proposed cut off Sensitivity (95% CI) Specificity 
29 79% (68%-90%) 103%
30 87% (78%-96%) 102%
31 94% (87%-100%) 99%
32 96% (91%-100%) 99% 
33 98% (94%-100%) 97%
34 98% (94%-100%) 97%
Table 36: the sensitivities and specificities for each proposed Cq cut-off value for MGB 
nodes 
 
By adopting cut-offs of 29 and 30, there are too many false negatives with sensitivities 
of 79% and 87% respectively. The higher the cut-off value, the higher the number of 
nodes that become Metasin positive and GeneSearch negative. With a cut-off of 34, 11 
nodes are Metasin positive and GeneSearch negative. 5 of these nodes were shown to 
be negative on histology and therefore introduces 5 false positive nodes. The 
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specificity is also lower at 97%. It appears that having a cut-off of 32 or 33 would be 
the best values when balancing sensitivity and specificity. 
 
Similar analysis was carried out using the number of cases rather than nodes.   
 
 Metasin  
GeneSearch Positive Negative 
Positive 30 5
Negative 0 119 
Table 37.1: cases results for a MGB cut-off value of 29 
 
 Metasin  
GeneSearch Positive Negative 
Positive 33 2
Negative 1 118 
 Table 37.2: cases results for a MGB cut-off value of 30 
 
 Metasin  
GeneSearch Positive Negative 
Positive 33 2
Negative 2 117 
Table 37.3: cases results for a MGB cut-off value of 31 
 
 Metasin  
GeneSearch Positive Negative 
Positive 34 1
Negative 3 116 
Table 37.4: cases results for a MGB cut-off value of 32 
 
 Metasin  
GeneSearch Positive Negative 
Positive 35 0
Negative 5 114 
Table 37.5: cases results for a MGB cut-off value of 33 
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 Metasin  
GeneSearch Positive Negative 
Positive 35 0
Negative 5 114 
Table 37.6: cases results for a MGB cut-off value of 34 
 
Proposed cut off Sensitivity (95% CI) Specificity
29 86% (74%-97%) 104%
30 94% (86%-100%) 100%
31 94% (86%-100%) 100% 
32 97% (91%-100%) 98% 
33 100% 96%
34 100% 96%
Table 38: the sensitivities and specificities for each proposed Cq cut-off value for MGB 
cases 
 
By adopting a cut-off of 32 for MGB, there would be less false positives introduced 
than cut-offs for 33 and 34. The specificity is also higher at 98% compared to 96% for 
the cut-offs 33 and 34.  
 
In summary, the optimum cut-off values for CK19 lie between 32 and 33 and for MGB 
around 32.   
 
6.2 Establishing the cut off points for positive and negative nodes and the cut- off 
points for macrometastasis and micrometastasis: Scatterplot  
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Graph 5. The graph plots CK19 vs MGB for all positive nodes and is colour coded according to histopathological size of the metastatic 
deposit.
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Once all the GeneSearch positive and negative samples were run on Metasin, the Cq 
values were plotted on the graph above and the lines drawn to separate the positive 
and negative nodes. Extrapolation from the graph identified the optimum cut-off Cq 
values for positive and negative nodes on Metasin to be: 
CK19 = 32 
MGB = 32.3 
 
The optimum cut-offs established in the previous section (6.1) were around 32 for 
MGB and 32-33 for CK19. The optimum cut-offs extrapolated from the scatterplot is 
consistent with these findings.  
The number of patients used in the statistical analysis for determining the cut-offs 
during the validation of the GeneSearch assay was 274, 120 more patients than were 
included in the Metasin data analysis. Therefore, it was decided to adopt the cut-offs 
of 32 and 32.3 respectively for CK19 and MGB (taken from the scatterplot above) until 
the number of cases run on Metasin was at least at large, or larger, than 274 cases and 
when review with a larger dataset could be carried out. 
 
By adopting the cut offs of 32 and 32.3 for CK19 and MGB respectively, the sensitivity 
and specificity as well as the positive and negative predictive values of the Metasin 
assay are calculated for nodes and cases. 
 
 Metasin  
GeneSearch Positive Negative 
Positive 64 4
Negative 4 280 
Table 39: showing the distribution of nodes  
 
Sensitivity of Metasin is 94% (88% - 99%, 95% CI) 
Specificity of Metasin is 100% 
Positive predictive value is 94% 
Negative predictive value is 98% 
 
 
152 
 
 Metasin  
GeneSearch Positive Negative 
Positive 37 2
Negative 4 111 
Table 40: showing the distribution of cases 
 
Sensitivity of Metasin is 95% (88% - 100%, 95% CI) 
Specificity of Metasin is 98% 
Positive predictive value is 90% 
Negative predictive value is 98% 
 
In determining the cut-off values for distinguishing macrometastases and 
micrometastases, the same method was used by extrapolating from the scatterplot. A 
cut-off of 25 for CK19 and 26 for MGB were found to be consistent with the data. 
The GeneSearch cut-offs for nodes containing micro- or macrometastases is 25 for 
CK19 and 26 for MGB.  As the number of micrometastasis included in the Metasin data 
is fewer than 20 cases, the cut-offs of GeneSearch are adopted until a larger dataset is 
tested.  
 
The table below compares the number of macro and micrometastases detected by 
Metasin and Histology for all concordant positive nodes. 
 
 Metasin   
Histology Macro Micro Total 
Macro 
50 
(81.9%) 
2 
(3.2%)
52 
(85.2%) 
Micro 
1 
(1.6%) 
8 
(13%)
9 
(14.7%) 
Total 
51 
(84%) 
10 
(16.4%) 
61 
(100%) 
Table 41: Comparison of tumour volumes in concordant positive nodes between 
Metasin and histology (n=61) 
 
Out of 61 nodes, 50 were found to have macrometastasis by both Metasin and 
histology and 8 cases with micrometastasis for both. There were 2 cases which were 
found to be micrometastases by Metasin but macrometastases by histology and 1 case 
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which was found to be a macrometastasis by Metasin but a micrometastasis on 
histology. These 3 discordant results are most likely due to tissue allocation bias 
caused by allocating alternate slices to the PCR assays and to histology. 
 
The table below sumarises the cut-off values for both Metasin and GeneSearch assays. 
 
Assay Marker Positive/Negative Cut-off Macro- Micrometastasis Cut-off
GeneSearch CK19 30 25
GeneSearch MGB 31 26
Metasin CK19 32 25 
Metasin MGB 32.3 26
Table 42 A comparison of the Cut off values of GeneSearch and Metasin 
 
6.3 Comparing the sensitivity and specificity of Metasin and GeneSearch for the 
dataset 
 
The sensitivity and specificity of GeneSearch is calculated in order to compare the 
assay’s performance with Metasin. Histology is used as the gold standard when 
calculating the sensitivity and specificity of Veridex and GeneSearch is used as the gold 
standard when calculating the sensitivity and specificity of Metasin. 
 
 Histology 
GeneSearch Positive Negative 
Positive 60 8
Negative 5 279 
Table 43: Nodes results when comparing GeneSearch with histology 
Sensitivity of GeneSearch is 92% (85% - 98%, 95% CI) 
Specificity of GeneSearch is 99% 
 
 Histology 
GeneSearch Positive Negative 
Positive 36 3 
Negative 4 111 
Table 44: Cases results when comparing GeneSearch with histology 
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Sensitivity of GeneSearch is 90% (81% - 99%, 95% CI) 
Specificity of GeneSearch is 100% 
 
The following two tables compare the sensitivity and specificity of Veridex and Metasin 
for the dataset. 
 
 Sensitivity (95% CI) Specificity
GeneSearch 92% (85% - 98%) 99% 
Metasin 94% (88% - 99%) 100% 
Table 45: Comparing the sensitivity and specificity of Metasin and GeneSearch by 
nodes 
 
 Sensitivity (95% CI) Specificity
GeneSearch 90% (81% - 99%) 100% 
Metasin 95% (88% - 100%) 98% 
Table 46: Comparing the sensitivity and specificity of Metasin and GeneSearch by cases 
 
Metasin is shown to have a higher sensitivity than GeneSearch. However, these results 
use histology as the gold standard for GeneSearch and GeneSearch as the gold 
standard for Metasin. The sensitivity and specificity for Metasin when using histology 
as the gold standard is calculated and compared to GeneSearch. 
 
 Histology  
Metasin Positive Negative 
Positive 61 7 
Negative 3 281 
Table 47: Comparing Metasin with histology nodes results 
Sensitivity of Metasin is 95% (89% - 100%, 95% CI) 
Specificity of Metasin is 98% 
 
 Histology  
Metasin Positive Negative 
Positive 37 4 
Negative 2 111 
Table 48: Comparing Metasin with histology cases results 
Sensitivity of Metasin is 95% (88% - 100%, 95% CI) 
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Specificity of Metasin is 98% 
 
The following two tables compare sensitivity and specificity of Metasin and 
GeneSearch using histology as the gold standard for both 
 
 Sensitivity (95% CI) Specificity
GeneSearch 92% (85% - 98%) 99% 
Metasin 95% (88% - 100%) 98% 
Table 49: Comparing sensitivity and specificity of Metasin and GeneSearch using 
histology as the gold standard for both, nodes results 
 
 Sensitivity (95% CI) Specificity
GeneSearch 90% (81% - 99%) 100% 
Metasin 95% (88% - 100%) 98% 
Table 50: Comparing sensitivity and specificity of Metasin and GeneSearch using 
histology as the gold standard for both, cases results 
 
In conclusion, Metasin is shown to have a higher sensitivity than GeneSearch for both 
nodes and cases.  
 
6.4 Line of agreement   
 
In order to appreciate the agreement between the two assays, the results of all nodes 
were plotted onto scatter graphs.  
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Graph 6.1 Plotting the Cq values of GeneSearch CK19 and Metasin CK19 (Veridex = GeneSearch)   
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Graph 6.2 Plotting the Cq values of GeneSearch MGB and Metasin MGB (Veridex = GeneSearch)  
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When comparing the Cq values of both assays the following scattergraphs do not show 
a huge variation with the data points lying approximately along the 45° line. 
 
6.5 Cohen’s kappa 
 
Out of 154 patients, 111 patients were found to be negative, 37 patients were positive 
and 6 patients were discordant for GeneSearch and Metasin. The value of Kappa is 
0.90 and its confidence interval is 0.82 – 0.98, which does not include zero, showing 
the two assays significantly agree.  
 
Observer A GeneSearch 
Observer B Metasin
   
  Observer A   
Observer B 0 1   
0 111 2 113 (73.4%)
1 4 37 41 (26.6%)
  115 
(74.7%) 
39 
(25.3%) 
154
   
Weighted Kappaa 0.899 
Standard error 0.040 
95% CI 0.819 to 0.978 
a Linear weights 
 
Table 51. Cohen’s kappa 
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Figure 14. Distribution of concordant and discordant patients in Cohen’s kappa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
Veridex
Co
un
t
0 1
Metasin
0: Negative patients
1: Positive Patients
160 
 
Chapter 7 - The discordant results 
 
Out of 154 cases (352 nodes), there were 6 discordant cases (3.89%) when comparing 
Metasin and GeneSearch. There were 6 discordant nodes and 7 concordant nodes in 
the 6 cases. One positive concordant case with 5 nodes in total was found to have 3 
positive concordant nodes and two discordant nodes. Therefore, out of 352 nodes, 
there were 8 discordant nodes in total. The aim of this chapter is to analyse more 
closely the discordant cases between Metasin and GeneSearch and compare with the 
histology results. The discordant cases were also tested using agarose gel 
electrophoresis and the results found to be inconclusive.  
 
7.1 Comparing the results of GeneSearch, Metasin and Histology for the discordant 
cases 
 
A summary of the number of nodes and cases of Metasin found to be concordant and 
discordant with histology is tabulated. The discordance rate is also shown. The analysis 
is divided into nodes and cases. The initial analysis includes nodes or cases that were 
originally negative on histology but which after further levels were done, were found 
to be positive.
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 Case based  
 
Concordant 
cases  
Discordant 
cases  Total 
Discordant 
cases 
Discordant 
cases % 
 H+ M+ H- M- H+ M- H- M+    
Initial 
analysis 33 111 2 8 154 10 6.49% 
   
Deeper 
levels  37 111 2 4 154 6 3.89% 
        
 Node based       
 
Concordant 
nodes  
Discordant 
nodes  Total 
Discordant 
nodes 
Discordant 
nodes % 
 H+ M+ H- M- H+ M- H- M+    
Initial 
analysis 56 281 3 12 352 15 4.26% 
         
Deeper 
levels  61 281 3 7 352 10 2.84% 
Table 52: A summary of concordant and discordant nodes and cases when comparing Metasin with histology. H = histology, M = Metasin. 
Initial analysis is the first histological result before further levels were carried out. 
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The table above shows there were 10 discordant cases and 15 discordant nodes before 
further levels were carried out. After deeper levels, the number of discordant cases fell 
to 6 and the number of discordant nodes fell to 10. The discordance rates of 3.89% and 
2.84% for cases and nodes respectively is below the proposed accepted rate of 
discordance that GeneSearch set of 4%. 
 
A similar table is also presented comparing GeneSearch and histology 
A summary of the number of nodes and cases found to be concordant and discordant 
with Veridex and histology is tabulated. The discordance rate is also shown. 
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 Case based       
 
Concordant 
cases  
Discordant 
cases Total
Discordant 
cases
Discordant 
cases %
 H+ G+ H- G- H+ G- H- G+
Initial 
analysis 33 114 1 6 154 7 4.50% 
         
Deeper 
levels  36 111 4 3 154 7 4.50% 
  
 Node based       
 
Concordant 
nodes  
Discordant 
nodes  Total
Discordant 
nodes 
Discordant 
nodes % 
 H+ G+ H- G- H+ G- H- G+
Initial 
analysis 57 282 2 11 352 13 3.70% 
   
Deeper 
levels  60 279 5 8 352 13 3.70% 
Table 53: A summary of concordant and discordant nodes and cases when comparing histology with GeneSearch. G = GeneSearch, H = 
histology. Initial analysis is the first histological result before further levels were carried out. 
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The table above shows there were 7 discordant cases and 13 discordant nodes before 
further levels were carried out. After deeper levels, the number of discordant cases 
stayed at 7 and the number of discordant nodes stayed at 13. The discordance rate of 
4.5% for cases was above the accepted rate set by GeneSearch. However, the 
discordance rate for nodes is 3.7% which is below the discordance rate set by 
GeneSearch.  
 
The discordant cases has a significantly greater clinical consequence than the 
discordant nodes as a patient with a positive concordant node ie positive for both 
histology and Metasin, but with one or more discordant nodes is still labelled as a 
positive patient and therefore will still undergo axillary clearance. Therefore, analysis 
of discordant cases only will be described in detail.      
 
The table below shows the discordant cases comparing the Cq values of all three 
markers and the histology results with the size of the metastasis for the histology 
positive nodes. 
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Patient Specimen 
GS CK19 
Cq Value 
Metasin 
CK19 Cq 
Value 
GS 
MGB Cq 
Value 
Metasin 
MGB Cq 
Value GS Metasin 
Initial 
Histology 
Result 
Histology 
after 
levels 
1 08-12082B1 0 0 0 36.2 negative negative negative   
  08-12082B3 0 0 0 36.9 negative negative negative   
  08-12082C1 0 0 32.6 31.5 negative positive negative Negative 
  08-12082C3 0 0 35 34.2 negative negative negative   
                    
2 08-16837B 20.5 0 0 0 positive negative positive Macro 
                    
3 09-11238B 0 29.5 32.6 29.8 negative positive negative Micro 
                    
4 09-15813B 0 0 0 30.7 negative positive negative Micro
  09-15813C 0 0 0 0 negative negative negative   
                    
5 10-1643A 30.6 29.5 0 0 negative positive negative Micro 
  10-1643B 35.5 0 0 0 negative negative negative   
  10-1643C 0 0 0 0 negative negative negative   
                    
6 08-17635B1 34.8 0 0 0 negative negative negative   
  08-17635B2 29.9 0 31.7 36.2 positive negative negative Negative 
 
Table 54. GS = GeneSearch. All cases discordant for GeneSearch and Metasin are presented including the Cq values for Ck19 and MGB, 
the histology result before and after levels and the size of metastatic tumour deposit. The boxes highlighted in red are the discordant 
results 
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The table shows four cases where Metasin is positive and GeneSearch is negative. 
Three of those cases were shown to be positive on histology after deeper levels had 
been cut. Therefore, one case is negative for both histology and GeneSearch and 
considered a false positive result. 
There are two cases where GeneSearch is positive and Metasin is negative. One of 
these cases showed a macrometastasis indicating a false negative result for Metasin. 
The other case has not been shown to be positive on histology. If taking GeneSearch as 
the gold standard, this would be a false negative result but if considering histology as 
the gold standard, this would be a concordant result for Metasin.  
There is only one case where both GeneSearch and Metasin were negative and 
histology showed a macrometastasis, thus being a false negative for both assays. 
In summary, when comparing Metasin to histology, there is one false positive result 
and 2 false negative results. When comparing Metasin with GeneSearch, there are 2 
false negative results and 4 false positive results, 3 of which were in fact shown to be 
positive on histology. 
 
The table below compares the results of both nodes and cases with Metasin and 
GeneSearch. 
 
Node based 
discordance       
Concordant nodes  
Discordant 
nodes  Total 
Discordant 
nodes 
Discordant 
nodes % 
G+ M+ G- M- G+ M- G- M+
64 280 4 4 352 8 2.27%
       
Case based 
discordance       
Concordant cases  
Discordant 
cases  Total 
Discordant 
cases 
Discordant 
cases % 
G+ M+ G- M- G+ M- G- M+
37 111 2 4 154 6 3.89% 
Table 55: Comparing the results of cases and nodes of Metasin (M) vs GeneSearch (G)  
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Eight nodes were found to be discordant when comparing Metasin and GeneSearch 
results. Six of those nodes are from six discordant cases and two nodes are from one 
concordant case which had three other concordant positive nodes.  
 
The tables below summarise the number of cases and nodes tested, comparing 
Metasin to GeneSearch and histology.  
 
 
Table 56: Results of Metasin for cases and nodes compared with GeneSearch (left) and 
Histology (right) 
 
 
 
 
 
 
 
 
 
 
 
Metasin vs GeneSearch   Metasin vs Histology
Node Based Analysis  Node Based Analysis
Positive nodes 
64 
(18.2%) 
 
Positive nodes 
61 
(17.3) 
Negative nodes 
280 
(79%) 
 
Negative nodes 
282
(80%) 
Discordant nodes 
8 
(2.3%) 
 
Discordant nodes 
9
(2.5%) 
Total 352  Total 352 
    
Case Based Analysis   Case Based Analysis
Positive patients 
37 
(24%) 
 
Positive patients 
37
(24%) 
Negative patients 
111 
(72 %) 
 
Negative patients 
111
(72%) 
Discordant patients 
6 
(3.8%) 
 
Discordant patients 
6 
(3.8%) 
Total 154  Total 154
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Chapter 8 Validating the Metasin assay 
 
Several tests were carried out to validate the Metasin assay. The reproducibility of the 
assay was tested by running the same samples on different days with different users. 
The products were also run on a gel to confirm the right products were being 
amplified. The Cq values of monoplexed and multiplexed markers were also compared 
to see if multiplexing had an effect on the accuracy of the results. The RNA 
concentrations of some of the positive samples were compared to their PBGD Cq 
values for both Metasin and GeneSearch. Finally, a dilution series was also run using 
three positive samples and the efficiency calculated.   
 
8.1 Comparing Metasin Cq values of the same samples on different runs done on 
different days by different users to illustrate reproducibility of results 
 
Out of 16 positive cases (33 nodes) that were run, three nodes in three different cases 
had discordant MGB results. Two of these cases had concordant positive CK19 and so 
the cases were still positive. The third known positive case (15131B) is positive for 
MGB with a Cq value of 30.8 and negative for CK19 with a Cq value of 31.6 by 
GeneSearch. The case was found to be positive on Metasin with a MGB Cq value of 
31.7 on one day by one user and negative on Metasin with a MGB Cq value of 33.6 on 
the other day with the other user. 
The full table is available in the appendix (pg 226). 
 
The following histogram illustrates the difference between the set of results obtained 
by each user. CK19 showed the least difference in Cq value with the largest difference 
being 0.6. PBGD Cq value difference was seen to be 0.8. MGB had the greatest 
difference in Cq value with 1.9. 
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Graph 7. Comparison of Cq Values to assess reproducibility of the Metasin assay 
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8.2 RNA product identification  
 
The PCR products were run on a gel to ensure the correct amplicons were being replicated. 
 
 Figure 15 Gel electrophoresis of positive nodes that were monoplexed and triplexed 
Figure A shows the fluorescence of the PCR products after amplification of PBGD (lanes 1,2 and 3), CK19 (lanes 4,5 and 6) and MGB (lanes 
7 and 8). Lanes 9 to 13 show fluorescence of known positive nodes. The molecular weight marker (ΦXHae III marker) is shown on the left 
side and between lanes 6 and 7. The size markers correspond to CK19 (128 bp), PBGD (92bp) and MGB (69bp). Figure B shows the bands 
for each monoplexed marker and two triplexed samples more closely with a schematic on the right illustrating the expected band sizes 
corresponding to the three amplicons. 
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8.3 RNA concentration and yield 
 
The RNA concentrations of the samples are reflected in the PBGD Cq values and do not 
vary greatly. The ratio of A260/280 shows most samples around 2, indicating the RNA 
is pure with hardly any contamination of protein. The full table is available in the 
appendix (pg 228).  
 
8.4 Comparing monoplexed and multiplexed Cq values 
 
The table compares the Cq values of the monoplexed and multiplexed markers.  
 
Sample 
PBGD 
mono 
PBGD 
multi 
CK19 
mono 
CK19 
multi 
MGB 
mono 
MGB 
multi 
7867D 25.3 25.4 27.9 27.5 22.8 22.8
3256E 24.9 25.3 27.7 28.4 29.4 29
7638 22.7 23.3 16.3 16.6 16.3 19.4
6173B 25.2 25.7 20.3 20.3 20.8 22.9
Table 57 Comparing the Cq values of monoplexed and multiplexed markers.  
 
The results in these samples correlate closely.  
 
8.5 The no-RT step run 
 
A control run was done to check the mastermix that was to be used in the no RT run 
would work. 
Sample PBGD CK19 MGB 
17502B2 (positive control) 25.9 18.5 26.4
18609B (negative control) 27.3 0 0 
Table 58.1 Confirming the mastermix works with Cq values for the positive and 
negative control. 
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The assay was then run without the RT step. 
 
Sample PBGD 
7867D 0 
10762D 0 
3256E 0 
11531C1 0 
10931B 0 
745C 0 
925B 0 
17502B2 0 
12439B 0 
16837B 0 
2344C 0 
2487B 0 
12043B 0 
Table 58.2 The no RT step run results 
 
The table above shows no detection of PBGD and therefore no genomic DNA was 
shown to be present. 
   
8.6 Dilution series and PCR efficiency 
 
The RNA of three samples were diluted tenfold upto four times and run to give the 
efficiency of the PCR. The Cq values of all three samples are also given.  
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Table 59. Cq values in the dilution series  
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Graph 8. Standard curve and PCR efficiency of Metasin 
The efficiency is close to 100% (97.65%).   
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In summary, the PCR amplification was shown to produce the correct amplicons at the 
end of the reaction as evidenced by the expected bands seen when the PCR products 
were run on a gel.  The concentration of the RNA products did not vary widely and the 
RNA was found to be pure with the ratio of A260/280 approximately 2. Cq values of 
monoplexed and multiplexed markers correlated closely with no discordant results. 
The no-RT experiment showed no detectable PBGD. PCR efficiency was found to be 
almost 100%. When the assay was run on different days by different users, three 
nodes were discordant for MGB and one case was discordant highlighting the need for 
improvement in the reproducibility of the assay.  
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PART IV. DISCUSSION 
 
Chapter 9  
 
The purpose of the MD was to set-up and validate an intra-operative real-time RT-
qPCR assay to detect metastatic breast cancer metastases in sentinel lymph nodes. The 
aim was to be able to replace the commercial assay GeneSearch (Veridex) which was 
about to be withdrawn.  
Molecular pathology and diagnostics has a major impact on the diagnosis and 
treatment of patients with cancer. Real-time RT-qPCR is just one of many tools used by 
researchers, clinicians and technicians to diagnose various genetic forms of cancer. It is 
highly specific and sensitive, relying on appropriate primers which are specific to the 
target of interest.   
The Metasin assay was initially optimised using FAM-labelled hydrolysis probes on the 
LC480 platform. The clinical requirement of the Metasin assay is that the time taken to 
reach a result should not take longer than approximately 26 minutes, emulating the 
run time of GeneSearch. In order to achieve this, the LC480 was replaced with the 
SmartCycler and the primers and probes multiplexed in order to improve the speed of 
the Metasin assay.  
The table below summarises the steps taken for the LC480 and Metasin, including the 
methods employed in reducing the run time. 
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LC480 Metasin
Primer concentration Primer concentration
Probe concentration RNA volume
RNA volume  
Reducing the run time Reducing the run time
Annealing step Annealing step 
 Denaturing step 
 Reverse transcription step
Table 60. The optimising steps carried out on both platforms 
 
Once Metasin was optimised, 154 cases having 352 nodes were tested and their Cq 
values compared to those of GeneSearch. Out of 154 cases, 111 were found to be 
negative and 37 were found to be positive for both assays. Six cases were discordant. 
The sensitivity and specificity of Metasin were found to be 95% and 98% respectively. 
The sensitivity and specificity of GeneSearch were found to be 90% and 100% 
respectively. The error rate of Metasin was 3.89% compared to GeneSearch with 
4.50%.      
This chapter aims to discuss unexpected findings encountered during the validation 
process with a detailed discussion of the the discordant results. The effect the Metasin 
assay will have on patients and necessary further work are described. 
 
9.1 Validating the Metasin assay  
 
Several tests were taken to validate the assay. The RNA quantity was checked using a 
spectrophotometer. However, a further check for RNA quality was not performed and 
should be carried out to gain further reassurance regarding the integrity of the RNA 
extracted. The desired amplicons that were targeted during PCR were found to be 
present in the PCR product when tested using gel electrophoresis. When the RT step 
was omitted from the PCR run, no genomic DNA was detected. Comparing the results 
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of the monoplexed and multiplexed markers showed no overall significant differences 
in Cq values for the markers. PCR efficiency was found to be nearly 100% at 97.65%. 
The reproducibility test highlighted flaws in the assay which need to be addressed. The 
runs carried out to investigate reproducibility of results illustrate the importance of 
having a standardised assay which would help reduce the chance of user error. For 
example, large batches of pre-prepared primer and probe mixes could be tested on 
several known positive and negative samples and then stored before being used in a 
diagnostic run. Adequate training of users of the assay is crucial to minimise errors 
made by inexperienced users. Veteran users of the assay should train and supervise 
new users to check there are no bad practices or errors made or learnt which could be 
passed to others. A standard operating procedure (SOP) has already been drafted for 
the Metasin assay and is available on page 240. 
  
9.2 The discordant cases  
 
The majority of cases were concordant with Metasin and GeneSearch. Out of 154 
cases, there were 6 discordants, 3.9% of the total number of cases.  
 
9.2.1 Troubleshooting discordant cases 
 
In investigating the discordant results, an organised and logical trouble-shooting 
approach was developed. Different problem scenarios which came up during the 
optimising and validation process were addressed. Where appropriate, cases which fall 
into those scenarios are included. As noted earlier, the discordance rate of Metasin is 
3.89% and the cases described below form a minority of the overall cases tested. 
 
Problem: 
• The positive and/or negative control did not work and/or the PBGD Cq value for 
any node did not work 
Possible solution: 
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• Problem with the primer/probe mix 
• Problem with the Mastermix 
• No RNA was added 
If the nodes to be investigated registered a PBGD Cq value but the control/controls did 
not, then fresh RNA was extracted from a known positive and negative node and using 
the same primer/probe mix the assay was re-run. If the controls worked but no PBGD 
Cq value was obtained for the unknown nodes, fresh RNA was extracted and the assay 
repeated with the same primer/probe mix. 
In my experience, this would usually solve the problem of no PBGD in some nodes in 
the same assay.  
If no nodes were positive for PBGD, a fresh batch of primer/probe mix would be made 
up. Fresh Mastermix is always made up for new runs. 
 
Problem: 
• The controls worked, however, there is discordance 
Possible solution: 
1. Discordance with histology 
Metasin is negative and histology is positive 
New primer/probe mix was made up and fresh RNA extracted. If the result was 
positive then it was considered a user error. If the result was still negative, this could 
be taken as either a sampling error or a false negative result. 
Metasin is positive and histology is negative. 
The blocks of the discordant node are pulled out and upto 10 extra levels were cut and 
prepared for microscopic assessment along with immunohistochemistry for a 
pancytokeratin MNF116 and/or CK19. If the extra levels revealed metastatic tumour, 
Metasin was vindicated. There were three cases out of 154 where the initial histology 
result was negative, however, further levels and immunohistochemistry revealed 
micrometastases (please see tables 52 and 54). If the extra levels did not reveal 
metastasis, this could be taken as a sampling error or a false positive result. 
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2. Discordance with GeneSearch 
Metasin is positive and GeneSearch is negative  
If histology was positive, Metasin was correct and this was a case missed by 
GeneSearch. The GeneSearch assay was re-run for the node a second time to try to 
rule out user error. 
If histology was negative, extra levels were cut to try and determine the presence of 
metastases. If metastases were found, then Metasin was correct. If not, then the 
Metasin assay was re-run using fresh primer/probe mix and fresh extracted RNA. If the 
node was negative the second time round, the first false positive result was considered 
a user error or a contamination problem. If despite mixing a fresh batch of 
primer/probe mix which worked on the controls and extracting fresh RNA from the 
discordant node, the result was still positive, either there was still a contamination 
issue or it was a sampling error and a false negative GeneSearch result. One case out 
of the six discordant cases previously described in section 7.1 was positive for MGB 
only with a Cq value of 31.5 raising the possibility of a micrometastasis in the slice 
given to Metasin with none of the focus seen on the slide. The GeneSearch assay did 
detect MGB with a Cq value of 32.6 which was 1.6 away from a positive result. 
Metasin is negative and GeneSearch is positive 
If histology was negative, further levels and immunohistochemistry was done to try 
and confirm the node was positive on histology. If it remained negative, the 
GeneSearch assay was re-run for the node. If the second GeneSearch result was 
negative, then the first erroneous result was most likely due to user error or 
contamination. If it remained positive, this may be a false-positive result or Metasin 
may be giving a false-negative result and there may be sampling error. 
If histology is positive, then a fresh primer/probe mix was made, fresh RNA extracted 
and the Metasin assay run again. If the node was then positive, it was put as a user 
error. If the node remained negative for Metasin, the node was run again on 
GeneSearch to confirm it was positive. Despite repeated attempts at running the node 
on Metasin on different days with different operators, if it still remained negative, the 
same RNA used on Metasin was run on GeneSearch to test the RNA. In unresolved 
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cases, the PCR products from Metasin could be run on a gel to try and identify the 
three products PBGD, CK19 and MGB. If the products are visible on the gel, it suggests 
a probe problem where the product was present but could not be detected. If the 
products are not detected, it suggests a primer problem. The last step would be to 
consider sequencing the PCR products to detect the presence of PBGD, CK19 and MGB. 
Two out of the six discordant cases fall into this category. One case in which there was 
a macrometastasis on histology was thought to be possibly due to RNA degradation as 
the sample was constantly thawed and frozen over a two year period. The other case 
was histology negative where GeneSearch picked up CK19 with a Cq value of 29.9, just 
0.2 away from a negative result. Metasin did not detect any CK19.   
 
9.2.2 Discordance between Metasin and histology 
 
Histology will remain the gold standard for assessment of the sentinel lymph node and 
therefore submitting the whole node to Metasin is a step that may be too rash for 
most histopathologists who feel that histological evidence of metastasis is needed to 
constantly validate the Metasin assay findings. The drawback is the chance of sampling 
discordance whereby if a micrometastsis is present in the 2mm slice given to either 
test, a discrepancy will almost certainly arise.  
 
For the purposes of the assay, the view was taken that even if Metasin or histology did 
not detect a positive node, but the case overall was found to be positive with other 
nodes, then that was a concordant result. The majority of nodes and therefore cases 
were concordant. However, there were 6 cases that were found to be discordant for 
Metasin and histology, with 4 cases positive for Metasin and negative for histology and 
2 cases negative for Metasin and positive for histology. 
 
The table illustrates the possible outcomes and the possible reasons behind the 
discordance between the molecular assays and histology (Douglas-Jones and Wood, 
2009). 
Commented [SP3]: You were asked to expand this and include a 
comment on the likelihood of these various scenarios. At present it 
still implies that these are frequent occurrences. Please amend and 
add an additional paragraph. 
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Molecular assay (Metasin and GeneSearch) Histology Interpretation
Positive Positive Concordance
Positive Negative ? False positive ? 
Sampling error 
Negative Positive ? Sampling error
Negative Negative Concordance
Table 61: Showing the possible reasons for discordance 
 
Discordance between histology and both molecular assays is most likely due to 
sampling. Alternate slices of the node are given to the assays and histology resulting in 
unavoidable sampling discordance. An example of a case that highlights this point is 
the case where one node which was found to be positive with histology but negative 
with both Metasin and GeneSearch. 
A closer analysis was done of this node. The node was sliced into five slices and slices 
1, 3 and 5 were given to the molecular assays and slices 2 and 4 to histology.  For the 
histological assessment of a node, each slice is examined on three levels: L1, L2 and L3. 
In this particular node, the first level in slice 2 abutts the deep surface of slice 1. The 
second level in slice 2 was taken 150µm deep and the third level another 150µm deep. 
On histological examination of slice 2, levels 1 and 2 showed a macrometastatic 
tumour deposit measuring 3mm. 
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Figure 16. Diagram of the slices and the location of the macrometastasis 
The red dotted line indicates the unknown area. 
 
L3   L2   L1 
Molecular Assay Histology 
Slice 1 
Slice 2 Slice 3Slice 4 
Slice 5 
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Figure 17. Level 2 of slice 2 showing a 3mm macrometastasis (x10). 
 
The metastatic tumour deposit was seen in slice 2 only and in L1 and L2 but not L3. 
This indicates that the cancer did not spread through slice 2 to reach slice 3 and 
therefore the assays would have found slices 3 and 5 negative. However, L1 in slice 
2 was positive and so the deep surface of slice 1 was likely to be positive for 
metastatic cancer.  
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Figure 18. Level 1 of slice 2 showing part of the macrometastasis (x20). This level is 
the closest to slice 1. 
 
After analysing the histology results, the sample was run twice more on GeneSearch 
and three times on the LC480 and Metasin and the same results obtained. Therefore, 
this case represented a false negative for all three molecular assays. 
It would be unlikely for all three assays to be unsuccessful in picking up a 
macrometastasis. Therefore, the likeliest explanation is that the slice with the cancer 
may have been thicker than 2mm and contain the whole focus of tumour. The lymph 
node was measured to be 14mm in maximum length, which should result in 7 slices if 
the node was cut into 2mm slices. However, there were only 5 slices cut. This supports 
the idea that the slices were too thick and raises the possibility of the whole tumour 
deposit being in one slice that was given to histology.  
 
Despite the discordant cases, the error rate of Metasin of 3.89% falls below the error 
rate acceptable for the commercially available GeneSearch assay.   
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9.3 Impact of the assay on the patient and the Trust 
 
The validation results were found to be accurate enough for the Metasin to be first run 
alongside GeneSearch and then to be used as a diagnostic assay. The effect the assay 
will have on the patient and the Trust has been described in detail in the introduction. 
It will avoid an unnecessary second operation for the patient, reducing their anxiety 
and helping with their recovery. A reduction in second operations will also reduce the 
pressures on the Trust and the NHS in terms of the beds needed, operating time and 
theatres used. However, it should be kept in mind there may be other reasons for 
patients to undergo second operations, for example, in situations where a wide local 
excision has been found to have a positive margin.  
 
Metasin is cost-effective, a huge advantage in times of financial constraints and cost-
cutting in the NHS. It costs approximately £50 to test a sentinel lymph node using the 
Metasin assay. The average cost of a completion axillary clearance is estimated at 
£2227, a huge saving for the Trust (Nadi et al, 2012). 
 
Importantly, Metasin has also been shown to be more sensitive and specific in picking 
up metastases compared to conventional intraoperative techniques of frozen section 
and TIC, improving the detection rate.   
 
9.4 Future work 
 
The concept of detecting metastatic breast cancer in sentinel lymph nodes using the 
markers CK19 and MGB has been trialled and tested by various institutions and shows 
the GeneSearch assay is highly specific and sensitive.  Therefore, the concept of the 
Metasin assay which uses the same principle was already known and accepted. For 
Metasin to replace GeneSearch it would need to show the same level of performance, 
if not better.  
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During the optimisation process, a number of decisions were made regarding primer 
and probe concentrations and RNA volume used in the assay. These decisions were 
influenced by performance and to allow for easy calculations and preparation of the 
PCR mixture but also by cost and time restraints. In order to deliver a functioning assay 
at a specified time and within budget, certain procedures were not carried out. When 
optimising the assay, triplicate runs could have been run for all samples to ensure 
accurate results. Primer and probe sets could have been made into batches and tested 
on positive controls before being used in optimising runs instead of being used 
straightaway in runs. Discordant cases could have had sequencing of DNA to 
investigate the causes of discordance. The overall approach taken was largely 
pragmatic and due to the increased cost that would incur.  
 
There are further improvements that could be made. For example, instead of having a 
single reference gene, a panel of reference markers could be used in order to improve 
the reliability and accuracy of the assay. More samples would also need to be run to 
make the assay more statistically significant. Only then can the Cq cut-off values be re-
examined to ensure accuracy. RNA samples from a further 193 anonymised nodes 
were tested to assess the validity of the assay. All 104 negative nodes were found to 
be negative and all nodes with macro-metastases were found to be positive with 
Metasin. However, 15 out of 33 nodes with micrometastatses were found to be 
negative by Metasin with Cq values ranging from 0.1 to 1.1 from the cut-offs (Al-
Ramadhani et al, 2013). This raises the need for standardisation of the assay.  
 
However, there are a growing number of institutions that advocate sparing the patient 
with micrometastases an axillary clearance although this is not entirely accepted. 
Giuliano et al reported after the ZOO11 trial that patients with a positive sentinel 
lymph node who match their inclusion criteria should be spared axillary clearance as 
there was no additional benefit to overall survival (discussed further in section 1.2.1, 
pg 37).     
 
Commented [SP4]: You were asked to add a more detailed 
description of th Z11 study, which you have not done. Please amend 
and do this. 
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Contamination is also an important issue when using PCR. Ideally, the preparation 
stage and PCR stage should be done in separate rooms with a one-way sample flow. 
Other measures that would help are frequent glove changes, dedicated pipettes and 
experienced and trained laboratory staff. Currently, the Metasin assay is being used 
successfully as a diagnostic assay. A SOP has been produced which will enable the 
assay to become standardised and therefore limit the chances of error. The primer/ 
probe mixes can also be made either in large batches or by an external expert provider 
that can quality assure its product and provide assistance or advice when unexpected 
results occur. 
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APPENDICES 
 
Appendix 1 Materials and Method 
1.1 Full list of Materials 
The following list of equipment, reagents and primers and probes were used during 
the optimisation and validation of the Metasin assay. 
COMPANY PRODUCT NAME 
CATALOGUE 
NUMBER 
ROCHE LIGHTCYCLER 480 RNA HYDROLYSIS PROBES 4991885001 
QIAGEN RNEASY MINI KIT (50) 74104
QIAGEN  BUFFER RLT (220ml) 79216
CEPHEID 
CEPHEID 25 µL REACTION TUBES (for 
SmartCycler) 50 pcs/bag 900-0003 
QIAGEN VAC CONNECTORS 100/bag 19407
QIAGEN VAC VALVES 24/pk 19408 
OMNI 
INTERNATIONAL 
OMNI TIPS DISPOSABLE PROBES for Omni 
Homogeniser 25pk 7mmx110mm 30750 
VWR 
8mL PLASTIC CULTURE TUBES for 
homogenisation 13x100mm 125/bag 211.0074 
VWR 
15mL POLYSTYRENE TUBES for 
homogenisation 17x120mm  500/bag 734-0450 
VWR 
15ML CENTRIFUGE TUBE WITH FLAT CAP 
500/BAG 525-0400 
FISHER BRAND 
SAV-IT CLOSURES 12mm/13mm GREEN PK 
OF 100 02-707-10 
BECTOR 
DICKINSON 
50mL FALCON BLUEMAX POLPROPYLENE 
CONICAL TUBE for 70% Ethanol 25/pk 352098 
(TRADE WINDS 
DIRECT) DISPOSABLE FORCEPS (autoclavable) 100/pk DF8088N 
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FISHER BRAND WEIGHING DISH  89X89X25mm 500PCS/BOX 08-732-113 
SWANN-MORTON DISPOSABLE SCALPELS  (10/pk) SCA-310-030K 
FISHER 
BIOREAGENTS 
WATER STERILE DEPC TREATED (NUCLEASE 
FREE) 100mL BPE2484-100 
SWANN-MORTON 
MICROCENTRIFUGE TUBE SNAP TOP 
graduated 1.5mL 500/pk FB56089 
FISHER SCIENTIFIC 
PIPETTOR TIP SUREONE FILTER STERILE RACK 
MICROPOINT TIP 0.1 - 10µl graduated 960 
tips/pk FB78100 
FISHER SCIENTIFIC 
PIPETTOR TIP SUREONE FILTER STERILE RACK 
BEVELLED TIP 10-100µL 960 tips/pk FB78108 
FISHER  
PIPETTOR TIP SUREONE FILTER STERILE RACK 
MICROPOINT TIP graduated 100-1000µl 960 
tips/pk FB78112 
FISHER  
PIPETTOR TIP FINNTIP STERILE 2-10ML 24 
tips/pk  PMP-103-260E 
VWR 
PIPETTE TIP BIOHIT SAFETYSPACE FILTER TIP 
2-100/120µl      960 tips/pk 790101F 
CALBIOCHEM  β-MERCAPTOETHANOL 250ml 44203
SIGMA ALDRICH 
200-PROOF (ABSOLUTE) ETHANOL, molecular 
biology grade 245119-1L 
FISHER 
MICROCENTRIFUGE TUBES, 1.5ML WITH 
SCREW CAP & O-RING ATTACHER, AMBER TUL-918-096B 
VWR SUPERSPIN TUBES, 1.5ML YELLOW TUBES 211-0017 
VWR SUPERSPIN TUBES, 1.5ML ORANGE TUBES 211-0018 
VWR SUPERSPIN TUBES, 1.5ML PURPLE TUBES 211-0020 
VWR SUPERSPIN TUBES, 1.5ML    BLUE TUBES 211-0021 
ROCHE LIGHTCYCLER 480 SEALING FOIL, 50 FOILS  
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04729757001
ROCHE LIGHTCYCLER 480 MULTIWELL PLATE (96)   04729692001 
ROCHE 
LIGHTCYCLER COLOUR COMPENSATION SET 
(FOR 5 CALIBRATION REACTIONS)   12158850001 
ROCHE 
LIGHTCYCLER MULTICOLOUR DEMO SET (5 
COLOUR COMPENSATION RUNS) 03624854001 
QIAGEN 
QUANTITECT REVERSE TRANSCRIPTION KIT, 
200 X 20 ULS REACTIONS   205313 
ALPHA LAB 
0.1-10UL CLEAR TIP STERILE PIPETTE TIPS 
(96/PACK)   LW1136 
ALPHA LAB 
1-200UL CLEAR TIP STERILE PIPETTE TIPS 
(96/PACK) LW6365S 
ALDRICH 
MICROFUGE TUBE 1.5ML, SAFE-LOCK, 1000 
TUBES   7555874 
ALDRICH MICROFUGE TUBE  0.5ML   Z606332-500EA 
JENCONS BIOHIT FILTER TIPS, 0.1UL-10UL, 96 TIPS X 10  613-0857 
VERIDEX 
GENESEARCH BREAST LYMPH NODE (BLN) 
TEST KIT   2900004 
VERIDEX GENESEARCH RNA SAMPLE PREPARATION KIT  2900005 
COSTAR 
MICROCENTRIFUGE TUBE 1.7MI 500 
TUBES/BAG 3621 
BIOLABS ØX174 DNA-HAEIII DIGEST N3026S 
FLUKA 
ANALYTICAL AGAROSE 05066-50G 
SIGMA TBA BUFFER  
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PRIMERS 
 
Synthesis Scale: 0.010 7mol  
Condition: 10 nmol lyo  
Purification: GSF 
 
CK19 F2 (FORWARD PRIMER) 
CAgCCACTACTACACgACCATC   LENGTH 22MER 
 
CK19 R2 (REVERSE PRIMER) 
CAAACTTggTTCggAAgTCATC   LENGTH 22MER 
 
SCGB2A2_S (FORWARD PRIMER)      
CTCCCAgCACTgCTACgC   LENGTH 18MER 
 
SCGB2A2_b (REVERSE PRIMER) 
GgATTgATTgTCTTggAAATCACA   LENGTH 24MER 
 
PBGD_F (FORWARD PRIMER)    
TgTggTgggAACCAgCTC   LENGTH 18MER 
 
PBGD_R (REVERSE PRIMER) 
TgTTgAggTTTCCCCgAAT   LENGTH 19MER 
 
PROBES 
 
PBGD  (NM_000190) 
ctcctgaactccagatgcggga 
 
CK19  (NM_002276) 
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cagccagacgggcattgtcg 
 
MGB  (NM_002411) 
Ctctggctgccccttattggag 
 
1.2 Genetic sequences for the markers PBGD, CK19 and MGB 
 
The following are the gene sequences for the markers used in the assay. The bold red 
sequences are from the UPL website. The underlined sequences and the black bold 
letters are the primer sequences designed by TIB MOLBIOL. The blue sequences are 
the probes from TIB MOLBIOL. The probe sequences from the UPL website are not 
available to the public.  
 
PBGD mRNA (NM_000190) 
      1 agcaggtcct actatcgcct ccctctagtc tctgcttctt tggatccctg aggagggcag 
    61 aaggaagaaa acagcccaaa gatgagagtg attcgcgtgg gtacccgcaa gagccagctt 
  121 gctcgcatac agacggacag tgtggtggca acattgaaag cctcgtaccc tggcctgcag 
  181 tttgaaatca ttgctatgtc caccacaggg gacaagattc ttgatactgc actctctaag 
  241 attggagaga aaagcctgtt taccaaggag cttgaacatg ccctggagaa gaatgaagtg 
  301 gacctggttg ttcactcctt gaaggacctg cccactgtgc ttcctcctgg cttcaccatc 
  361 ggagccatct gcaagcggga aaaccctcat gatgctgttg tctttcaccc aaaatttgtt 
  421 gggaagaccc tagaaaccct gccagagaag agtgtggtgg gaaccagctc cctgcgaaga 
  481 gcagcccagc tgcagagaaa gttcccgcat ctggagttca ggagtattcg gggaaacctc 
  541 aacacccggc ttcggaagct ggacgagcag caggagttca gtgccatcat cctagcaaca 
  601 gctggcctgc agcgcatggg ctggcacaac cgggttgggc agatcctgca ccctgaggaa 
  661 tgcatgtatg ctgtgggcca gggggccttg ggcgtggaag tgcgagccaa ggaccaggac 
  721 atcttggatc tggtgggtgt gctgcacgat cccgagactc tgcttcgctg catcgctgaa 
  781 agggccttcc tgaggcacct ggaaggaggc tgcagtgtgc cagtagccgt gcatacagct 
  841 atgaaggatg ggcaactgta cctgactgga ggagtctgga gtctagacgg ctcagatagc 
  901 atacaagaga ccatgcaggc taccatccat gtccctgccc agcatgaagat ggccctgagg 
  961 atgacccaca gttggtaggc atcactgctc gtaacattcc acgagggccc cagttggctg 
1021 cccagaactt gggcatcagc ctggccaact tgttgctgag caaaggagcc aaaaccatcc 
1081 tggatgttgc acggcagctt aacgatgccc attaactggt ttgtggggca cagatgcctg 
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1141 ggttgctgct gtccagtgcc tacatcccgg gcctcagtgc cccattctca ctgctatctg 
1201 gggagtgatt accccgggag actgaactgc agggttcaag ccttccaggg atttgcctca 
1261 ccttggggcc ttgatgactg ccttgcctcc tcagtatgtg ggggcttcat ctctttagag 
1321 aagtccaagc aacagccttt gaatgtaacc aatcctacta ataaaccagt tctgaaggt  
 
 
CK19 mRNA (NM_002276)  
 
       1 agatatccgc ccctgacacc attcctccct tcccccctcc accggccgcg ggcataaaag  
     61 gcgccaggtg agggcctcgc cgctcctccc gcgaatcgca gcttctgaga ccagggttgc  
  121 tccgtccgtg ctccgcctcg ccatgacttc ctacagctat cgccagtcgt cggccacgtc  
  181 gtccttcgga ggcctgggcg gcggctccgt gcgttttggg ccgggggtcg cctttcgcgc  
  241 gcccagcatt cacgggggct ccggcggccg cggcgtatcc gtgtcctccg cccgctttgt  
  301 gtcctcgtcc tcctcggggg cctacggcgg cggctacggc ggcgtcctga ccgcgtccga  
  361 cgggctgctg gcgggcaacg agaagctaac catgcagaac ctcaacgacc gcctggcctc  
  421 ctacctggac aaggtgcgcg ccctggaggc ggccaacggc gagctagagg tgaagatccg  
  481 cgactggtac cagaagcagg ggcctgggcc ctcccgcgac tacagccact actacacgac  
  541 catccaggac ctgcgggaca agattcttgg tgccaccatt gagaactcca ggattgtcct  
  601 gcagatcgac aatgcccgtc tggctgcaga tgacttccga accaa (exon3)gtttg agacggaaca  
  661 ggctctgcgc atgagcgtgg aggccgacat caacggcctg cgcagggtgc tggatgagct  
  721 gaccctggcc aggaccgacc tggagatgca gatcgaaggc ctgaaggaag agctggccta  
  781 cctgaagaag aaccatgagg aggaaatcag tacgctgagg ggccaagtgg gaggccaggt  
  841 cagtgtggag gtggattccg ctccgggcac cgatctcgcc aagatcctga gtgacatgcg  
  901 aagccaatat gaggtcatgg ccgagcagaa ccggaaggat gctgaagcct ggttcaccag  
  961 ccggactgaa gaattgaacc gggaggtcgc tggccacacg gagcagctcc agatgagcag  
 1021 gtccgaggtt actgacctgc ggcgcaccct tcagggtctt gagattgagc tgcagtcaca  
 1081 gctgagcatg aaagctgcct tggaagacac actggcagaa acggaggcgc gctttggagc  
 1141 ccagctggcg catatccagg cgctgatcag cggtattgaa gcccagctgg gcgatgtgcg  
 1201 agctgatagt gagcggcaga atcaggagta ccagcggctc atggacatca agtcgcggct  
 1261 ggagcaggag attgccacct accgcagcct gctcgaggga caggaagatc actacaacaa  
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 1321 tttgtctgcc tccaaggtcc tctgaggcag caggctctgg ggcttctgct gtcctttgga  
 1381 gggtgtcttc tgggtagagg gatgggaagg aagggaccct tacccccggc tcttctcctg  
 1441 acctgccaat aaaaatttat ggtccaaggg aaaaaaaaaa aaaaaaaaaa  
 
 
MGB mRNA (NM_002411) 
    1 acagcggctt ccttgatcct tgccacccgc gactgaacac cgacagcagc agcctcacca  
   61 tgaagttgct gatggtcctc atgctggcgg ccctctccca gcactgctac gcag (exon 2)gctctg  
 121 gctgcccctt attggagaat gtgatttcca agacaatcaa tccacaagtg tctaagactg  
 181 aatacaaaga acttcttcaa gagttcatag acgacaatgc cactacaaat gccatagatg  
 241 aattgaagga atgttttctt aaccaaacgg atgaaactct gagcaatgtt gaggtgttta  
 301 tgcaattaat atatgacagc agtctttgtg atttatttta actttctgca agacctttgg  
 361 ctcacagaac tgcagggtat ggtgagaaac caactacgga ttgctgcaaa ccacaccttc  
 421 tctttcttat gtctttttac tacaaactac aagacaattg ttgaaacctg ctatacatgt  
 481 ttattttaat aaattgatgg ca  
 
1.3 Tables showing the volumes of homogenization buffer and the volume to be 
transferred to the spin column during RNA extraction and purification  
 
1.3.1 Volume of homogenization buffer required according to tissue weight 
Tissue weight (mg) Homogenization buffer (mL) 
3 – 149 2 
150 – 199 3 
200 – 249  4 
250 – 299  5 
300 – 349  6 
350 – 399  7 
400 – 449  8 
450 – 499  9 
500 – 550  10 
Greater than 550 To be divided further 
(GeneSearch test kit insert) 
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1.3.2 Volume of homogenate-ethanol mix to transfer to the spin column 
 
Tissue weight (mg) Volume of homogenate-ethanol mix (µl) 
3 – 39  700 
40 – 49  500 
50 – 59  400 
60 – 69  350 
70 – 79  300 
80 – 89  250 
90 – 99  225 
Greater than or equal to 100 200 
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Appendix 2 Results 
 
2.1 Optimisation results – changing RNA template volume 
 
For an RNA volume of 2µl, the following Cq values were obtained. 
 
Sample Marker Cq value GeneSearch Cq value
9041B PBGD 26.03 28.1 
 PBGD 26.25  
 CK19 ND 33.8 
 CK19 ND  
 MGB 29.99 30.4 
 MGB 30.5  
745C PBGD 25.48 26.4 
 PBGD 25.37  
 CK19 17.92 19.2 
 CK19 17.88  
 MGB 23.93 23.9 
 MGB 23.88  
14734B PBGD 25.79 28.1 
 PBGD 25.91  
 CK19 ND 0 
 CK19 ND  
 MGB ND 0 
 MGB ND  
ND = not detected 
For two of the samples, the PCR reaction did not detect CK19  
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For an RNA volume of 1µl, the following Cq values were obtained 
 
Sample Marker Cq value GeneSearch Cq value 
9041B PBGD 26.46 28.1 
 PBGD 26.55  
 CK19 ND 33.8 
 CK19 ND  
 MGB 30.45 30.4 
 MGB 30.83  
745C PBGD 25.77 26.4 
 PBGD 25.8  
 CK19 18.49 19.2 
 CK19 18.52  
 MGB 24.43 23.9 
 MGB 24.32  
14734B PBGD 26.26 28.1 
 PBGD 26.54  
 CK19 ND 0 
 CK19 ND  
 MGB ND 0 
 MGB ND  
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For an RNA volume of 5µl, the following Cq values were obtained 
 
Sample Marker Cq value GeneSearch Cq value 
9041B PBGD 28.83 28.1 
 PBGD 28.53  
 CK19 ND 33.8 
 CK19 ND  
 MGB 31.91 30.4 
 MGB 31.73  
745C PBGD 26.17 26.4 
 PBGD 27.83  
 CK19 17.75 19.2 
 CK19 20.77  
 MGB 23.16 23.9 
 MGB 24.46  
14734B PBGD 26.5 28.1 
 PBGD 26.21  
 CK19 ND 0 
 CK19 ND  
 MGB ND 0 
 MGB ND  
 
 
 
 
 
 
 
 
 
200 
 
2.2 The table compares the Cq values of positive nodes run on GeneSearch 
and the LC480 
 
Patient 
Node 
Number Histology Node 
PBGD-
G 
CK19-
G 
MGB-
G 
PBGD-
480 
CK19-
480 
MGB-
480 
 H08-    
1 12439 positive B SN 33.4 19.7 17.2 26.73 19.31 17.8
  positive C SN 30.3 21.1 18.4 27.16 21.29 18.48
2 13265 positive B SN 29.3 18.3 20.9 25.79 17.68 21.16
3 15461 positive B SN 29.1 23.8 25.7 26.86 26.86 26.1
4 16836 positive B SN 25.2 19.5 0 25.37 19.35 35.83
5 16837 positive B SN 27.3 20.5 0 26.02 23.6 0
6 16922 positive B SN 28.9 18.4 18.3 25.58 17.88 17.67
  positive C SN 32.3 19.2 18.9 25.91 16.89 17.44
  positive D SN 34.5 16.8 17.1 25.37 18.3 16.91
7 17635 positive B2 SN 27.2 29.9 31.7 25.78 27.7 33.45
 H09-    
8 7867 positive D SN 27.3 27.6 24.7 26.09 26.78 26.27
9 8759 positive B SN 26.4 25.2 0 25.47 23.79 37.14
  positive C SN 23.8 19.4 35.1 23.92 19.45 33.9
  positive D SN 23.9 16.1 26.3 23.19 15.61 26.49
  positive E SN 25.2 19 33.9 24.94 19.56 33.9
  positive F SN 26.6 20.2 0 24.93 19.98 33.81
  positive G SN 29.1 21.2 35.4 26.4 20.47 34.77
  positive H SN 26.4 19.3 34.7 24.75 18.47 34.98
  positive I SN 26.4 20.5 26.5 25.32 20 27.05
10 9041 negative B SN 28.1 33.8 30.4 25.86 0 31.56
11 10762 positive D SN 32.8 19.8 16.1 25.92 19.6 16.84
  positive E SN 33.9 18.4 15.6 26.19 18.11 16.06
12 10931 positive B SN 28.4 31.8 27.1 26.79 0 27.87
13 12395 positive B SN 28.6 0 0 27.12 0 0
14 13447 positive D SN 32.6 19.5 18.3 26.21 19.65 18.51
  positive E SN 33.3 19.3 18.2 26.63 18.97 17.6
15 15131 positive B SN 25.7 31.6 30.8 26.11 0 32.78
16 16039 positive B SN 25.7 21.6 21.4 25.94 20.43 20.63
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  positive C SN 25.7 20.2 18.6 25.53 19.71 18.46
17 17502 positive B SN 25.9 19.2 22.1 24.84 17.88 22.58
  positive C SN 26.1 19.8 24.4 26.23 19.98 24.86
18 18243 positive B SN 27.6 22.5 18.1 26.69 22.69 18.8
  positive C SN 27 0 29.5 26.62 0 30.03
 H10-    
19 745 positive B SN 24.8 22.4 29.2 26.59 23.46 30.94
  positive C SN 26.4 19.2 23.9 26.67 19.17 25.03
20 925 positive B SN 27.5 22.8 34.3 27.24 22.8 35.32
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2.3 The table compares the Cq values of the negative nodes run on 
GeneSearch (G) and the LC480 
 
Patient 
Node 
number Histology Node 
PBGD-
G 
CK19-
G 
MGB-
G 
PBGD-
480 
CK19-
480 
MGB-
480 
 H09         
1 10 negative B SN 28.6 0 0 26 0 0 
  negative C SN 28.4 0 0 26.66 0 0 
2 7867 negative B SN 27.6 0 0 26.07 0 0 
  negative C SN 27.8 32.8 0 25.98 0 0 
  negative E SN 28.3 34.8 0 26.12 0 0 
  negative F SN 27.8 0 0 26.45 0 0 
3 7913 negative B SN 27.5 0 0 25.99 0 0 
  negative C SN 29.6 0 0 26.71 0 0 
4 9041 negative D SN 28.9 0 0 25.59 0 0
5 9481 negative B SN 27.9 0 0 26.74 0 0 
  negative C SN 28.8 0 0 26.26 0 0 
  negative D SN 29.4 0 0 26.66 0 0
6 10134 negative B SN 29.6 0 0 26.94 0 0 
  negative C SN 29.4 0 0 27.05 0 0 
  negative D SN 27.9 0 0 26.17 0 0 
  negative E SN 28.6 0 0 26.29 0 0 
7 10136 negative B SN 27.5 0 0 25.75 0 0 
  negative C SN 27.8 0 0 25.96 0 0 
8 10639 negative B SN 27.8 0 0 25.94 0 0 
  negative C SN 27.4 0 0 25.61 0 0 
9 10762 negative B1 SN 28.6 0 0 26.32 0 0 
  negative B2 SN 28.2 0 0 27.26 0 0 
10 10929 negative B SN 28.7 0 0 26.53 0 0 
  negative C SN 29.2 0 0 26.17 0 0
11 11238 negative B SN 32 0 32.6 27.47 0 31.36 
12 11387 negative B SN 27.6 0 0 25.87 0 0 
  negative C SN 27.5 33.5 0 26 0 0
  negative D SN 27.6 0 0 26.71 0 0 
13 11531 negative B2 SN 28.2 0 0 26.18 0 37.04 
  negative D SN 28.5 0 34 26.91 0 33.22 
14 11529 negative B SN 28.6 0 0 27.19 0 0 
  negative C SN 28.6 0 0 26.96 0 37.09 
15 12043 negative B SN 30.2 0 0 27.56 0 0 
16 12041 negative B SN 29.9 0 0 27.56 0 0 
17 12393 negative B SN 28.2 0 0 27.77 0 0 
  negative C SN 27.8 0 0 26.91 0 0 
  negative D SN 29.4 0 0 27.6 0 0 
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  negative E SN 27.7 0 0 26.87 0 0 
18 12708 negative B SN 28.8 0 0 26.74 0 0 
19 13003 negative B SN 27.6 0 0 26.43 0 0
  negative C SN 26.7 0 0 25.81 0 37.86 
  negative D SN 27.3 0 0 26.88 0 0 
20 13447 negative B SN 32.3 0 0 27.49 0 0 
21 13643 negative B1 SN 27.5 0 0 27.18 0 0 
  negative B2 SN 27.5 0 0 26.77 0 0 
  negative C SN 28.5 0 0 27.17 0 0 
  negative D SN 29.6 0 0 27.18 0 35.63 
22 13742 negative B SN 29.9 0 0 27.23 0 0 
  negative C SN 29.5 0 0 27.26 0 0 
23 14108 negative B SN 29.4 0 0 26.68 0 0 
  negative D SN 28.8 0 0 26.68 0 0 
  negative E SN 32 0 0 26.68 0 0
24 14106 negative B SN 27.5 0 0 26.56 0 37.76 
  negative C SN 26.9 0 0 26.84 0 37.75 
25 14732 negative B SN 29.2 0 34.5 26.66 0 32.21
26 14734 negative B SN 28.1 0 0 26.69 0 0 
  negative C SN 26.3 0 35.8 25.49 0 34.7 
  negative E SN 26.1 0 0 26.14 0 0 
27 15572 negative B1 SN 27.6 0 0 26.16 0 0 
  negative B2 SN 27.5 0 0 27.31 0 0 
28 15570 negative B2 SN 28.4 0 0 27.32 0 0 
  negative B1 SN 27.8 0 0 26.96 0 0 
29 15664 negative B SN 25.7 0 0 25.57 0 0 
  negative C SN 26.7 0 0 26 0 0 
30 15809 negative B SN 26.3 0 0 25.44 0 0 
  negative C1 SN 26.1 0 0 26.18 0 0 
  negative D SN 26.5 0 0 26.07 0 0 
  negative E SN 26.3 0 0 26.47 0 0 
  negative F SN 27.3 0 0 26.72 0 0 
  negative G SN 26.2 0 0 25.8 0 0
31 15811 negative B SN 26.3 0 0 25.73 0 0 
  negative C SN 26.7 0 0 26.04 0 0 
32 15813 negative B SN 26.3 0 0 26.68 0 0 
  negative C SN 26.1 0 0 26.72 0 0 
33 16202 negative B SN 26.7 0 0 26.49 0 35.24 
34 16204 negative B SN 27.2 0 0 26.33 0 0 
35 16377 negative B SN 26 0 0 26.45 0 0 
36 16757 negative B SN 27 0 0 26.42 0 0 
  negative C SN 26.6 0 0 26.56 0 0 
37 16941 negative B1 SN 26.2 0 0 25.94 0 0 
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  negative B2 SN 26.5 0 0 25.76 0 0 
  negative B3 SN 29.1 0 0 27.04 0 0 
38 16945 negative B SN 26.4 0 0 25.88 0 0
39 16947 negative B SN 27.2 0 0 26.11 0 0 
  negative C SN 26.2 0 0 26.1 0 0 
40 17075 negative B SN 27.3 0 0 26.26 0 0 
41 17151 negative B SN 25.6 0 0 25.87 0 0 
42 17498 negative B1 SN 26.1 0 0 25.44 0 0 
  negative B2 SN 27.2 0 0 27.16 0 0 
43 17500 negative B SN 26.5 0 0 26.35 0 40 
  negative C SN 27.7 0 0 26.83 0 0 
44 18014 negative B SN 28.6 0 0 26.98 0 0 
  negative C SN 26.9 0 0 26.66 0 0 
45 18016 negative B SN 26.5 0 0 26.68 0 0 
46 18155 negative B SN 27.1 0 0 25.93 0 0
  negative C1 SN 26.9 0 0 26.49 0 0 
47 18157 negative B1 SN 26.2 0 0 26.74 0 0 
  negative B2 SN 27.8 0 0 27.17 0 0
48 18241 negative B SN 27.9 0 0 27.12 0 0 
  negative C SN 28.2 0 0 27.13 0 0 
49 18472 negative B1 SN 26.8 0 0 25.93 0 0 
  negative C SN 27.8 0 0 26.52 0 0 
50 18525 negative B SN 26.2 0 0 26.68 0 0 
51 18609 negative B SN 29 0 0 27.44 0 0 
  negative C SN 25.6 33.5 0 25.61 0 0 
  negative D SN 25 0 0 27.56 0 0 
 H-10         
52 577 negative B SN 26.6 0 0 26.54 0 0 
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2.4 The table shows the results of all positive patients, comparing 
GeneSearch (GS) and Metasin Cq values 
(Red highlights discordant results) 
Patient Specimen 
GS 
PBGD 
Cq 
Value 
Metasin 
PBGD 
Cq 
Value 
GS 
CK19 
Cq 
Value 
Metasin 
CK19 Cq 
Value 
GS 
MGB 
Cq 
Value 
Metasin 
MGB Cq 
Value 
1 08-12439B 33.4 26.9 19.7 18.1 17.2 16.5 
  08-12439C 30.3 26.4 21.1 19.2 18.4 17 
2 08-13265B 29.3 29.2 18.3 19.3 20.9 23.5 
3 08-15461B 29.1 28.6 23.8 24.4 25.7 27.9 
4 08-16922D 34.5 26.5 16.8 16.3 17.1 20.7 
5 H09-10762D 32.8 26.5 19.8 18.1 16.1 15.3 
  H09-10762E 33.9 26.1 18.4 15.5 16.1 15.5 
6 H09-10931B 28.4 26.2 31.8 31.7 27.1 25.6 
7 
H09-
11531C1 31.4 24.9 18.9 15.7 18 17.5 
  
H09-
11531C2 32.9 25.3 17.5 16.5 16.6 15.9 
  H09-11531D 28.5 28.2 0 0 34 37.9 
8 H09-13447B 32.3 27.8 0 0 0 0 
  H09-13447C 32.9 28.2 0 0 35.4 33 
  H09-13447D 32.6 25.4 19.5 16.8 18.3 16.5 
  H09-13447E 33.3 24.7 19.3 16.6 18.2 16.7 
9 H09-15131B 25.7 25.1 31.6 0 30.8 31.7 
  H09-15131C 26.3 24.8 0 0 35.8 35.1 
  H09-15131D 33.4 25.4 0 0 0 0 
  H09-15131E 26.1 25.3 0 0 0 0 
10 H09-16039B 25.7 24.8 21.6 17.8 21.4 19.8 
  H09-16039C 25.7 26.7 20.2 16.4 18.6 16.2 
11 H09-17502B 25.9 24.2 19.2 15.6 22.1 21.6 
  H09-17502C 26.1 24.2 19.8 16.2 24.4 23 
12 H09-18243B 27.6 27.4 22.5 22.3 18.1 20.6 
  H09-18243C 27 24.9 0 20.9 29.5 30.4 
13 H09-7867B 27.6 25.6 0 0 0 41.7 
  H09-7867C 27.8 25.8 32.8 0 0 0 
  H09-7867D 27.3 25.7 27.6 27.7 24.7 23.7 
  H09-7867E 28.3 25.6 34.8 0 0 40.9 
14 H09-8759B 26.4 24.5 25.2 23.3 0 0 
  H09-8759C 23.8 23.9 19.4 19.1 35.1 0 
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  H09-8759D 23.9 24.5 16.1 17 26.3 30.5 
  H09-8759E 25.2 25.1 19 18.9 33.9 33.4 
  H09-8759F 26.6 24 20.2 18.6 0 32.5 
  H09-8759G 29.1 24.5 21.2 17.7 35.4 31.4 
  H09-8759H 26.4 24.1 19.3 17.1 34.7 30.9 
  H09-8759I 26.4 25.1 20.5 19 26.5 24.1 
15 H09-9041B 28.1 25.4 33.8 0 30.4 29.8 
  H09-9041C 27.4 28.4 35 0 0 0 
  H09-9041D 28.9 29.6 0 0 0 0 
16 H10-2344B 26.5 25.6 0 0 0 0 
  H10-2344C 27.5 25.9 30.4 0 29.4 27.8 
  H10-2344D 30 34.4 0 0 0 0 
17 H10-3256B 26.4 26.3 0 0 0 0 
  H10-3256C 25 24.8 0 0 0 0 
  H10-3256D 25.4 24.4 0 0 0 0 
  H10-3256E 26.5 25.7 26.8 28.4 30.5 29.9 
18 H10-3258A1 24.1 24.6 19.3 27.4 28.5 0 
  H10-3258A2 24.8 24.3 20.4 19.1 30.3 30.4 
  H10-3258B 26.9 26.7 27.9 0 0 34.4 
  H10-3258C1 27.7 25.8 29.5 0 0 0 
  H10-3258C2 27.8 25.4 28.7 0 0 28.4 
19 H10-4108A1 28.2 26.2 20.5 18.7 17.3 15.5 
  H10-4108A2 26.2 26.2 24.1 23 28 28.5 
  H10-4108A3 26.5 25.8 0 0 0 0 
20 H10-5068B 31 25.2 25 20.2 26.3 23.4 
  H10-5068C 25.5 24.9 23.1 21.8 29.9 30.8 
21 H10-5070B 25.9 23.8 18.5 16.5 19.3 17.9 
  H10-5070C 27.2 25.6 19 17.8 18.9 18.1 
22 H10-5799E1 29.5 25.7 19.2 18.3 14.4 13.8 
  H10-5799E2 28.8 28.3 0 0 26.2 26.2 
  H10-5799F 30.6 25.6 16.8 16.2 13.2 12.6 
23 H10-6173B 24.9 25.3 21.2 20.4 22.2 22.9 
24 H10-6399B1 25.5 26.4 30.2 0 34.7 0 
  H10-6399B2 27 26.8 24.1 23.3 27 27.2 
25 H10-6487B 26.1 26.3 19.4 19.6 19.7 21.3 
  H10-6487C 25.3 25.9 26.6 28.3 25.3 26.2 
26 H10-6548B 24.3 24.5 19.7 17.2 26.7 28.5 
  H10-6548C 26.4 28 0 0 0 0 
  H10-6548D 25.9 25.9 23.2 21.2 31.8 34.2 
  H10-6548E 28.4 28.5 0 0 0 0 
27 H10-6949A1 29.4 29.3 21.7 19.5 22.4 22.2 
  H10-6949A2 30.4 27.4 22.1 18.2 22.4 19.8 
  H10-6949C 26.2 26.2 0 0 0 0 
207 
 
28 H10-745B 24.8 24.3 22.4 16.3 29.2 22.3 
  H10-745C 26.4 24.3 19.2 16.1 23.9 28.3 
29 H10-7525B 26.2 25.6 19 16.2 0 0 
  H10-7525C 25.9 27.5 0 0 0 0 
  H10-7525D 29.8 27.9 22.7 19.9 0 0 
  H10-7525E 27 28.4 0 0 0 0 
30 H10-7587B 28.6 30.5 30.4 0 31.5 34.9 
  H10-7587C 27.9 27.3 26.5 25.3 28.3 29.5 
  H10-7587D1 31.7 31 0 0 0 0 
31 H10-7638B 25 22.9 20 16.6 20.1 19.2 
32 H10-8489B 25.5 26.3 29.8 31.3 29.8 32.3 
  H10-8489C 27 26.5 0 0 0 0 
33 H10-9031B 26.5 27.2 21.8 19.3 27.6 28.3 
  H10-9031C 27.2 27.7 0 0 0 0 
  H10-9031D 27.4 28.3 0 0 0 0 
34 H10-9153B 29.9 30 24.9 25.5 22.4 23.2 
  H10-9153C 27.1 28.8 0 0 35.3 38.6 
  H10-9153F 27.5 29.6 0 0 0 0 
35 H10-925B 27.5 27.1 22.8 20.5 34.3 34.4 
36 H10-9351B1 27.8 30.9 21.4 21.9 22.5 24.1 
  H10-9351B2 28.7 29.8 20.2 20.3 20.2 20.5 
37 H10-9442B 27.5 29.2 28.3 0 27.1 29.2 
  H10-9442C1 26.6 27.2 0 0 0 0 
  H10-9442C2 28.8 29.6 0 0 0 0 
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2.5 The table below compares the Cq values of all the positive nodes of 
GeneSearch (GS) and Metasin 
(Red highlights discordant results) 
Node  Specimen 
GS 
PBGD 
Cq 
Value 
Metasin 
PBGD 
Cq 
Value 
GS 
CK19 
Cq 
Value 
Metasin 
CK19 Cq 
Value 
GS 
MGB 
Cq 
Value 
Metasin 
MGB Cq 
Value 
1 08-12439B 33.4 26.9 19.7 18.1 17.2 16.5 
2 08-12439C 30.3 26.4 21.1 19.2 18.4 17 
3 08-13265B 29.3 29.2 18.3 19.3 20.9 23.5 
4 08-15461B 29.1 28.6 23.8 24.4 25.7 27.9 
5 08-16922D 34.5 26.5 16.8 16.3 17.1 20.7 
6 H09-10762D 32.8 26.5 19.8 18.1 16.1 15.3 
7 H09-10762E 33.9 26.1 18.4 15.5 16.1 15.5 
8 H09-10931B 28.4 26.2 31.8 31.7 27.1 25.6 
9 H09-11531C1 31.4 24.9 18.9 15.7 18 17.5 
10 H09-11531C2 32.9 25.3 17.5 16.5 16.6 15.9 
11 H09-13447D 32.6 25.4 19.5 16.8 18.3 16.5 
12 H09-13447E 33.3 24.7 19.3 16.6 18.2 16.7 
13 H09-15131B 25.7 25.1 31.6 0 30.8 31.7 
14 H09-16039B 25.7 24.8 21.6 17.8 21.4 19.8 
15 H09-16039C 25.7 26.7 20.2 16.4 18.6 16.2 
16 H09-17502B 25.9 24.2 19.2 15.6 22.1 21.6 
17 H09-17502C 26.1 24.2 19.8 16.2 24.4 23 
18 H09-18243B 27.6 27.4 22.5 22.3 18.1 20.6 
19 H09-18243C 27 24.9 0 20.9 29.5 30.4 
20 H09-7867D 27.3 25.7 27.6 27.7 24.7 23.7 
21 H09-8759B 26.4 24.5 25.2 23.3 0 0 
22 H09-8759C 23.8 23.9 19.4 19.1 35.1 0 
23 H09-8759D 23.9 24.5 16.1 17 26.3 30.5 
24 H09-8759E 25.2 25.1 19 18.9 33.9 33.4 
25 H09-8759F 26.6 24 20.2 18.6 0 32.5 
26 H09-8759G 29.1 24.5 21.2 17.7 35.4 31.4 
27 H09-8759H 26.4 24.1 19.3 17.1 34.7 30.9 
28 H09-8759I 26.4 25.1 20.5 19 26.5 24.1 
29 H09-9041B 28.1 25.4 33.8 0 30.4 29.8 
30 H10-2344C 27.5 25.9 30.4 0 29.4 27.8 
31 H10-3256E 26.5 25.7 26.8 28.4 30.5 29.9 
32 H10-3258A1 24.1 24.6 19.3 27.4 28.5 0 
33 H10-3258A2 24.8 24.3 20.4 19.1 30.3 30.4 
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34 H10-3258C2 27.8 25.4 28.7 0 0 28.4 
35 H10-4108A1 28.2 26.2 20.5 18.7 17.3 15.5 
36 H10-4108A2 26.2 26.2 24.1 23 28 28.5 
37 H10-5068B 31 25.2 25 20.2 26.3 23.4 
38 H10-5068C 25.5 24.9 23.1 21.8 29.9 30.8 
39 H10-5070B 25.9 23.8 18.5 16.5 19.3 17.9 
40 H10-5070C 27.2 25.6 19 17.8 18.9 18.1 
41 H10-5799E1 29.5 25.7 19.2 18.3 14.4 13.8 
42 H10-5799E2 28.8 28.3 0 0 26.2 26.2 
43 H10-5799F 30.6 25.6 16.8 16.2 13.2 12.6 
44 H10-6173B 24.9 25.3 21.2 20.4 22.2 22.9 
45 H10-6399B2 27 26.8 24.1 23.3 27 27.2 
46 H10-6487B 26.1 26.3 19.4 19.6 19.7 21.3 
47 H10-6487C 25.3 25.9 26.6 28.3 25.3 26.2 
48 H10-6548B 24.3 24.5 19.7 17.2 26.7 28.5 
49 H10-6548D 25.9 25.9 23.2 21.2 31.8 34.2 
50 H10-6949A1 29.4 29.3 21.7 19.5 22.4 22.2 
51 H10-6949A2 30.4 27.4 22.1 18.2 22.4 19.8 
52 H10-745B 24.8 24.3 22.4 16.3 29.2 22.3 
53 H10-745C 26.4 24.3 19.2 16.1 23.9 28.3 
54 H10-7525B 26.2 25.6 19 16.2 0 0 
55 H10-7525D 29.8 27.9 22.7 19.9 0 0 
56 H10-7587C 27.9 27.3 26.5 25.3 28.3 29.5 
57 H10-7638B 25 22.9 20 16.6 20.1 19.2 
58 H10-8489B 25.5 26.3 29.8 31.3 29.8 32.3 
59 H10-9031B 26.5 27.2 21.8 19.3 27.6 28.3 
60 H10-9153B 29.9 30 24.9 25.5 22.4 23.2 
61 H10-925B 27.5 27.1 22.8 20.5 34.3 34.4 
62 H10-9351B1 27.8 30.9 21.4 21.9 22.5 24.1 
63 H10-9351B2 28.7 29.8 20.2 20.3 20.2 20.5 
64 H10-9442B 27.5 29.2 28.3 0 27.1 29.2 
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2.6 Table of all patients found negative on GeneSearch (GS) and Metasin 
 
 
Patient  Specimen 
GS PBGD 
Cq Value 
Metasin 
PBGD 
Cq 
Value 
GS CK19 
Cq Value 
Metasin 
CK19 Cq 
Value 
GS 
MGB 
Cq 
Value 
Met
asin 
MG
B Cq 
Valu
e 
1 08-10986B 28.2 26.3 31.3 0 0 0 
2 08-11058A 29.9 26.9 0 0 0 0 
  08-11058B 28 27 0 0 0 0 
3 08-11465A 28.1 26.8 0 0 0 0 
  08-11465B 27.1 26.7 0 0 0 0 
  08-11465C 27.4 25.6 0 0 0 0 
  08-11465D 27.3 25.6 0 0 0 0 
  08-11465E 27.8 26.5 0 0 0 0 
4 08-11753A 28.6 26.7 0 0 0 0 
  08-11753B 29.2 28 0 0 0 0 
  08-11753C 27.5 26.8 0 0 0 0 
5 08-11839B1 27.9 27.2 0 0 0 0 
  08-11839B2 27.7 26.4 0 0 0 0 
  08-11839B3 27.6 26.4 0 0 0 0 
  08-11839C1 28.8 26.4 0 0 0 0 
  08-11839C2 27.6 26.6 0 0 0 0 
  08-11839C3 31.4 28.6 0 0 0 0 
6 08-12488B1 27.6 27 0 0 0 0 
  08-12488B2 27.4 25.9 0 0 0 0 
7 08-12779B 27.3 26.1 0 0 0 0 
  08-12779C 28.3 26.4 0 0 0 0 
8 08-12781B 27.9 25.6 0 0 0 0 
9 08-14328B 28.2 26.7 0 0 0 0 
  08-14328C 26 25.7 0 0 0 0 
10 08-14714B 27.8 25.9 0 0 0 0 
  08-14714C 27.6 25.7 0 0 0 0 
11 08-14920B 29.7 26.8 0 0 0 0 
12 08-15390B 28.1 25.2 0 0 0 0 
  08-15390C 27.6 25.2 0 0 0 0 
13 08-15833B 27.4 26.1 0 0 0 0 
14 08-17257B 27.7 26.1 0 0 0 0 
15 08-17325B 29.7 25.3 0 33.7 0 0 
  08-17325C 28.4 25.5 0 0 0 0 
  08-17325D 27.8 24.7 0 33.3 0 0 
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  08-17325E 28.1 25.4 0 34.4 0 0 
  08-17325F 27.8 25.4 0 33.9 0 0 
16 08-17631B 29.2 26 0 0 0 0 
  08-17631C 28.2 25.9 0 0 0 0 
17 08-17633B 27.5 25.5 0 0 0 0 
  08-17633C 27 24.1 34 0 0 0 
18 08-17779B1 29.6 25.4 35.8 0 0 44.3 
  08-17779B2 30.8 24.7 0 0 0 0 
19 08-17781B 31.8 28.5 0 0 0 0 
20 08-18324B 28.1 25.6 0 0 0 0 
21 08-18475B 29.7 25.7 0 0 0 0 
22 08-18477B 29.1 25.8 0 0 0 0 
  08-18477C 29.3 25.9 0 0 0 0 
23 08-18857B 28.2 25.1 34.9 0 0 0 
24 H09-10134B 29.6 26.9 0 0 0 0 
  H09-10134C 29.4 26.3 0 0 0 0 
  H09-10134D 27.9 25.2 0 0 0 0 
  H09-10134E 28.6 24.5 0 0 0 0 
25 H09-10136B 27.5 24.6 0 0 0 0 
  H09-10136C 27.8 24.7 0 0 0 0 
26 H09-10639B 27.8 25.6 0 0 0 0 
  H09-10639C 27.4 24.4 0 0 0 37.5 
27 H09-10929B 28.7 27 0 0 0 0 
  H09-10929C 29.2 25.7 0 0 0 0 
28 H09-11387B 27.6 25.5 0 0 0 39.9 
  H09-11387C 27.5 25.4 33.5 0 0 0 
  H09-11387D 27.6 25.8 0 0 0 43.8 
29 H09-11529B 28.6 26 0 0 0 0 
  H09-11529C 28.6 26.1 0 0 0 0 
30 H09-12041B 30.2 27.4 0 0 0 0 
31 H09-12043B 29.9 27.4 0 0 0 0 
32 H09-12393B 28.2 24.6 0 0 0 0 
  H09-12393C 27.8 25.2 0 0 0 0 
  H09-12393D 29.4 27.1 0 0 0 40.6 
  H09-12393E 27.7 26.2 0 0 0 42.6 
33 H09-12395B 28.6 26.1 0 0 0 0 
34 H09-12708B 28.8 25.7 0 0 0 0 
35 H09-13003B 27.6 24.9 0 0 0 0 
  H09-13003C 26.7 24.4 0 0 0 0 
  H09-13003D 27.3 25.5 0 0 0 0 
36 
H09-
13643B1 27.5 24.6 0 0 0 0 
  H09- 28.5 25.2 0 0 0 0 
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13643B2 
  H09-13643C 29.6 27 0 0 0 0 
  H09-13643D 27.7 25.2 0 0 0 35.7 
37 H09-13742B 29.9 25.7 0 0 0 0 
  H09-13742C 29.5 26.3 0 0 0 0 
38 H09-14108C 29.4 27.9 0 0 0 0 
  H09-14108D 30.7 29 0 0 0 0 
  H09-14108E 28.8 27.3 0 0 0 0 
  H09-14108F 32 30.3 0 0 0 0 
39 H09-14590B 28.5 26.1 0 0 0 0 
  H09-14590C 29.7 26.2 0 0 0 0 
  H09-14590D 27.3 25.9 0 0 0 0 
  H09-14590E 27.7 26.4 0 0 0 0 
  H09-14590F 26.6 26.4 0 0 0 0 
40 H09-14592B 27.4 26.8 0 0 0 0 
41 H09-14732B 29.2 26.3 0 0 34.5 32.7 
42 H09-14734B 28.1 25.8 0 0 0 0 
43 H09-15535B 26.4 25.1 0 0 0 0 
  H09-15535C 26.5 25.9 0 0 0 0 
  H09-15535D 28.4 26.6 0 0 0 0 
44 H09-15570B 28.4 28.3 0 0 0 0 
  H09-15570C 27.8 26.3 0 0 0 0 
45 
H09-
15572B1 27.6 25.7 0 0 0 0 
  
H09-
15572B2 27.5 28.7 0 0 0 0 
46 H09-15664B 25.7 26.1 0 0 0 0 
  H09-15664C 26.7 26 0 0 0 0 
47 H09-15809B 26.3 25.2 0 0 0 0 
  H09-15809C 26.1 25.7 0 0 0 0 
  H09-15809D 26.6 26.3 0 0 0 0 
  H09-15809E 25.8 26.1 0 0 0 0 
  H09-15809F 26.5 26.3 0 0 0 0 
  H09-15809G 26.3 25.4 0 0 0 0 
48 H09-15811B 26.3 26.2 0 0 0 0 
  H09-15811C 26.7 26.1 0 0 0 0 
49 H09-16202B 26.7 25.4 0 0 0 35 
50 H09-16204B 27.2 25.7 0 0 0 0 
51 H09-16377B 26 24.8 0 0 0 0 
52 H09-16757B 27 25.9 0 0 0 0 
  H09-16757C 26.6 25.6 0 0 0 0 
53 
H09-
16941B1 26.2 25.4 0 0 0 0 
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H09-
16941B2 26.5 24.8 0 0 0 34.4 
  
H09-
16941B3 29.1 25.7 0 0 0 0 
54 H09-16945B 26.4 25.4 0 0 0 0 
55 H09-16947B 27.2 25.2 0 0 0 0 
  H09-16947C 26.2 25.5 0 0 0 0 
56 H09-17075B 27.3 25.8 0 0 0 0 
57 H09-17151B 25.6 25.5 0 0 0 0 
58 
H09-
17498B1 26.1 24.8 0 0 0 0 
  
H09-
17498B2 27.2 25.4 0 0 0 0 
59 H09-17500B 26.5 25 0 0 0 0 
  H09-17500C 27.7 25.1 0 0 0 0 
60 H09-18014B 28.6 27 0 0 0 0 
  H09-18014C 26.9 27 0 0 0 0 
61 H09-18016B 26.5 24.9 0 0 0 0 
62 H09-18155B 27.1 26 0 0 0 0 
  
H09-
18155C1 26.9 27 0 0 0 0 
  
H09-
18155C2 26.5 25.4 0 0 0 0 
63 H09-18157B 26.2 26.1 0 0 0 0 
  H09-18157C 27.8 26.3 0 0 0 0 
64 H09-18241B 27.9 26.7 0 0 0 0 
  H09-18241C 28.2 26.5 0 0 0 0 
65 
H09-
18472B1 26.8 25.8 0 0 0 0 
  
H09-
18472B2 32.1 30.6 0 0 0 0 
  H09-18472C 27.8 26.2 0 0 0 0 
66 H09-18525B 26.2 25.9 0 0 0 0 
67 H09-18609B 29 26.4 0 0 0 0 
  H09-18609C 25.6 24.7 33.5 0 0 0 
  H09-18609D 25 25.6 0 0 0 43.7 
68 H09-7913B 27.5 25.4 0 0 0 0 
  H09-7913C 29.6 27.3 0 0 0 0 
69 H09-7915B1 30.5 27.3 0 0 0 0 
  H09-7915C 29.1 30.2 0 0 0 0 
70 H09-7965B1 28.7 29.1 0 0 0 0 
  H09-7965B2  28.5 28.8 0 0 0 0 
71 H09-8667C 29.5 29.7 0 0 0 0 
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72 H09-9039B 28.9 29.7 0 0 0 0 
  H09-9039C 28.5 26.8 0 0 0 42.4 
73 H09-9145B 28.4 29.3 0 0 0 0 
  H09-9145C 28.5 29.7 0 0 0 0 
  H09-9145D 28.1 28.8 0 0 0 0 
  H09-9145E1 30.1 29.7 0 0 0 0 
  H09-9145E2 30.2 28.2 0 0 0 0 
74 H09-9481B 27.9 28.3 0 0 0 0 
  H09-9481C 28.8 26.4 0 0 0 0 
  H09-9481D 29.4 25.8 0 0 0 0 
75 H10-1294B 28.2 27 0 0 0 0 
  H10-1294C 27.5 26.3 0 0 0 0 
76 H10-1443B1 26.1 26 32.9 0 0 0 
  H10-1443B2 26.4 25.1 36 0 0 0 
  H10-1443D 26.5 25.4 0 0 0 0 
77 H10-1445B 25.5 24 33.9 0 0 0 
  H10-1445C 25.8 24.2 33.1 0 0 0 
  H10-1445D 26.3 25.2 34 0 0 0 
  H10-1445E 25.9 25.1 35 0 0 0 
78 H10-1978B 28 27 0 0 0 0 
  H10-1978C 26.6 25.7 0 0 0 0 
  H10-1978D 26.5 24.6 0 0 0 0 
79 H10-2487B 25.3 24.8 0 0 0 0 
  H10-2487C 26.1 24.8 0 0 0 0 
80 H10-2618A 25.9 27.2 0 0 0 43.1 
  H10-2618B 25.4 28.3 0 0 0 0 
81 H10-2620A 26.3 25.3 0 0 0 0 
82 H10-2712B 26.2 32 0 0 0 0 
  H10-2712C 25.3 27.1 33.9 0 0 0 
  H10-2712D 26.6 33 0 0 0 0 
83 H10-2920B 28.2 26.8 0 0 0 0 
  H10-2920C 28.3 26.4 0 0 0 0 
  H10-2920D 26.4 25.9 0 0 0 0 
84 H10-3302B1 26.7 27 0 0 0 0 
  H10-3302B5 24.9 25.6 32.5 0 0 0 
85 H10-3466B 27.3 26.8 0 0 0 0 
  H10-3466C 27.2 25.9 0 0 0 0 
86 H10-3635B 25.3 25.2 0 0 0 0 
  H10-3635C 25.7 25.8 0 0 0 0 
  H10-3635D 25.8 25 0 0 0 0 
87 H10-3820B 26.3 26 0 0 0 0 
88 H10-3989B 24.7 24.5 0 0 0 0 
  H10-3989C 26.2 25.8 0 0 0 0 
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  H10-3989D 25.8 24.9 0 0 0 0 
89 H10-3991A 27.2 29.8 0 0 0 0 
  H10-3991B 25.9 26 0 0 0 0 
90 H10-4499B 25.3 30.7 0 0 0 0 
  H10-4499C 28.9 28.4 0 0 0 0 
  H10-4499D 27.3 31.5 0 0 0 0 
  H10-4499E 26.5 25.4 0 0 0 0 
91 H10-4945B 29.3 25.4 0 0 0 0 
  H10-4945C 27.2 28.1 0 0 0 0 
  H10-4945D 27.3 26.3 0 0 0 0 
92 H10-5123B 25.1 27.1 0 0 0 0 
  H10-5123C 25.1 27.7 0 0 0 0 
  H10-5123D 27.1 28.6 0 0 0 0 
93 H10-5675B 25.9 27.6 0 0 0 0 
  H10-5675C 27.5 28.8 0 0 0 0 
94 H10-577B 26.6 24.8 0 0 0 0 
95 H10-5809B 26.2 26.4 0 0 0 0 
  H10-5809C 27.2 27 0 0 0 0 
96 H10-6546B 26.8 25.3 0 0 0 33 
  H10-6546C 26.3 28.2 0 0 0 0 
  H10-6546D 28.1 28.7 0 0 0 0 
97 H10-6949C 26.2 26.2 0 0 0 0 
98 H10-7287B 26.1 27.3 0 0 0 0 
99 H10-7375B 26.1 27.5 0 0 0 0 
100 H10-747B 26.1 25.1 0 0 0 0 
  H10-747C 27.4 25 0 0 0 0 
101 H10-8267A 27.4 28.7 0 0 0 0 
  H10-8267B1 28.7 29.5 0 0 0 0 
  H10-8267B2 28.1 28.3 0 0 0 0 
102 H10-8352B 26.9 27.7 0 0 0 0 
  H10-8352C 27.5 27.2 0 0 0 0 
103 H10-8528B 26.1 28.2 34.9 0 0 0 
104 H10-8737B 26.7 26.2 0 0 0 0 
  H10-8737C 27 26.4 0 0 0 0 
105 H10-8936B 25.3 29.9 0 0 0 0 
  H10-8936C 25.5 28.7 0 0 0 0 
  H10-8936D 26.6 29.7 0 0 0 0 
106 H10-8938B 27.3 30 0 0 0 0 
  H10-8938C 25.2 26.8 0 0 0 0 
107 H10-9033B 26.6 27.9 0 0 0 0 
  H10-9033C 26.2 28 0 0 0 0 
  H10-9033D 26.7 29.1 0 0 0 0 
108 H10-9308B 26.6 29.2 0 0 0 0 
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  H10-9308C 25.8 27.1 0 0 0 0 
  H10-9308D 26.3 27.8 0 0 0 0 
109 H10-9310B 27 27.6 0 0 0 38.8 
  H10-9310C 28.1 29 0 0 0 0 
  H10-9310D 27.5 28.9 0 0 0 0 
110 H10-9442C1 26.6 27.2 0 0 0 0 
  H10-9442C2 28.8 29.6 0 0 0 0 
111 H10-9444B 25.7 26.4 0 0 0 0 
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2.7 Table of all nodes found negative on GeneSearch (GS) and Metasin 
 
 
Patient Specimen 
GS PBGD 
Cq Value 
Metasin 
PBGD Cq 
Value 
GS CK19 
Cq Value 
Metasin 
CK19 Cq 
Value 
GS 
MGB 
Cq 
Value 
Metasi
n MGB 
Cq 
Value 
1 08-10986B 28.2 26.3 31.3 0 0 0 
2 08-11058A 29.9 26.9 0 0 0 0 
  08-11058B 28 27 0 0 0 0 
3 08-11465A 28.1 26.8 0 0 0 0 
  08-11465B 27.1 26.7 0 0 0 0
  08-11465C 27.4 25.6 0 0 0 0 
  08-11465D 27.3 25.6 0 0 0 0 
  08-11465E 27.8 26.5 0 0 0 0 
4 08-11753A 28.6 26.7 0 0 0 0 
  08-11753B 29.2 28 0 0 0 0 
  08-11753C 27.5 26.8 0 0 0 0 
5 08-11839B1 27.9 27.2 0 0 0 0 
  08-11839B2 27.7 26.4 0 0 0 0 
  08-11839B3 27.6 26.4 0 0 0 0 
  08-11839C1 28.8 26.4 0 0 0 0 
  08-11839C2 27.6 26.6 0 0 0 0 
  08-11839C3 31.4 28.6 0 0 0 0 
1 08-12082B1 28.5 26.5 0 0 0 36.2 
  08-12082B3 28.5 26.6 0 0 0 36.9 
  08-12082C3 29.1 26.4 0 0 35 34.2 
6 08-12488B1 27.6 27 0 0 0 0 
  08-12488B2 27.4 25.9 0 0 0 0 
7 08-12779B 27.3 26.1 0 0 0 0 
  08-12779C 28.3 26.4 0 0 0 0 
8 08-12781B 27.9 25.6 0 0 0 0 
9 08-14328B 28.2 26.7 0 0 0 0 
  08-14328C 26 25.7 0 0 0 0 
10 08-14714B 27.8 25.9 0 0 0 0 
  08-14714C 27.6 25.7 0 0 0 0 
11 08-14920B 29.7 26.8 0 0 0 0 
12 08-15390B 28.1 25.2 0 0 0 0 
  08-15390C 27.6 25.2 0 0 0 0 
13 08-15833B 27.4 26.1 0 0 0 0 
14 08-17257B 27.7 26.1 0 0 0 0 
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15 08-17325B 29.7 25.3 0 33.7 0 0 
  08-17325C 28.4 25.5 0 0 0 0 
  08-17325D 27.8 24.7 0 33.3 0 0 
  08-17325E 28.1 25.4 0 34.4 0 0 
  08-17325F 27.8 25.4 0 33.9 0 0 
16 08-17631B 29.2 26 0 0 0 0 
  08-17631C 28.2 25.9 0 0 0 0 
17 08-17633B 27.5 25.5 0 0 0 0 
  08-17633C 27 24.1 34 0 0 0 
  08-17635B1 27.8 25.6 34.8 0 0 0 
18 08-17779B1 29.6 25.4 35.8 0 0 44.3 
  08-17779B2 30.8 24.7 0 0 0 0 
19 08-17781B 31.8 28.5 0 0 0 0 
20 08-18324B 28.1 25.6 0 0 0 0 
21 08-18475B 29.7 25.7 0 0 0 0 
22 08-18477B 29.1 25.8 0 0 0 0 
  08-18477C 29.3 25.9 0 0 0 0 
23 08-18857B 28.2 25.1 34.9 0 0 0 
  09-15813C 26.1 25.3 0 0 0 0 
31 H09-10134B 29.6 26.9 0 0 0 0 
  H09-10134C 29.4 26.3 0 0 0 0 
  H09-10134D 27.9 25.2 0 0 0 0 
  H09-10134E 28.6 24.5 0 0 0 0 
32 H09-10136B 27.5 24.6 0 0 0 0 
  H09-10136C 27.8 24.7 0 0 0 0 
33 H09-10639B 27.8 25.6 0 0 0 0 
  H09-10639C 27.4 24.4 0 0 0 37.5 
34 H09-10929B 28.7 27 0 0 0 0 
  H09-10929C 29.2 25.7 0 0 0 0 
35 H09-11387B 27.6 25.5 0 0 0 39.9 
  H09-11387C 27.5 25.4 33.5 0 0 0 
  H09-11387D 27.6 25.8 0 0 0 43.8 
36 H09-11529B 28.6 26 0 0 0 0 
  H09-11529C 28.6 26.1 0 0 0 0 
  H09-11531D 28.5 28.2 0 0 34 37.9 
38 H09-12041B 30.2 27.4 0 0 0 0 
37 H09-12043B 29.9 27.4 0 0 0 0 
39 H09-12393B 28.2 24.6 0 0 0 0 
  H09-12393C 27.8 25.2 0 0 0 0 
  H09-12393D 29.4 27.1 0 0 0 40.6 
  H09-12393E 27.7 26.2 0 0 0 42.6 
40 H09-12395B 28.6 26.1 0 0 0 0 
41 H09-12708B 28.8 25.7 0 0 0 0 
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42 H09-13003B 27.6 24.9 0 0 0 0 
  H09-13003C 26.7 24.4 0 0 0 0 
  H09-13003D 27.3 25.5 0 0 0 0 
  H09-13447B 32.3 27.8 0 0 0 0 
  H09-13447C 32.9 28.2 0 0 35.4 33 
43 
H09-
13643B1 27.5 24.6 0 0 0 0 
  
H09-
13643B2 28.5 25.2 0 0 0 0 
  H09-13643C 29.6 27 0 0 0 0 
  H09-13643D 27.7 25.2 0 0 0 35.7 
44 H09-13742B 29.9 25.7 0 0 0 0 
  H09-13742C 29.5 26.3 0 0 0 0 
45 H09-14108C 29.4 27.9 0 0 0 0 
  H09-14108D 30.7 29 0 0 0 0 
  H09-14108E 28.8 27.3 0 0 0 0 
  H09-14108F 32 30.3 0 0 0 0 
46 H09-14590B 28.5 26.1 0 0 0 0 
  H09-14590C 29.7 26.2 0 0 0 0 
  H09-14590D 27.3 25.9 0 0 0 0 
  H09-14590E 27.7 26.4 0 0 0 0 
  H09-14590F 26.6 26.4 0 0 0 0 
47 H09-14592B 27.4 26.8 0 0 0 0 
48 H09-14732B 29.2 26.3 0 0 34.5 32.7 
49 H09-14734B 28.1 25.8 0 0 0 0 
  H09-15131C 26.3 24.8 0 0 35.8 35.1 
  H09-15131D 33.4 25.4 0 0 0 0 
  H09-15131E 26.1 25.3 0 0 0 0 
50 H09-15535B 26.4 25.1 0 0 0 0 
  H09-15535C 26.5 25.9 0 0 0 0 
  H09-15535D 28.4 26.6 0 0 0 0 
52 H09-15570B 28.4 28.3 0 0 0 0 
  H09-15570C 27.8 26.3 0 0 0 0 
51 
H09-
15572B1 27.6 25.7 0 0 0 0 
  
H09-
15572B2 27.5 28.7 0 0 0 0 
53 H09-15664B 25.7 26.1 0 0 0 0 
  H09-15664C 26.7 26 0 0 0 0 
54 H09-15809B 26.3 25.2 0 0 0 0 
  H09-15809C 26.1 25.7 0 0 0 0 
  H09-15809D 26.6 26.3 0 0 0 0 
  H09-15809E 25.8 26.1 0 0 0 0 
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  H09-15809F 26.5 26.3 0 0 0 0 
  H09-15809G 26.3 25.4 0 0 0 0 
55 H09-15811B 26.3 26.2 0 0 0 0 
  H09-15811C 26.7 26.1 0 0 0 0 
56 H09-16202B 26.7 25.4 0 0 0 35 
57 H09-16204B 27.2 25.7 0 0 0 0 
58 H09-16377B 26 24.8 0 0 0 0 
59 H09-16757B 27 25.9 0 0 0 0 
  H09-16757C 26.6 25.6 0 0 0 0 
60 
H09-
16941B1 26.2 25.4 0 0 0 0 
  
H09-
16941B2 26.5 24.8 0 0 0 34.4 
  
H09-
16941B3 29.1 25.7 0 0 0 0 
61 H09-16945B 26.4 25.4 0 0 0 0 
62 H09-16947B 27.2 25.2 0 0 0 0 
  H09-16947C 26.2 25.5 0 0 0 0 
63 H09-17075B 27.3 25.8 0 0 0 0 
64 H09-17151B 25.6 25.5 0 0 0 0 
65 
H09-
17498B1 26.1 24.8 0 0 0 0 
  
H09-
17498B2 27.2 25.4 0 0 0 0 
66 H09-17500B 26.5 25 0 0 0 0 
  H09-17500C 27.7 25.1 0 0 0 0 
67 H09-18014B 28.6 27 0 0 0 0 
  H09-18014C 26.9 27 0 0 0 0 
68 H09-18016B 26.5 24.9 0 0 0 0 
69 H09-18155B 27.1 26 0 0 0 0 
  
H09-
18155C1 26.9 27 0 0 0 0 
  
H09-
18155C2 26.5 25.4 0 0 0 0 
70 H09-18157B 26.2 26.1 0 0 0 0 
  H09-18157C 27.8 26.3 0 0 0 0 
71 H09-18241B 27.9 26.7 0 0 0 0 
  H09-18241C 28.2 26.5 0 0 0 0 
72 
H09-
18472B1 26.8 25.8 0 0 0 0 
  
H09-
18472B2 32.1 30.6 0 0 0 0 
  H09-18472C 27.8 26.2 0 0 0 0 
73 H09-18525B 26.2 25.9 0 0 0 0 
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74 H09-18609B 29 26.4 0 0 0 0 
  H09-18609C 25.6 24.7 33.5 0 0 0 
  H09-18609D 25 25.6 0 0 0 43.7 
5 H09-7867B 27.6 25.6 0 0 0 41.7 
  H09-7867C 27.8 25.8 32.8 0 0 0 
  H09-7867E 28.3 25.6 34.8 0 0 40.9 
25 H09-7913B 27.5 25.4 0 0 0 0 
  H09-7913C 29.6 27.3 0 0 0 0 
24 H09-7915B1 30.5 27.3 0 0 0 0 
  H09-7915C 29.1 30.2 0 0 0 0 
30 H09-7965B1 28.7 29.1 0 0 0 0 
  H09-7965B2  28.5 28.8 0 0 0 0 
26 H09-8667C 29.5 29.7 0 0 0 0 
27 H09-9039B 28.9 29.7 0 0 0 0 
  H09-9039C 28.5 26.8 0 0 0 42.4 
  H09-9041C 27.4 28.4 35 0 0 0 
  H09-9041D 28.9 29.6 0 0 0 0 
28 H09-9145B 28.4 29.3 0 0 0 0 
  H09-9145C 28.5 29.7 0 0 0 0 
  H09-9145D 28.1 28.8 0 0 0 0 
  H09-9145E1 30.1 29.7 0 0 0 0 
  H09-9145E2 30.2 28.2 0 0 0 0 
29 H09-9481B 27.9 28.3 0 0 0 0 
  H09-9481C 28.8 26.4 0 0 0 0 
  H09-9481D 29.4 25.8 0 0 0 0 
77 H10-1294B 28.2 27 0 0 0 0 
  H10-1294C 27.5 26.3 0 0 0 0 
78 H10-1443B1 26.1 26 32.9 0 0 0 
  H10-1443B2 26.4 25.1 36 0 0 0 
  H10-1443D 26.5 25.4 0 0 0 0 
79 H10-1445B 25.5 24 33.9 0 0 0 
  H10-1445C 25.8 24.2 33.1 0 0 0 
  H10-1445D 26.3 25.2 34 0 0 0 
  H10-1445E 25.9 25.1 35 0 0 0 
  10-1643B 28.4 26.7 0 0 0 0 
9 10-1643C 27.8 25.6 34.8 0 0 0 
80 H10-1978B 28 27 0 0 0 0 
  H10-1978C 26.6 25.7 0 0 0 0 
  H10-1978D 26.5 24.6 0 0 0 0 
18 H10-2344B 26.5 25.6 0 0 0 0 
  H10-2344D 30 34.4 0 0 0 0 
81 H10-2487B 25.3 24.8 0 0 0 0 
  H10-2487C 26.1 24.8 0 0 0 0 
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82 H10-2618A 25.9 27.2 0 0 0 43.1 
  H10-2618B 25.4 28.3 0 0 0 0 
83 H10-2620A 26.3 25.3 0 0 0 0 
84 H10-2712B 26.2 32 0 0 0 0 
  H10-2712C 25.3 27.1 33.9 0 0 0 
  H10-2712D 26.6 33 0 0 0 0 
85 H10-2920B 28.2 26.8 0 0 0 0 
  H10-2920C 28.3 26.4 0 0 0 0 
  H10-2920D 26.4 25.9 0 0 0 0 
19 H10-3256B 26.4 26.3 0 0 0 0 
  H10-3256C 25 24.8 0 0 0 0 
  H10-3256D 25.4 24.4 0 0 0 0 
86 H10-3302B1 26.7 27 0 0 0 0 
  H10-3302B5 24.9 25.6 32.5 0 0 0 
87 H10-3466B 27.3 26.8 0 0 0 0 
  H10-3466C 27.2 25.9 0 0 0 0 
88 H10-3635B 25.3 25.2 0 0 0 0 
  H10-3635C 25.7 25.8 0 0 0 0 
  H10-3635D 25.8 25 0 0 0 0 
89 H10-3820B 26.3 26 0 0 0 0 
90 H10-3989B 24.7 24.5 0 0 0 0 
  H10-3989C 26.2 25.8 0 0 0 0 
  H10-3989D 25.8 24.9 0 0 0 0 
91 H10-3991A 27.2 29.8 0 0 0 0 
  H10-3991B 25.9 26 0 0 0 0 
  H10-4108A3 26.5 25.8 0 0 0 0 
92 H10-4499B 25.3 30.7 0 0 0 0 
  H10-4499C 28.9 28.4 0 0 0 0 
  H10-4499D 27.3 31.5 0 0 0 0 
  H10-4499E 26.5 25.4 0 0 0 0 
93 H10-4945B 29.3 25.4 0 0 0 0 
  H10-4945C 27.2 28.1 0 0 0 0 
  H10-4945D 27.3 26.3 0 0 0 0 
94 H10-5123B 25.1 27.1 0 0 0 0 
  H10-5123C 25.1 27.7 0 0 0 0 
  H10-5123D 27.1 28.6 0 0 0 0 
95 H10-5675B 25.9 27.6 0 0 0 0 
  H10-5675C 27.5 28.8 0 0 0 0 
75 H10-577B 26.6 24.8 0 0 0 0 
96 H10-5809B 26.2 26.4 0 0 0 0 
  H10-5809C 27.2 27 0 0 0 0 
28 H10-6399B1 25.5 26.4 30.2 0 34.7 0 
97 H10-6546B 26.8 25.3 0 0 0 33 
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  H10-6546C 26.3 28.2 0 0 0 0 
  H10-6546D 28.1 28.7 0 0 0 0 
  H10-6548C 26.4 28 0 0 0 0 
  H10-6548E 28.4 28.5 0 0 0 0 
98 H10-6949C 26.2 26.2 0 0 0 0 
99 H10-7287B 26.1 27.3 0 0 0 0 
100 H10-7375B 26.1 27.5 0 0 0 0 
76 H10-747B 26.1 25.1 0 0 0 0 
  H10-747C 27.4 25 0 0 0 0 
  H10-7525C 25.9 27.5 0 0 0 0 
  H10-7525E 27 28.4 0 0 0 0 
33 H10-7587B 28.6 30.5 30.4 0 31.5 34.9 
  H10-7587D1 31.7 31 0 0 0 0 
  H10-8267A 28.7 29.5 0 0 0 0 
  H10-8267B1 28.1 28.3 0 0 0 0 
102 H10-8267B2 26.9 27.7 0 0 0 0 
  H10-8352B 27.5 27.2 0 0 0 0 
103 H10-8352C 26.1 28.2 34.9 0 0 0 
  H10-8489C 27 26.5 0 0 0 0 
104 H10-8528B 26.7 26.2 0 0 0 0 
  H10-8737B 27 26.4 0 0 0 0 
105 H10-8737C 25.3 29.9 0 0 0 0 
  H10-8936B 25.5 28.7 0 0 0 0 
  H10-8936C 26.6 29.7 0 0 0 0 
106 H10-8936D 27.3 30 0 0 0 0 
  H10-8938B 25.2 26.8 0 0 0 0 
107 H10-8938C 26.6 27.9 0 0 0 0 
  H10-9031C 27.2 27.7 0 0 0 0 
  H10-9031D 27.4 28.3 0 0 0 0 
  H10-9033B 26.2 28 0 0 0 0 
  H10-9033C 26.7 29.1 0 0 0 0 
108 H10-9033D 26.6 29.2 0 0 0 0 
  H10-9153C 27.1 28.8 0 0 35.3 38.6 
  H10-9153F 27.5 29.6 0 0 0 0 
  H10-9308B 25.8 27.1 0 0 0 0 
  H10-9308C 26.3 27.8 0 0 0 0 
109 H10-9308D 27 27.6 0 0 0 38.8 
  H10-9310B 28.1 29 0 0 0 0 
  H10-9310C 27.5 28.9 0 0 0 0 
110 H10-9310D 26.6 27.2 0 0 0 0 
  H10-9442C1 26.6 27.2 0 0 0 0 
  H10-9442C2 28.8 29.6 0 0 0 0 
 111 H10-9444B 26.3 25.4 35.5 0 0 0 
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2.8 The table compares the Cq values of positive cases from the LC480 (480) and 
Metasin (M) assays.  
 
(The yellow highlighted numbers highlight the discordant results) 
 
Sample PBGD-480 PBGD-M CK19-480 CK19-M MGB-480 MGB-M
12439 B 26.73 30.4 19.31 20.7 17.8 19.1
C 27.16 26.9 21.29 18.1 18.48 16.5
13265 B 25.79 29.2 17.68 19.3 21.16 23.5
15461 B 26.86 28.6 26.86 24.4 26.1 27.9
16837 B 26.02 27.9 23.6 0 0 0
16922 D 25.37 26.5 18.3 0 16.91 20.7
17635 B2 25.78 28.6 27.7 0 33.45 36.2
7867 D 26.09 25.7 26.78 27.7 26.27 23.7
8759 B 25.47 24.5 23.79 23.3 37.14 0
C 23.92 23.9 19.45 19.1 33.9 0
D 23.19 24.5 15.61 17 26.49 30.5 
E 24.94 25.1 19.56 18.9 33.9 33.4
F 24.93 24 19.98 18.6 33.81 32.5 
G 26.4 24.5 20.47 17.7 34.77 31.4 
H 24.75 24.1 18.47 17.1 34.98 30.9
I 25.32 25.1 20 19 27.05 24.1 
9041 B 25.86 25.4 0 0 31.56 29.8
10762 D 25.92 26.5 19.6 18.1 16.84 15.3
E 26.19 26.1 18.11 15.5 16.06 15.5
10931 B 26.79 26.2 0 31.7 27.87 25.6
13447 D 26.21 25.4 19.65 16.8 18.51 16.5
E 26.63 24.7 18.97 16.6 17.6 16.7
15131 B 26.11 25.1 0 0 32.78 31.7
16039 B 25.94 24.8 20.43 17.8 20.63 19.8
C 25.53 26.7 19.71 16.4 18.46 16.2
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17502 B 24.84 24.2 17.88 15.6 22.58 21.6
C 26.23 24.2 19.98 16.2 24.86 23
18243 B 26.69 27.4 22.69 22.3 18.8 20.6
C 26.62 24.9 0 20.9 30.03 30.4
745 B 26.59 24.3 23.46 16.3 30.94 22.3
C 26.67 24.3 19.17 16.1 25.03 28.3
925 B 27.24 27.1 22.8 20.5 35.32 34.4
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2.9 The table compares the Cq values of the same positive samples run on 
different days by two different users (day 1 and day 2) 
 
(The yellow highlighted values are discordant) 
 
Sample PBGD 1 PBGD 2 CK19 1 CK19 2 MGB 1 MGB 2
7867 D 25.3 25.7 27.8 27.7 24.9 23.7
8759 B 24.2 24.5 23.6 23.3 0 0
C 23.5 23.9 19.2 19.1 0 0
D 24.1 24.5 17.4 17 31.8 30.5
E 24.6 25.1 18.9 18.9 34.4 33.4
F 23.5 24 18.7 18.6 33.7 32.5
G 24.2 24.5 17.8 17.7 32.5 31.4
H 23.6 24.1 17.2 17.1 32.2 30.9
I 24.7 25.1 19 19 25.1 24.1 
9041 B 24.8 25.4 0 0 31.3 29.8
10762 D 26.1 26.5 18.3 18.1 16.9 15.3 
E 25.6 26.1 16.2 15.5 16.2 15.5 
10931 B 25.8 26.2 0 31.7 27.5 25.6
11531 C1 24.4 24.9 16 15.7 17.5 17.5 
C2 24.8 25.3 16.6 16.5 16.7 15.9
13447 D 24.8 25.4 17.2 16.8 17.5 16.5
E 24.3 24.7 16.7 16.6 18.2 16.7
15131 B 24.6 25.1 0 0 33.6 31.7
16039 B 24.4 24.8 18.2 17.8 20.7 19.8
C 26.3 26.7 16.4 16.4 17.2 16.2
17502 B1 23.8 24.2 15.7 15.6 22.3 21.6
B2 23.5 24.2 16.2 16.2 22.4 23
18243 C 24.3 24.9 21 20.9 31.3 30.4
745 B 23.6 24.3 16.4 16.3 29.5 22.3
C 24 24.3 16.3 16.1 24.4 28.3
Commented [SP5]: Why is this not highlighted? Asked same 
question on hard copy and not answered yet. 
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925 B 26.7 27.1 20.9 20.5 35.9 34.4
2344 C 25.4 25.9 0 0 28.9 27.8
3258 A1 23.8 24.6 19.4 27.4 31.7 0
A2 23.7 24.3 19.1 19.1 31.4 30.4
B2 26.1 26.7 0 0 35.8 34.4
C1 25.2 25.8 0 0 0 0
C2 25 25.4 0 0 29.2 28.4
3256 E 25.3 25.7 29 28.4 31.2 29.9
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2.10 The table contains the GeneSearch and Metasin extracted RNA concentration 
of positive nodes and a comparison with the reference gene PBGD Cq value  
 
 
    GeneSearch     Metasin
Sample 
PBGD-
G 
RNA conc 
(ug/ml)  
A260/ 
280 
A260/
230 
PBGD-
M 
RNA conc 
(ug/ml)  
A260/
280 
A260/
230 
7867 27.6 134 2.094 0.278 25.6 66 2.062 1.269
  27.8 126 2.1 0.426 25.8 128 2.065 0.821 
  27.3 128 2.133 0.444 25.7 176 2.047 1.294 
  28.3 96 2 0.457 25.6 134 2.03 1.264
  27.8 82 1.952 0.788 26.5 156 2.053 1.2
8759 26.4 212 2.078 0.477 24.5 176 2.095 1.205 
  23.8 142 2.029 0.568 23.9 358 2.081 1.421 
  23.9 382 2.054 0.946 24.5 344 2.098 1.036
  25.2 270 2.077 0.703 25.1 360 2.118 1.154
  26.6 270 2.077 0.531 24 330 2.089 1.086
  29.1 108 2.077 0.255 24.5 160 2 1.067 
  26.4 74 2.056 0.125 24.1 334 2.088 1.21 
  26.4 72 2 0.186 25.1 258 2.115 1.229
9041 28.1 76 2 0.528 25.4 52 2.364 5.2
  27.4 118 2.034 0.373 28.4 162 2.25 11.6 
9481 27.9 110 1.964 0.585 28.3 126 2.1 0.346 
  28.8 116 2 0.362 26.4 158 1.975 0.975
  29.4 78 1.95 0.487 25.8 164 2 0.617
10639 27.8 118 2.034 0.578 25.6 154 2.139 0.542 
  27.4 174 2.023 0.654 24.4 206 2.146 0.725 
10762 28.6 202 1.942 0.461 26.4 166 2.075 0.456
  28.2 132 1.941 0.496 26.4 182 2.068 0.615 
  32.8 120 2.069 0.472 26.5 70 1.944 0.407 
  33.9 94 2.043 0.385 26.1 126 2.032 0.521 
10931 28.4 166 1.976 0.446 26.2 186 1.979 0.495
11238 32 84 1.909 0.3 27 188 1.958 0.707 
229 
 
11387 27.6 188 1.958 0.566 25.5 172 2 0.729 
  27.5 194 2.021 0.366 25.4 256 2.098 1 
  27.6 178 1.978 0.503 25.8 246 2.016 0.904 
11531 29 128 2.065 0.176 25.7 190 1.979 0.864
  28.2 136 2.061 0.442 25.5 202 1.98 0.808 
  32.9 60 1.875 0.065 25.3 172 2.048 0.614 
  28.5 202 1.98 0.234 28.2 264 2.031 0.663 
12395 28.6 140 2.059 0.833 26.1 236 2 0.559
  32.9 18 2.25 0.134 28.2 14 1.75 0.14 
  32.6 98 2.042 0.516 25.4 166 2.128 0.5 
  33.3 162 2.025 0.596 24.7 284 2.119 1.06
13742 29.9 66 1.833 0.589 25.7 118 2.034 0.476
  29.5 162 2.025 0.435 26.3 158 2.026 0.731 
14732 29.2 136 1.943 0.428 26.3 132 21.129 0.512 
15131 25.7 174 2.071 0.6 25.1 218 2.057 0.58
  26.3 150 2.027 0.475 24.8 200 2.041 0.676
  33.4 102 1.889 0.927 25.4 114 1.966 0.438 
  26.1 176 2 0.423 25.3 216 2.077 0.837 
15664 25.7 202 2.02 0.754 26.1 280 2.09 1.061
  26.7 210 1.981 0.991 26 226 2.055 0.856
15813 26.3 172 2.048 0.677 25.8 212 2.12 0.862 
  26.1 212 2.038 0.716 25.3 270 2.143 1.08 
16039 25.7 268 2.03 1.196 24.8 366 2.056 1.123
  25.7 244 2.033 1.326 26.7 322 2.118 1.006 
  26.5 112 2 0.519 24.8 136 2.125 0.482 
  29.1 48 2.182 0.2 25.7 100 2.083 0.427 
17502 25.9 210 2.1 0.538 24.2 32 2 0.107
  26.1 190 2.065 0.397 24.2 214 2.14 0.594 
18243 27.6 292 2.056 0.619 27.4 300 2.113 0.456 
  27 206 1.981 0.433 24.9 214 2.098 0.673 
18472 26.8 94 1.958 0.635 25.8 176 2.047 0.978
  27.8 74 2.056 0.303 26.2 128 2.065 0.719 
230 
 
745 24.8 150 2.083 0.577 24.3 174 2.071 0.584 
  26.4 150 2.027 0.387 24.3 200 2.174 0.641 
925 27.5 100 1.923 0.549 27.1 156 2.053 0.433 
1443 26.1 106 1.963 0.515 26 200 2.041 0.654
  26.4 134 2.03 0.578 25.1 134 2.161 0.598 
  26.5 144 2 0.673 25.4 112 2 0.326 
1445 25.5 168 2.1 0.382 24 248 2.102 0.992 
  25.8 142 2.152 0.514 24.2 230 2.13 1.095
  26.3 150 2.027 0.339 25.2 162 2.077 0.771 
  25.9 160 2.105 0.39 25.1 150 2.083 1.027 
1643 25.8 148 2.114 0.409 25.2 216 2.077 0.885
  26.3 122 2.103 0.462 25.4 204 2.125 0.607
  28.4 58 1.933 0.358 26.7 86 2.048 0.589 
2344 26.5 122 2.103 0.61 25.6 208 2.039 0.945 
  27.5 140 2.059 0.519 25.9 164 2.103 0.752
  30 96 2.087 0.279 34.4 170 2.073 0.503
2620 26.3 102 2.04 0.26 25.3 126 2.1 0.525 
3258 24.1 88 1.193 0.647 24.6 218 2.137 0.553 
  24.8 148 2.056 0.13 24.3 296 2.085 0.841
  26.9 118 1.844 0.418 26.7 72 2 0.396
  27.7 118 1.903 0.711 25.8 94 2.043 0.263 
  27.8 180 1.957 1.023 25.4 130 1.97 0.684 
3256 26.4 116 2 0.227 26.3 198 2.063 0.892
  25 186 2.114 0.296 24.8 198 2.106 0.917 
  25.4 84 2 0.082 24.4 254 2.016 1.067 
  26.5 56 2.333 0.067 25.7 202 2.104 0.759 
3820 26.3 64 2.133 0.323 26 156 2.108 0.549
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1. Clinical Relevance / purpose of examination 
 
The Metasin BLN Assay is a qualitative, in vitro diagnostic test which enables rapid 
detection of > 0.2mm metastases in nodal tissue removed from breast sentinel lymph 
node biopsies.  The results from this test can be used to guide the intra-operative or 
post-operative decision to remove additional lymph nodes.   
 
2. Principle of examination 
 
The Metasin BLN Assay is a real time reverse transcriptase polymerase chain reaction 
(RT-PCR) assay that detects the presence of breast tumour cell metastasis in lymph 
nodes through the detection of gene expression markers Mammaglobin (MG) and 
Cytokeratin (CK 19).  These markers are present in higher levels in breast tissue, but 
not in nodal tissue.  The Cepheid SmartCycler® system is used to generate expression 
data for these genes of interest.  Expression results are then applied against 
predetermined criteria to create a qualitative result (Positive, Negative or Invalid).  
 
To standardise the distribution of tissue sampling, lymph nodes are divided into 
sections and alternating sections are combined and processed using the Metasin BLN 
Assay.  The remaining sections are used for routine histology.  Each lymph node is 
individually processed.  The nodal tissue is homogenised to release RNA molecules.  
RNA is purified from the tissue homogenate and RT-PCR is performed. 
 
The real time RT-PCR reaction is performed in a homogeneous, one-step, enclosed 
reaction.  Three gene markers (MG, CK 19 and an internal control gene [PBGD]) are 
included in the reaction.  Each gene marker is detected using fluorescent molecules 
with different excitation and emission wavelengths.  Following each temperature cycle 
of the PCR reaction the fluorescence is measured and amplification of the gene marker 
is detected through increased fluorescence.  The cut-off (Ct) value is determined when 
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the fluorescent signal exceeds a pre-defined threshold limit.  If the Ct value for either 
or both gene markers is less than the cut-off value then the sample is positive.   
 
 
3. Related procedures / SOPs 
 
Breast Sentinel PCR Stock Check 
Sentinel Lymph Node Biopsy 
Pipette Proficiency Record 
 
4. Hazards and safety precautions 
 
All biological specimens and reagents coming into contact with the specimen(s) are 
considered biohazardous and should be handled with care. 
 
Prior to and after performing PCR analysis, bench surfaces must be wiped down with 
Tristel.  Buffer RLT spills to be wiped dry using RNase-free water before using Tristel. 
 
Microbial contamination of reagents must be avoided.  RNA is susceptible to 
degradation it is therefore important to maintain RNase free conditions.  All personnel 
should follow safety precautions and wear the appropriate personal protective 
equipment (laboratory coat, gloves) at all times.  Gloves should be changed between 
specimen preparation and PCR amplification/detection activities to avoid 
contamination.  A fume hood should be used for preparing the sample preparation kit 
reagents, particularly when using β-mercaptoethanol.  A face shield may be worn 
when making up and handling the homogenisation buffer.   
 
The homogenisation buffer (Buffer RLT Lysis buffer) contains guanidine thiocyanate.  
This is associated with the following risk and safety phrases: Harmful by inhalation, in 
contact with skin and if swallowed (R20/21/22), contact with acids liberates very toxic 
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gas (R32), in case of contact with eyes rinse immediately with plenty of water and seek 
medical advice (S26), if swallowed seek medical advice immediately and show label or 
container (S46).  
 Guanidine thiocyanate can form highly reactive compounds when combined 
with bleach.  If spilt, use a suitable laboratory detergent and water to clean spills 
followed by bleach solution if decontamination is required. 
 
Buffer RW1 (Wash Buffer 1) contains 10% ethanol (Flammable, R10). 
 
Buffer RPE (Wash buffer 2) contains sodium azide.  Harmful if swallowed.  After 
contact with skin, wash with plenty of soap. 
 
Some of the reagents contain Proclin 300 preservative.  Symptoms of overexposure to 
Proclin 300 may include irritation of skin, eyes, mucous membranes and upper 
respiratory tract. 
 
After running the amplification reaction, to avoid amplicon contamination do not open 
sample or control tubes under any circumstances in the PCR area.  After each run, 
clean the work areas (including applicable equipment) using Tristel. 
 
Avoid contaminating reagents with bleach.  Contamination will cause erroneous 
results. 
 
5. Specimen requirements and means of identification 
 
Before preparing the lymph node, set up a fresh disposable cutting board, put a fresh 
blade on the scalpel and use a fresh pair of gloves. Change gloves, scalpel blades, 
forceps, and cutting surface between lymph nodes – this is essential to minimise 
sample cross-contamination.  For further details on slicing lymph node please refer to 
LP Sentinel Lymph Node Biopsy. 
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• Care must be taken to minimise contamination of the lymph node with breast 
or primary tumour tissue, as this may lead to a false positive result. 
• Lymph node tissue should be received in an appropriately labelled specimen 
pot.  For transport purposes these are usually placed inside a larger specimen 
pot.    
• To prepare working Buffer RLT, add 450µl β-mercaptoethanol (β-ME) to one 
bottle of Buffer RLT and mix well.  Reagent is stable for 30 days after β-ME has 
been added, make a note of expiry date on bottle.  Warning! Β-ME is toxic, 
wear appropriate PPE and dispense in a fume hood. 
• Label Buffer RW1 as ‘Wash Buffer 1’. 
• To prepare Buffer RPE, add 44mL absolute 200-proof ethanol to the Buffer RPE 
concentrate and mix well, label this bottle as ‘Wash Buffer 2’.  Reagent is stable 
for 30 days when stored at ambient temperature after ethanol addition, make 
a note of expiry date on bottle. 
• To prepare 70% ethanol, add 7mL 200-proof molecular biology grade ethanol 
to 3mL of nuclease-free water.  Ensure solution is mixed well prior to use – 
incomplete mixing prior to use may cause erroneous results. 
• The lymph node should be prepared as soon as possible to minimise RNA 
degradation.   
• Each lymph node should be processed as a separate specimen.  Tissue is stable 
for 45 minutes at room temperature after removal from the patient. 
• Tissue homogenate and purified RNA should be stored in the -70ºC freezer and 
have a diagnostic shelf life of 21 days and 9 weeks respectively.  Please log case 
number and date of preparation, disposal date on chart on Freezer log folder. 
 
6. Equipment and special supplies 
 
Cepheid SmartCycler® Diagnostic System including: 
• I-CORE™ blocks 
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• Mini-centrifuge 
• Plastic sample racks 
• Computer (incl. monitor from Cepheid) 
• Tube puller 
• Cepheid 25µL reaction tubes for Cepheid SmartCycler® (900-0003) 
 
• Printer 
• 1.7 mL polypropylene microcentrifuge tubes, certified DNase- and RNase-
free (COSTAR 3621) 
• 1.5mL microcentrifuge tubes (FISHER SCIENTIFIC FB56089) 
• 0.5ml microcentrifuge tube  
• Vacuum System (KNF LAB LABOPORT® NF840 FT.18) 
• Qiagen® VacConnectors (19407) 
• Qiagen® VacValves (19408) 
• Vacuum source (capable of drawing -800 to -1000 mbar)   
• Qiagen® QIAvac 24 Plus Vacuum Manifold (19413) 
• Qiagen® Vacuum Regulator (19530) 
• Omni Homogenizer (QLH-02) 
• Omni Adaptor  
• Omni Tip™ Disposable Probes for Omni Homogenizer (OMNI 
INTERNATIONAL 30750) 
• 8mL polypropylene culture tubes for homogenization (VWR 211.0074) 
• SAV-IT closures (FISHER BRAND 02-707-10) 
• 14mL polypropylene tubes for homogenisation  
• Disposable forceps (TWD DF8088N) 
• Scale  
• Weighing boats (FISHER BRAND 08-732-113) 
 
• Calibrated pipettors: 
- Finnpipette  1000µl (THERMO SCIENTIFIC) 
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- Finnpipette F2 10 - 100µl (THERMO SCIENTIFIC 4642070) 
- Finnpipette F2 1 - 10µl (THERMO SCIENTIFIC FJ46041) 
 
• Pipette-Aid 
• Aerosol resistant, DNase- and RNase-free tips: 
- Pipettor tip sureone filter sterile rack micropoint tip 0.1 - 10µl (FISHER 
SCIENTIFIC FB78100) 
- Pipettor tip sureone filter sterile rack bevelled tip 10 - 100µl (FISHER 
SCIENTIFIC FB78112) 
- Pipettor tip sureone filter sterile rack micropoint tip 100 - 1000µl (FISHER 
SCIENTIFIC FB78112 
- Pipettor tip finntip sterile 2 – 10mL (FISHER SCIENTIFIC PMP-103-260E) 
- Pipettor tip finntip sterile  
• Cepheid centrifuge (700.2378) 
• Centrifuge  
• Vortex (IKA® Vortex Genius 3)  
• Disposable scalpels (SWANN-MORTON SCA-310-030) 
 
 
7. Reagents, standards and internal quality control materials 
 
• Qiagen RNeasy Mini Kit (QIAGEN 74104) 
• LightCycler 480 RNA Master Hydrolysis Probes (ROCHE 04 991 885 001)  
• β-Mercaptoethanol (CALBIOCHEM 44203) 
• 200-Proof (Absolute) Ethanol, molecular biology grade (SIGMA ALDRICH 
245119-1L) 
• Water sterile non-DEPC treated (nuclease-free) (FISHER BIOREAGENTS 
VX10977049) 
 
8. Calibration 
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Before commencing with processing check vacuum pressure of vacuum 
manifold is between 800 – 1000mbar. 
 
Pipettes should be calibrated regularly and pipette proficiency tests performed.  
A sticker should be attached to the pipette with date of calibration and initials 
of the individual performing the test.  Calibration results should be kept in the 
individuals training manual.  Please refer to pipette competency forms 
LF730048. 
  
9. Procedure / instructions for performance of the examination 
 
Prior to proceeding, please follow the Assay Preparation Check List. 
 
The procedure is divided into 3 sections: 
1. Lymph Node Tissue Homogenisation & RNA Extraction 
2. RNA Amplification Setup 
3. SmartCycler® Operation 
 
The check list and all procedures are given below as per manufacturer’s instructions, 
for further details please refer to documentation under reference section of SOP. 
  
257 
 
     Metasin BLN Assay preparation Checklist   
 
Sentinel Node Dissection Area: 
• Turn Scale on 
• Wipe workspace with Tristel 
• Check supply of weigh boats 
• Check supply of scalpels 
• Check supply of forceps 
• Disposable cutting boards 
• Transparent Ruler 
• Notepad, Pen, Marker 
• Formalin Pots 
 
Sentinel Node Homogenisation Area: 
• Check supply of homogenisation probes 
• Label homogenisation tubes 
• Ensure adequate supply of working homogenisation buffer 
o Prepare more if required by adding 450µl of β-mercaptoethanol to a 
45ml bottle of Buffer RLT.   
o Note on the bottle the 30day expiry date from the day β-
mercaptoethanol is added to Buffer RLT 
o Prepare one 14ml homogenisation tube with 5ml of Buffer RLT 
o Prepare one 8ml homogenisation tube with 2ml of Buffer RLT 
 
RNA Extraction Area: 
• Ensure adequate supply of 70% ethanol:  
Preparation of 70% Ethanol 
Final Desired Volume Volume 200-proof Ethanol to 
Add 
Volume Nuclease Free water 
to add 
50ml 35ml 15ml
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10ml 7ml 3ml
 
• Attach VacValves and clean VacConnectors to manifold 
• Check Qiagen RNeasy Mini Kit to ensure adequate reagent quantities and 
volumes: 
o RNA spin columns 
o Buffer RWI (Wash Buffer 1) 
o Ensure that adequate supply of working Buffer RPE (Wash Buffer 2) 
is prepared 
 Prepare more if required by adding 44ml of 200-proof 
ethanol, molecular biology grade to a new bottle of Buffer 
RPE concentrate 
o Label 2 sets of 1.5ml centrifuge tubes per sample 
o Set centrifuge/confirm centrifuge settings (0.5min, >10,000 rpm) 
o Confirm vacuum and manifold operation by turning vacuum on and 
verifying vacuum is adequate (~800 to ~ 1000mbar) 
o Set 200µl pipette to 50µl, check tip supply 
 
Amplification area: 
 Label cepheids, remember to include positive control (PC) and negative control 
(NC). 
 Set up SmartCycler® as follows: 
o Turn on SmartCycler® and computer, log on to the SmartCycler® Dx 
software. 
o From the CREATE RUN Screen, select METASIN BLN Assay 
o Enter Run Name as date (DD-MM-YY) and Histology number; enter the PCR 
Kit lot # & expiration date (YYYY-MM-DD).  
 
 
Preparation for RNA AMPLIFICATION PROCEDURE 
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Start this procedure once the sentinel lymph nodes have arrived in the department.   
 
NB. This procedure is based on having up to 4 nodes with positive and negative 
control.  For more nodes additional primer/probe mix (BROWN tube) and activator 
(WHITE tube) will be required. 
e.g. 5 nodes = 2 BROWN tubes 
 
Use a fresh tip for each step below: 
 
1. Use fresh gloves. 
2. Ensure cepheids are labelled correctly and placed in the blue Cepheid rack 
on the cool block. 
3. Thaw adequate supply of primer/probe mix (BROWN tube) and activator 
(YELLOW tube aliqouts), positive and negative controls. 
4. Pulse spin all thawed reagents before use and place these in the cool box 
with the enzyme mix (RED tube). 
5. Add 57µl of enzyme mix into the mouth of the brown tube.  Discard tip. 
6. Add 10µl of activator into the mouth of the brown tube.  This constitutes 
the Master Mix. 
7. Mix thoroughly by flicking the base of tube 5 times, then pulse spin for 6 
seconds. 
8. Aliquot 21µl of the Master Mix into each of the cepheids. 
9. Add 4µl of Negative Control to “NC” tube; discard tip; close tube. 
10. Add 4µl of Positive Control to “PC” tube; discard tip; close tube. 
11. Spin the Control Cepheids and place in relevant ICORs. 
12. Leave other Cepheids on rack until sample RNA has been extracted (see 
RNA AMPLIFICATION PROCEDURE - p10) 
 
Lymph Node Dissection 
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These nodes are sliced as per protocol and all slices are processed histologically. 
  
1: Use cut up board and blades provided, change board and blades for each node.  
 
2: Weigh LN in weigh boat after removal of fat & record weight in mg. 
 
3. Record dimensions of node (mm). 
 
  The minimum amount for Metasin processing is 3mg (0.003g)  if the nodes weigh less 
than this in total then DO NOT GIVE SAMPLE TO METASIN as the procedure at present 
is not licensed for whole node processing, keep all tissue and process using 
conventional histological technique. 
 
3: If LN is less than 4mm, equally bisect and place histology slice downwards in 
TURQUOISE cassette between blue foams, give other slice for Metasin processing. 
 
4: if  LN is greater than 4mm, bread slice every 2mm 
along the short axis (not transversely) and placed with 
non opposing cut edges down. 
 
5: Alternate slices to be given for Metasin processing, 
slice number needs noting on 
form. (1, 3, 4… or 2, 4, 6…) The BMS will decide which slices will be sent for Metasin. 
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6. Place the slices for histology weight boat labeled with node number and place in 
fume hood.  Pour some formalin over the tissue to fix them.  On completion of Metasin 
assay, transfer the slices into Turquoise CASSETTES maintaining the same orientation 
(between blue foams) no more than two slice per cassette are placed from front to 
back as cut, record details on adhesive labels available in the BRSN folder.  Attach the 
labels to the back of specimen request form for the BRSN. 
 
Cassettes labelled BRSN are placed into the routine refix pot and processed the 
following day on a routine programme, there is no requirement for these to be placed 
on an overnight breast run unless the nodes are particularly fatty and require longer 
processing via the breast programme.  
 
 
Lymph Node Tissue Homogenisation 
Work under fume hood in well ventilated area  
1. Determine weight (mg) of tissue to be used in assay. 
2. Mince the slices of tissue using scalpel into smaller fragments. 
3. Determine the amount of Buffer RLT and appropriate sized tube for each 
sample according to table below: 
 
Tissue Weight (mg) Buffer RLT (ml) Tube Size (ml)
3-149 2  
8 150-199 3 
200-249 4 
250-299 5 
 
 
14 
300-349 6 
350-399 7 
400-449 8 
450-500 9 
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500-550 10 
>550 See note 
 
NOTE:  Tissue weighing greater than 550mg will not be adequately homogenised.  
Divide the tissue into equivalent parts prior to homogenisation and proceed as if they 
were individual specimens. 
 
4. Transfer tissue into the homogenisation tube. 
5. Add buffer RLT to homogenisation tube. 
6. Homogenise tissue completely. 
 
METASIN RNA PURIFICATION 
 
1. In a 1.5ml tube, mix 400µl of homogenate with 400µl of 70 % ethanol and 
vortex for 10 seconds. 
2. Determine the amount of homogenate:ethanol mix to add to column: 
Tissue Weight (mg) Homogenate:Ethanol Mix ( µl)
3-39 700
40-49 500
50-59 400 
60-69 350
70-79 300 
80-89 250
90-99 225
≥100 200
 
3. Add the indicated volume to the column 
4. Apply vacuum.  Allow the entire sample to filter completely. 
5. Close VacValves. Add 700µl of Buffer RW1 (Wash Buffer 1) to the column and 
filter 
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6. Close VacValves. Add 700µl of Buffer RPE (Wash Buffer 2) to the column and 
filter 
7. Close VacValves.  Remove each column from the Vacuum Manifold and place 
into the round-bottom collection tube supplied with the column. 
8. Centrifuge tube containing the column for 30 seconds at >10,000RPM 
9. Discard collection tube.  Remove the Column and put into new 1.7ml centrifuge 
tube. 
10. Add 50µl of RNase-free water directly to the filter membrane of the column. 
11. Centrifuge for 30seconds at >10,000PRM 
12. Ensure 1.7ml centrifuge tube is labelled.  Discard the column.  Approximately 
50µl of eluted RNA solution will be contained in the collection tube.  
 
RNA AMPLIFICATION PROCEDURE 
 
Use a fresh tip for each step below: 
 
1. Add 4µl purified RNA to pre-prepared cepheids; discard tip; close tube. 
2. Repeat step 1 for each additional RNA sample. 
3. Ensure caps are snapped. 
4. Spin all Cepheid tubes in the SmartCycler® centrifuge for 6 seconds. 
5. Discard the BROWN and WHITE tube after use & return reagents to freezer. 
6.  On the SmartCycler® screen, add the number of specimens to be tested 
where prompted.  Select APPLY. 
7. For patient specimens, change “Spec” in Sample ID column of Site Table to 
node ID (e.g B, C, D) if multiple nodes are being run from the patient. 
8. After all specimens have been placed in the SmartCycler®, select START 
RUN. 
9. When prompted, re-enter password. 
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10. At the end of the test (approx. 28 mins) in the VIEW RESULTS Screen, click 
on Results Table and check control results to determine if the run was valid.  
Both qualitative and quantitative results are provided. 
11.  Phone relevant theatre and give the results to theatre staff member.  
Ensure name of staff member is noted on the request form and ensure 
they are able to reiterate the results.   
12.  Both qualitative and quantitative results must also be noted on the 
request form. 
  MASTER MIX PREPARATION/RESULTS TEMPLATE 
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Qiagen Lot No:____________ 
 
Roche Lot No: ____________ 
 
 
 
                                                                 Date: 
S _______-__________                          BMS: 
 
PREPARE MASTER MIX IN BROWN TUBE 
Lot No:  
ADDED  
ENZYME MIX 
(RED TUBE) 
57µL
ACTIVATOR 
(WHITE TUBE) 
10µL
Flick tube (X6 & Pulse spin (6 secs) 
MASTER MIX (LN + 2)
Max. 4N/brown tube 
21µl / 
Cepheid 
-VE CONTROL 
 
4µl
+VE CONTROL 
 
4µl
RNA 4µl
CUT OFF VALUES:   +VE if  
CK19 ≤32 
                                                                    ( 
Macro <25 ) 
MGB≤32.3
(Macro 
<26) 
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Node Weight 
(mg) 
Slices Metasin 
Weight 
PBGD CK19 MGB
    
    
    
    
    
    
   RESULT:  
 
Results Given to: 
 
 
 
10. Limitations / pitfalls of the examination (including 
interference, cross reactions and reportable intervals. 
 
• It is important to avoid contaminating lymph nodes with breast tissue.  
Breast tissue can yield false positive results.   
 
• Presence of excess fat surrounding the lymph node tissue decreases the 
sensitivity of the test and can lead to an “Invalid” result. 
 
• Fixing the tissue in formalin prior to testing will result in an “Invalid” result. 
 
• Pooling of separate lymph nodes must not occur as it may result in a loss of 
test sensitivity and cause erroneous results. 
 
• Processing at ambient temperatures above 30OC may lead to loss of test 
sensitivity.   
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• Tissue <50mg in weight may produce a higher Invalid test rate with the 
Metasin BLN Assay. 
 
• The Metasin BLN assay has been designed to work with sentinel lymph 
node procedures yielding no more than 6 samples per run.  2 runs may be 
performed simultaneously or sequentially accommodating a total of 12 
samples per SmartCycler. 
 
• The assay is not designed for use with formalin-fixed tissue. 
 
• Accurate pipetting is essential for optimal results. 
 
11. Recording, calculation and transcription of results 
 
All results are reported by a pathologist.  Once the run is completed (approximately 24 
minutes) the software displays the result as positive or negative, this information is 
phoned through to theatre staff together with the quantitative result (e.g. macro-
/micro-metastases) by a qualified BMS.  
 
If a run fails, testing may be repeated dependent on the mode of failure. 
 
External control failures: If run is invalidated, the assay can be repeated using residual 
RNA sample from patient lymph node(s) and external controls from the assay test kit. 
 
Internal control failures: If sample fails due to all markers (including internal control) 
being negative for a given patient (from one or more lymph nodes), RNA can be re-
purified from the homogenate(s) and assay repeated. 
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NB. The tissue homogenate and purified RNA are stable up to 60 minutes at ambient 
temperature. 
 
12. Internal quality control procedures and other criteria for 
which acceptability are judged 
 
External controls are provided for MG and CK19 (positive control) and for PBGD 
(negative control).  These must be included in each run.  The controls monitor the 
quality of the reagents and the instrument performance thereby reflecting on the 
performance of the assay. 
 
The internal control consists of detection of mRNA from a house keeping gene (PBGD) 
always expressed in lymph node tissue, and thereby acts as a control against false 
negative results.  This control monitors sample quality, sample preparation and the RT-
PCR reaction.  Extremely high expression of the cancer markers (MG and CK19) may 
inhibit detection of the internal control.  In this circumstance, assays in which one or 
both cancer markers are positive in at least one lymph node are considered valid, 
regardless of the internal control result. 
 
13. Reporting reference limits including alert/critical results 
 
 
NB. Ensure validity of Positive and Negative Controls before giving results to 
pathologists.   
 
Results from runs with one or more Invalid controls must be repeated and must not be 
reported. 
   
14. Performance criteria 
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The cutoff values are specific for each marker.  External control values must be valid.  
Samples with Ct values less than or equal to one or both of the cutoff values for MG or 
CK19 are considered positive.  If the MG and CK19 Ct values are above their cutoffs the 
Internal Control Ct value must be below its cutoff for MG and CK19 to be considered 
negative.  If the MG and CK19 Ct values are negative and the Ct value for the Internal 
Control gene is greater than or equal to its cutoff, then the result for that sample is 
considered “Invalid”. 
 
The cutoff Ct values for the markers are as follows: CK19 ≤ 32, MG ≤ 32.3 & Internal 
Control < 36. 
 
If result is “Valid” the Patient Results section shows the test result to be “Positive” or 
“Negative”.  The result is per patient not per lymph node.  If at least one lymph node 
being tested for a patient is positive for either marker, the Patient result is “Positive”, 
regardless of results obtained with other samples from that patient.  Conversely, if 
Patient result is not “Positive” and the internal control result from one or more of the 
patients’ lymph nodes is “Invalid”, then the Patient result is “Invalid”.   
 
15. Result Reporting and authorisation of reports 
 
The pathologist assigned to the case will be informed of the result and the result will 
be noted on the patients histology form. 
 
16. References 
 
• Cepheid SmartCycler® Diagnostic Operator manual 
• QIAGEN RNeasy Mini Kit insert 
• ROCHE LightCycler 480 RNA hydrolysis kit insert 
• Int. J. Mol. Sci. 2013, 14, 12931-12952; doi:10.3390/ijms140712931 
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